

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number: WO 99/38973
C12N 15/12, A61K 38/17, C07K 14/47, 16/18, A61K 35/14	A2	(43) International Publication Date: 5 August 1999 (05.08.99)
(21) International Application Number: PCT/US99 (22) International Filing Date: 26 January 1999 (26) (30) Priority Data: 09/015,029 28 January 1998 (28.01.98) 09/015,022 28 January 1998 (28.01.98) 09/040,828 18 March 1998 (18.03.98) 09/040,831 18 March 1998 (18.03.98) 09/040,831 18 March 1998 (18.03.98) 09/122,192 23 July 1998 (23.07.98) 09/122,191 23 July 1998 (23.07.98) 09/219,245 22 December 1998 (22.12.98)	5.01.9 L L L	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
(71) Applicant: CORIXA CORPORATION [US/US]; Sui 1124 Columbia Street, Seattle, WA 98104 (US).	te 20	Without international search report and to be republished
(72) Inventors: REED, Steven, G.; 2843 – 122nd Place Bellevue, WA 98005 (US). LODES, Michael, J.; 36th Avenue S.W., Seattle, WA 98126 (US). FRUI Tony, N.; P.O. Box 99232, Seattle, WA 99232-023 MOHAMATH, Raodoh; 4205 South Morgan, Seattle 98118 (US).	9223 DAKI 2 (US	- S,).
(74) Agents: MAKI, David, J. et al.; Seed and Berry 6300 Columbia Center, 701 Fifth Avenue, Seattle 98104-7092 (US).	•	

(54) Title: COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR THEIR USE

(57) Abstract

Compounds and methods for treating lung cancer are provided. The inventive compounds include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such polypeptides, or polynucleotides encoding such polypeptides, are also provided, together with polynucleotides for preparing the inventive polypeptides.

COMPOUNDS FOR THERAPY AND DIAGNOSIS
OF LUNG CANCER AND METHODS FOR THEIR USE

TECHNICAL FIELD

20

25

The present invention relates generally to compositions and methods for the treatment of lung cancer. The invention is more specifically related to nucleotide sequences that are preferentially expressed in lung tumor tissue, together with polypeptides encoded by such nucleotide sequences. The inventive nucleotide sequences and polypeptides may be used in vaccines and pharmaceutical compositions for the treatment of lung cancer.

BACKGROUND OF THE INVENTION

Lung cancer is the primary cause of cancer death among both men and women in the U.S., with an estimated 172,000 new cases being reported in 1994. The five-year survival rate among all lung cancer patients, regardless of the stage of disease at diagnosis, is only 13%. This contrasts with a five-year survival rate of 46% among cases detected while the disease is still localized. However, only 16% of lung cancers are discovered before the disease has spread.

Early detection is difficult since clinical symptoms are often not seen until the disease has reached an advanced stage. Currently, diagnosis is aided by the use of chest x-rays, analysis of the type of cells contained in sputum and fiberoptic examination of the bronchial passages. Treatment regimens are determined by the type and stage of the cancer, and include surgery, radiation therapy and/or chemotherapy. In spite of considerable research into therapies for the disease, lung cancer remains difficult to treat.

Accordingly, there remains a need in the art for improved vaccines, treatment methods and diagnostic techniques for lung cancer.

SUMMARY OF THE INVENTION

Briefly stated, the present invention provides compounds and methods for the therapy of lung cancer. In a first aspect, isolated polynucleotides encoding lung tumor polypeptides are provided, such polynucleotides comprising a nucleotide sequence selected

.5

10

15

20

25

herein; and (b) detecting in the sample a protein or polypeptide that binds to the binding agent. In preferred embodiments, the binding agent is an antibody, most preferably a monoclonal antibody.

In related aspects, methods are provided for monitoring the progression of lung cancer in a patient, comprising: (a) contacting a biological sample obtained from a patient with a binding agent that is capable of binding to one of the polypeptides disclosed herein; (b) determining in the sample an amount of a protein or polypeptide that binds to the binding agent; (c) repeating steps (a) and (b); and comparing the amounts of polypeptide detected in steps (b) and (c).

Within related aspects, the present invention provides antibodies, preferably monoclonal antibodies, that bind to the inventive polypeptides, as well as diagnostic kits comprising such antibodies, and methods of using such antibodies to inhibit the development of lung cancer.

The present invention further provides methods for detecting lung cancer comprising: (a) obtaining a biological sample from a patient; (b) contacting the sample with a first and a second oligonucleotide primer in a polymerase chain reaction, at least one of the oligonucleotide primers being specific for a polynucleotide that encodes one of the polypeptides disclosed herein; and (c) detecting in the sample a DNA sequence that amplifies in the presence of the first and second oligonucleotide primers. In a preferred embodiment, at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181.

In a further aspect, the present invention provides a method for detecting lung cancer in a patient comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with an oligonucleotide probe specific for a polynucleotide that encodes one of the polypeptides disclosed herein; and (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe. Preferably, the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181. In related aspects, diagnostic kits comprising the above oligonucleotide probes or primers are provided.

SEQ ID NO: 14 is the determined cDNA sequence for L355C1.cons SEQ ID NO: 15 is the determined cDNA sequence for L366C1.cons SEQ ID NO: 16 is the determined cDNA sequence for L163C1a SEQ ID NO: 17 is the determined cDNA sequence for LT86-1 SEQ ID NO: 18 is the determined cDNA sequence for LT86-2 SEQ ID NO: 19 is the determined cDNA sequence for LT86-3 SEQ ID NO: 20 is the determined cDNA sequence for LT86-4 SEQ ID NO: 21 is the determined cDNA sequence for LT86-5 SEQ ID NO: 22 is the determined cDNA sequence for LT86-6 SEQ ID NO: 23 is the determined cDNA sequence for LT86-7 SEQ ID NO: 24 is the determined cDNA sequence for LT86-8 SEQ ID NO: 25 is the determined cDNA sequence for LT86-9 SEQ ID NO: 26 is the determined cDNA sequence for LT86-10 SEQ ID NO: 27 is the determined cDNA sequence for LT86-11 SEQ ID NO: 28 is the determined cDNA sequence for LT86-12 SEQ ID NO: 29 is the determined cDNA sequence for LT86-13 SEQ ID NO: 30 is the determined cDNA sequence for LT86-14 SEQ ID NO: 31 is the determined cDNA sequence for LT86-15 SEQ ID NO: 32 is the predicted amino acid sequence for LT86-1 SEQ ID NO: 33 is the predicted amino acid sequence for LT86-2 SEQ ID NO: 34 is the predicted amino acid sequence for LT86-3 SEQ ID NO: 35 is the predicted amino acid sequence for LT86-4 SEQ ID NO: 36 is the predicted amino acid sequence for LT86-5 SEQ ID NO: 37 is the predicted amino acid sequence for LT86-6 SEQ ID NO: 38 is the predicted amino acid sequence for LT86-7 SEQ ID NO: 39 is the predicted amino acid sequence for LT86-8 SEQ ID NO: 40 is the predicted amino acid sequence for LT86-9 SEQ ID NO: 41 is the predicted amino acid sequence for LT86-10 SEQ ID NO: 42 is the predicted amino acid sequence for LT86-11 SEQ ID NO: 43 is the predicted amino acid sequence for LT86-12

J,

SEQ ID NO: 74 is the predicted amino acid sequence for LT86-21 SEQ ID NO: 75 is the predicted amino acid sequence for LT86-22 SEQ ID NO: 76 is the predicted amino acid sequence for LT86-26 SEQ ID NO: 77 is the predicted amino acid sequence for LT86-27 SEQ ID NO: 78 is the determined extended cDNA sequence for L86S-12 SEQ ID NO: 79 is the determined extended cDNA sequence for L86S-36 SEQ ID NO: 80 is the determined extended cDNA sequence for L86S-46 SEQ ID NO: 81 is the predicted extended amino acid sequence for L86S-12 SEQ ID NO: 82 is the predicted extended amino acid sequence for L86S-36 SEQ ID NO: 83 is the predicted extended amino acid sequence for L86S-46 SEQ ID NO: 84 is the determined 5'cDNA sequence for L86S-6 SEQ ID NO: 85 is the determined 5'cDNA sequence for L86S-11 SEQ ID NO: 86 is the determined 5'cDNA sequence for L86S-14 SEQ ID NO: 87 is the determined 5'cDNA sequence for L86S-29 SEQ ID NO: 88 is the determined 5'cDNA sequence for L86S-34 SEQ ID NO: 89 is the determined 5'cDNA sequence for L86S-39 SEQ ID NO: 90 is the determined 5'cDNA sequence for L86S-47 SEQ ID NO: 91 is the determined 5'cDNA sequence for L86S-49 SEQ ID NO: 92 is the determined 5'cDNA sequence for L86S-51 SEQ ID NO: 93 is the predicted amino acid sequence for L86S-6 SEQ ID NO: 94 is the predicted amino acid sequence for L86S-11 SEQ ID NO: 95 is the predicted amino acid sequence for L86S-14

SEQ ID NO: 95 is the predicted amino acid sequence for L86S-14
SEQ ID NO: 96 is the predicted amino acid sequence for L86S-29
SEQ ID NO: 97 is the predicted amino acid sequence for L86S-34
SEQ ID NO: 98 is the predicted amino acid sequence for L86S-39
SEQ ID NO: 99 is the predicted amino acid sequence for L86S-47
SEQ ID NO: 100 is the predicted amino acid sequence for L86S-49
SEQ ID NO: 101 is the predicted amino acid sequence for L86S-51
SEQ ID NO: 102 is the determined DNA sequence for SLT-T1
SEQ ID NO: 103 is the determined 5' cDNA sequence for SLT-T2

15

20

SEQ ID NO: 134 is the determined cDNA sequence for PSLT-69 SEQ ID NO: 135 is the determined cDNA sequence for PSLT-71 SEQ ID NO: 136 is the determined cDNA sequence for PSLT-73 SEQ ID NO: 137 is the determined cDNA sequence for PSLT-79 SEQ ID NO: 138 is the determined cDNA sequence for PSLT-03 SEQ ID NO: 139 is the determined cDNA sequence for PSLT-09 SEQ ID NO: 140 is the determined cDNA sequence for PSLT-011 SEQ ID NO: 141 is the determined cDNA sequence for PSLT-041 SEQ ID NO: 142 is the determined cDNA sequence for PSLT-62 SEQ ID NO: 143 is the determined cDNA sequence for PSLT-6 SEQ ID NO: 144 is the determined cDNA sequence for PSLT-37 SEQ ID NO: 145 is the determined cDNA sequence for PSLT-74 SEQ ID NO: 146 is the determined cDNA sequence for PSLT-010 SEQ ID NO: 147 is the determined cDNA sequence for PSLT-012 SEQ ID NO: 148 is the determined cDNA sequence for PSLT-037 SEQ ID NO: 149 is the determined 5' cDNA sequence for SAL-3 SEQ ID NO: 150 is the determined 5' cDNA sequence for SAL-24 SEQ ID NO: 151 is the determined 5' cDNA sequence for SAL-25 SEQ ID NO: 152 is the determined 5' cDNA sequence for SAL-33 SEQ ID NO: 153 is the determined 5' cDNA sequence for SAL-50 SEQ ID NO: 154 is the determined 5' cDNA sequence for SAL-57 SEQ ID NO: 155 is the determined 5' cDNA sequence for SAL-66 SEQ ID NO: 156 is the determined 5' cDNA sequence for SAL-82 SEQ ID NO: 157 is the determined 5' cDNA sequence for SAL-99 SEQ ID NO: 158 is the determined 5' cDNA sequence for SAL-104 SEQ ID NO: 159 is the determined 5' cDNA sequence for SAL-109 SEQ ID NO: 160 is the determined 5' cDNA sequence for SAL-5 SEQ ID NO: 161 is the determined 5' cDNA sequence for SAL-8 SEQ ID NO: 162 is the determined 5' cDNA sequence for SAL-12

SEQ ID NO: 163 is the determined 5' cDNA sequence for SAL-14

SEQ ID NO: 194 is the predicted amino acid sequence for SAL-5 SEQ ID NO: 195 is the predicted amino acid sequence for SAL-8 SEQ ID NO: 196 is the predicted amino acid sequence for SAL-12 SEQ ID NO: 197 is the predicted amino acid sequence for SAL-14 5 SEQ ID NO: 198 is the predicted amino acid sequence for SAL-16 SEQ ID NO: 199 is the predicted amino acid sequence for SAL-23 SEQ ID NO: 200 is the predicted amino acid sequence for SAL-26 SEQ ID NO: 201 is the predicted amino acid sequence for SAL-29 SEQ ID NO: 202 is the predicted amino acid sequence for SAL-32 SEQ ID NO: 203 is the predicted amino acid sequence for SAL-39 SEQ ID NO: 204 is the predicted amino acid sequence for SAL-42 SEQ ID NO: 205 is the predicted amino acid sequence for SAL-43 SEQ ID NO: 206 is the predicted amino acid sequence for SAL-44 SEQ ID NO: 207 is the predicted amino acid sequence for SAL-48 15 SEQ ID NO: 208 is the predicted amino acid sequence for SAL-68 SEQ ID NO: 209 is the predicted amino acid sequence for SAL-72 SEQ ID NO: 210 is the predicted amino acid sequence for SAL-77 SEQ ID NO: 211 is the predicted amino acid sequence for SAL-86 SEQ ID NO: 212 is the predicted amino acid sequence for SAL-88 SEQ ID NO: 213 is the predicted amino acid sequence for SAL-93 SEQ ID NO: 214 is the predicted amino acid sequence for SAL-100 SEQ ID NO: 215 is the predicted amino acid sequence for SAL-105 SEQ ID NO: 216 is a second predicted amino acid sequence for SAL-50

25 DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the therapy of lung cancer. The compositions described herein include polypeptides, fusion proteins and polynucleotides. Also included within the present invention are molecules (such as an antibody or fragment thereof) that bind to the inventive polypeptides. Such molecules are referred to herein as "binding agents."

4. "我们们就是一个人的人们也没有有什么。""我们,我就是一个人的人,我们就是一个人的人,我们也不会有什么。" "我们是我们的人,我们们也是我们就是我们的人,我们就是我们的人,我们就是我们的人,我们们也是我们的人,我们们也是我们的人,我们们也是我们的人,我们们也是我们们

10

15

20

25

of the proteins described herein may be identified in antibody binding assays. Such assays may generally be performed using any of a variety of means known to those of ordinary skill in the art, as described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. For example, a polypeptide may be immobilized on a solid support (as described below) and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A. Alternatively, a polypeptide may be used to generate monoclonal and polyclonal antibodies for use in detection of the polypeptide in blood or other fluids of lung cancer patients. Methods for preparing and identifying immunogenic portions of antigens of known sequence are well known in the art and include those summarized in Paul, Fundamental Immunology, 3rd ed., Raven Press, 1993, pp. 243-247.

The term "polynucleotide(s)," as used herein, means a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases and includes DNA and corresponding RNA molecules, including HnRNA and mRNA molecules, both sense and anti-sense strands, and comprehends cDNA, genomic DNA and recombinant DNA, as well as wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and corresponds to a DNA molecule in a generally one-to-one manner. An mRNA molecule corresponds to an HnRNA and DNA molecule from which the introns have been excised. A polynucleotide may consist of an entire gene, or any portion thereof. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all such operable anti-sense fragments.

The compositions and methods of the present invention also encompass variants of the above polypeptides and polynucleotides.

A polypeptide "variant," as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the antigenic properties of the polypeptide are retained. In a preferred embodiment, variant polypeptides differ from an identified sequence by substitution, deletion or addition of five amino acids or fewer. Such variants may generally be identified by modifying one of the above polypeptide sequences, and evaluating the antigenic properties of the modified polypeptide using, for example, the representative procedures described herein. Polypeptide

SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5X SSC, overnight or, in the event of cross-species homology, at 45°C with 0.5X SSC; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. Such hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode an immunogenic polypeptide that is encoded by a hybridizing DNA sequence.

Two nucleotide or polypeptide sequences are said to be "identical" if the sequence of nucleotides or amino acid residues in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins - Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Resarch Foundaiton, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) Fast and sensitive multiple sequence alignments on a microcomputer CABIOS 5:151-153; Myers, E.W. and Muller W. (1988) Optimal alignments in linear space CABIOS 4:11-17; Robinson, E.D. (1971) Comb. Theor 11:105; Santou, N. Nes, M. (1987) The neighbor joining method. A new method for reconstructing phylogenetic trees Mol. Biol. Evol. 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) Numerical Taxonomy - the Principles and Practice of Numerical Taxonomy. Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) Rapid similarity searches of nucleic acid and protein data banks Proc. Natl. Acad., Sci. USA 80:726-730.

libraries prepared from SCID mice with mouse anti-tumor sera, as described below in Example 4. Examples of cDNA sequences that may be isolated using this technique are provided in SEQ ID NO: 149-181.

A gene encoding a polypeptide described herein (or a portion thereof) may, alternatively, be amplified from human genomic DNA, or from lung tumor cDNA, via polymerase chain reaction. For this approach, sequence-specific primers may be designed based on the nucleotide sequences provided herein and may be purchased or synthesized. An amplified portion of a specific nucleotide sequence may then be used to isolate the full length gene from a human genomic DNA library or from a lung tumor cDNA library, using well known techniques, such as those described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY (1989).

Once a DNA sequence encoding a polypeptide is obtained, the polypeptide may be produced recombinantly by inserting the DNA sequence into an expression vector and expressing the polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polynucleotide that encodes the recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line, such as COS or CHO cells. The DNA sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof. Supernatants from suitable host/vector systems which secrete the recombinant polypeptide may be first concentrated using a commercially available filter. The concentrate may then be applied to a suitable purification matrix, such as an affinity matrix or ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify the recombinant polypeptide.

Such techniques may also be used to prepare polypeptides comprising portions or variants of the native polypeptides. Portions and other variants having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as

extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180, The linker sequence may be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons require to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided that comprise a polypeptide of the present invention together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (see, for example, Stoute et al. New Engl. J. Med., 336:86-91 (1997)).

Polypeptides that comprise an immunogenic portion of a lung tumor protein may generally be used for therapy of lung cancer, wherein the polypeptide stimulates the patient's own immune response to lung tumor cells. The present invention thus provides methods for using one or more of the compounds described herein (which may be polypeptides, polynucleotides or fusion proteins) for immunotherapy of lung cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may be afflicted with disease, or may be free of detectable disease. Accordingly, the compounds disclosed herein may be used to treat lung cancer or to inhibit the development of lung cancer. In a preferred embodiment, the compounds are administered

25

30

ጜ

ordinary skill in the art. The DNA may also be "naked," as described, for example, in published PCT application WO 90/11092, and Ulmer et al., Science 259:1745-1749, 1993, reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

Routes and frequency of administration, as well as dosage, will vary from individual to individual and may parallel those currently being used in immunotherapy of other diseases. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 10 doses may be administered over a 3-24 week period. Preferably, 4 doses are administered, at an interval of 3 months, and booster administrations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that is effective to raise an immune response (cellular and/or humoral) against lung tumor cells in a treated patient. A suitable immune response is at least 10-50% above the basal (i.e., untreated) level. In general, the amount of polypeptide present in a dose (or produced in situ by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 µg. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.01 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a lipid, a wax and/or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and/or magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic glycolide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.

(Natural Killer cells, lymphokine-activated killer cells), B cells, or antigen presenting cells (such as dendritic cells and macrophages) expressing the disclosed antigens. The polypeptides disclosed herein may also be used to generate antibodies or anti-idiotypic antibodies (as in U.S. Patent No. 4,918,164), for passive immunotherapy.

The predominant method of procuring adequate numbers of T-cells for adoptive immunotherapy is to grow immune T-cells in vitro. Culture conditions for expanding single antigen-specific T-cells to several billion in number with retention of antigen recognition in vivo are well known in the art. These in vitro culture conditions typically utilize intermittent stimulation with antigen, often in the presence of cytokines, such as IL-2, and non-dividing feeder cells. As noted above, the immunoreactive polypeptides described herein may be used to rapidly expand antigen-specific T cell cultures in order to generate sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage or B-cells, may be pulsed with immunoreactive polypeptides or transfected with a polynucleotide sequence(s), using standard techniques well known in the art. For cultured T-cells to be effective in therapy, the cultured T-cells must be able to grow and distribute widely and to survive long term in vivo. Studies have demonstrated that cultured T-cells can be induced to grow in vivo and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever et al. Ibid).

The polypeptides disclosed herein may also be employed to generate and/or isolate tumor-reactive T-cells, which can then be administered to the patient. In one technique, antigen-specific T-cell lines may be generated by *in vivo* immunization with short peptides corresponding to immunogenic portions of the disclosed polypeptides. The resulting antigen specific CD8+ CTL clones may be isolated from the patient, expanded using standard tissue culture techniques, and returned to the patient.

Alternatively, peptides corresponding to immunogenic portions of the polypeptides may be employed to generate tumor reactive T cell subsets by selective in vitro stimulation and expansion of autologous T cells to provide antigen-specific T cells which may be subsequently transferred to the patient as described, for example, by Chang et al.

(Crit. Rev. Oncol. Hematol., 22(3), 213, 1996).

at least about 80%, and preferably at least about 90%) of the patients for which lung cancer would be indicated using the full length protein, and that indicate the absence of lung cancer in substantially all of those samples that would be negative when tested with full length protein. The representative assays described below, such as the two-antibody sandwich assay, may generally be employed for evaluating the ability of a binding agent to detect metastatic human lung tumors.

The ability of a polypeptide prepared as described herein to generate antibodies capable of detecting primary or metastatic human lung tumors may generally be evaluated by raising one or more antibodies against the polypeptide (using, for example, a representative method described herein) and determining the ability of such antibodies to detect such tumors in patients. This determination may be made by assaying biological samples from patients with and without primary or metastatic lung cancer for the presence of a polypeptide that binds to the generated antibodies. Such test assays may be performed, for example, using a representative procedure described below. Polypeptides that generate antibodies capable of detecting at least 20% of primary or metastatic lung tumors by such procedures are considered to be useful in assays for detecting primary or metastatic human lung tumors. Polypeptide specific antibodies may be used alone or in combination to improve sensitivity.

Polypeptides capable of detecting primary or metastatic human lung tumors

20 may be used as markers for diagnosing lung cancer or for monitoring disease progression in
patients. In one embodiment, lung cancer in a patient may be diagnosed by evaluating a
biological sample obtained from the patient for the level of one or more of the above
polypeptides, relative to a predetermined cut-off value. As used herein, suitable "biological
samples" include blood, sera, urine and/or lung secretions.

The level of one or more of the above polypeptides may be evaluated using any binding agent specific for the polypeptide(s). A "binding agent," in the context of this invention, is any agent (such as a compound or a cell) that binds to a polypeptide as described above. As used herein, "binding" refers to a noncovalent association between two separate molecules (each of which may be free (i.e., in solution) or present on the surface of a cell or a solid support), such that a "complex" is formed. Such a complex may be free or immobilized (either covalently or noncovalently) on a support material. The ability to bind may generally

be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 µg, and preferably about 100 ng to about 1 µg, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site on the polypeptide is added. The amount of second antibody that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20TM (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is

that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without lung cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for lung cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for lung cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized antibody as the sample passes through the membrane. A second, labeled antibody then binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody may then be performed as described above. In the strip test format, one end of the membrane to which antibody is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second antibody and to the area of immobilized antibody. Concentration of second antibody at the area of immobilized antibody indicates the presence of lung cancer. Typically, the concentration of second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody

of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Monoclonal antibodies of the present invention may also be used as therapeutic reagents, to diminish or eliminate lung tumors. The antibodies may be used on their own (for instance, to inhibit metastases) or coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct reaction

be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used.

Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify lung tumor-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a polynucleotide encoding a lung tumor protein of the present invention. The presence of the amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a polynucleotide encoding a lung tumor protein of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.

The following the state of the

THE RESERVE OF THE SECOND SECO

Company of Fre

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 19 December 1997

PREPARATION OF LUNG TUMOR-SPECIFIC cDNA SEQUENCES USING DIFFERENTIAL DISPLAY RT-PCR

This example illustrates the preparation of cDNA molecules encoding lung tumor-specific polypeptides using a differential display screen.

Tissue samples were prepared from breast tumor and normal tissue of a patient with lung cancer that was confirmed by pathology after removal of samples from the patient. Normal RNA and tumor RNA was extracted from the samples and mRNA was isolated and converted into cDNA using a (dT)₁₂AG (SEQ ID NO: 47) anchored 3' primer. Differential display PCR was then executed using a randomly chosen primer (SEQ ID NO: 48). Amplification conditions were standard buffer containing 1.5 mM MgCl₂, 20 pmol of primer, 500 pmol dNTP and 1 unit of Taq DNA polymerase (Perkin-Elmer, Branchburg, NJ). Forty cycles of amplification were performed using 94 °C denaturation for 30 seconds, 42 °C annealing for 1 minute and 72 °C extension for 30 seconds. Bands that were repeatedly observed to be specific to the RNA fingerprint pattern of the tumor were cut out of a silver stained gel, subcloned into the pGEM-T vector (Promega, Madison, WI) and sequenced. The isolated 3' sequences are provided in SEQ ID NO: 1-16.

> Comparison of these sequences to those in the public databases using the BLASTN program, revealed no significant homologies to the sequences provided in SEQ ID NO: 1-11. To the best of the inventors' knowledge, none of the isolated DNA sequences have previously been shown to be expressed at a greater level in human lung tumor tissue than in normal lung tissue.

aminopeptidase. Clone LT86-9 appears to contain two inserts, with the 5' sequence showing homology to the previously identified antisense sequence of interferon alpha-induced P27. and the 3' sequence being similar to LT86-6. Clone LT86-14 (SEQ ID NO: 30) was found to show some homology to the trithorax gene and has an "RGD" cell attachment sequence and a beta-Lactamase A site which functions in hydrolysis of penicillin. Clones LT86-1, LT86-2, LT86-4, LT86-5 and LT86-10 (SEQ ID NOS: 17, 18, 20, 21 and 26, respectively) were found to show homology to previously identified genes. A subsequently determined extended cDNA sequence for LT86-4 is provided in SEQ ID NO: 66, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 67.

Subsequent studies led to the isolation of five additional clones, referred to as LT86-20, LT86-21, LT86-22, LT86-26 and LT86-27. The determined 5' cDNA sequences for LT86-20, LT86-22, LT86-26 and LT86-27 are provided in SEQ ID NO: 68 and 70-72. respectively, with the determined 3' cDNA sequences for LT86-21 being provided in SEQ ID NO: 69. The corresponding predicted amino acid sequences for LT86-20, LT86-21, LT86-15 22, LT86-26 and LT86-27 are provided in SEQ ID NO: 73-77, respectively. LT86-22 and LT86-27 were found to be highly similar to each other. Comparison of these sequences to those in the gene bank as described above, revealed no significant homologies to LT86-22 and LT86-27. LT86-20, LT86-21 and LT86-26 were found to show homology to previously identified genes.

THE CONTRACT OF THE CONTRACT OF THE PROPERTY O

the first of property of the second of the property of the second of the

我们的原则是**是**我们的,我们就是我们的一个人,我们的一个人,我们就是我们的一个人,我们就是我们的一个人。

garage and the control of the contro

TOWN TO A STATE OF THE STATE OF

on the figure of the office of the first part of the state of the stat

,我们是自身更大,如此他都有工业的政策的专人的理解,但是是有一个企业,并不是我们要的自身的发展,在基本的企业,不是一个的企业。

化硫酸铁铁 网络大腿 计成

5

20

predicted amino acid sequences are provided in SEQ ID NO: 93-101, respectively. L86S-30, L86S-39 and L86S-47 were found to be similar to each other. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to L86S-14. L86S-29 was found to show some homology to a previously identified EST. L86S-6, L86S-11, L86S-34, L86S-39, L86S-47, L86S-49 and L86S-51 were found to show some homology to previously identified genes.

In further studies, a directional cDNA library was constructed using a Stratagene kit with a Lambda Zap Express vector. Total RNA for the library was isolated from two primary squamous lung tumors and poly A+ RNA was isolated using an oligo dT column. Antiserum was developed in normal mice using a pool of sera from three SCID mice implanted with human squamous lung carcinomas. Approximately 700,000 PFUs were screened from the unamplified library with *E. coli* absorbed mouse anti-SCID tumor serum. Positive plaques were identified as described above. Phage was purified and phagemid excised for 180 clones with inserts in a pBK-CMV vector for expression in prokaryotic or eukaryotic cells.

The determined cDNA sequences for 23 of the isolated clones are provided in SEQ ID NO: 126-148. Comparison of these sequences with those in the public database as described above revealed no significant homologies to the sequences of SEQ ID NO: 139 and 143-148. The sequences of SEQ ID NO: 126-138 and 140-142 were found to show homology previously identified human polynucleotide sequences.

PCT/US99/01642 WO 99/38973

tags (ESTs). The sequences of SEQ ID NO: 150, 155 and 159-181 were found to show homology to sequences previously identified in humans.

The state of the second second

e la sestient de groupe de la grecope de la décidit de la communité de la communité de la communité de la comm

ang kepada ang paggarang ang pang ang paggarang ang panggarang ang panggarang ang panggarang panggarang panggar

port the right of the company of the control of the

routhing of his corps of this is a corp of the second of the corps of the second of the corps of the corps of

Springer to the contribution of the contributi

CONTRACTOR OF THE SOLD PRODUCT OF THE SOLD PRO

was programme a series of the season of the series of the

the contraction of the second of the contraction of the contraction of the contraction of the contraction of

and the second of the second o

ranktoga, to traktorak komika oraktarak, in traktario gatoria, en katalia eta katalia eta katalia eta eta eta

and the major is a sufficient of the property of the site of the same of the same in the same of the same

and the control of the second of the control of the

and the second of the second o

43

Example 6

ISOLATION OF DNA SEQUENCES ENCODING LUNG TUMOR ANTIGENS

DNA sequences encoding antigens potentially involved in squamous cell lung

5 tumor formation were isolated as follows:

A lung tumor directional cDNA expression library was constructed employing the Lambda ZAP Express expression system (Stratagene, La Jolla, CA). Total RNA for the library was taken from a pool of two human squamous epithelial lung carcinomas and poly A+ RNA was isolated using oligo-dT cellulose (Gibco BRL, Gaithersburg, MD). Phagemid were rescued at random and the cDNA sequences of isolated clones were determined.

The determined cDNA sequence for the clone SLT-T1 is provided in SEQ ID NO: 102, with the determined 5' cDNA sequences for the clones SLT-T2, SLT-T3, SLT-T5, SLT-T7, SLT-T9, SLT-T10, SLT-T11 and SLT-T12 being provided in SEQ ID NO: 103-110, respectively. The corresponding predicted amino acid sequence for SLT-T1, SLT-T2, SLT-T3, SLT-T10 and SLT-T12 are provided in SEQ ID NO: 111-115, respectively. Comparison of the sequences for SLT-T2, SLT-T3, SLT-T5, SLT-T7, SLT-T9 and SLT-T11 with those in the public databases as described above, revealed no significant homologies. The sequences for SLT-T10 and SLT-T12 were found to show some homology to sequences previously identified in humans.

The sequence of SLT-T1 was determined to show some homology to a PAC clone of unknown protein function. The cDNA sequence of SLT-T1 (SEQ ID NO: 102) was found to contain a mutator (MUTT) domain. Such domains are known to function in removal of damaged guanine from DNA that can cause A to G transversions (see, for example, el-Deiry, W.S., 1997 Curr. Opin. Oncol. 9:79-87; Okamoto, K. et al. 1996 Int. J. Cancer 65:437-41; Wu, C. et al. 1995 Biochem. Biophys. Res. Commun. 214:1239-45; Porter, D.W. et al. 1996 Chem. Res. Toxicol. 9:1375-81). SLT-T1 may thus be of use in the treatment, by gene therapy, of lung cancers caused by, or associated with, a disruption in DNA repair.

Example 7 SYNTHESIS OF POLYPEPTIDES

Polypeptides may be synthesized on a Perkin Elmer/Applied Biosystems

Division 430A peptide synthesizer using FMOC chemistry with HPTU (O-BenzotriazoleN,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence
may be attached to the amino terminus of the peptide to provide a method of conjugation,
binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from
the solid support may be carried out using the following cleavage mixture: trifluoroacetic
acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the
peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be
dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to
purification by C18 reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing
0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following
lyophilization of the pure fractions, the peptides may be characterized using electrospray or
other types of mass spectrometry and by amino acid analysis.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

PCT/US99/01642

- 9. A vaccine comprising the polypeptide of claim 2 and an immune response enhancer.
- 10. The vaccine of claim 9 wherein the immune response enhancer is an adjuvant.
 - 11. A vaccine comprising the polynucleotide of claims 1 or 4 and an immune response enhancer.

10

- 12. The vaccine of claim 11 wherein the immune response enhancer is an adjuvant.
- 13. A pharmaceutical composition for the treatment of lung cancer comprising a polypeptide and a physiologically acceptable carrier, the polypeptide comprising an immunogenic portion of a lung protein or of a variant thereof, wherein said protein comprises an amino acid sequence encoded by a polynucleotide comprising a sequence selected from the group consisting of:
- (a) sequences recited in SEQ ID NO: 12-18, 20, 21, 26, 49, 50, 52, 54, 64, 66, 68, 69, 71, 78, 84, 85, 88, 91, 92, 116-120, 126-138, 140-142, 150, 155 and 159-181;
 - (b) sequences complementary to the sequences of SEQ ID NO: 12-18, 20, 21, 26, 49, 50, 52, 54, 64, 66, 68, 69, 71, 78, 84, 85, 88, 91, 92, 116-120, 126-138, 140-142, 150, 155 and 159-181; and
 - (c) variants of the sequences of (a) and (b).

.25

- 14. A vaccine for the treatment of lung cancer comprising a polypeptide and an immune response enhancer, said polypeptide comprising an immunogenic portion of a lung protein or of a variant thereof, wherein said protein comprises an amino acid sequence encoded by a polynucleotide comprising a sequence selected from the group consisting of:
- 30 (a) sequences recited in SEQ ID NO: 12-18, 20, 21, 26, 49, 50, 52, 54, 64, 66, 68, 69, 71, 78, 84, 85, 88, 91, 92, 116-120, 126-138, 140-142, 150, 155 and 159-181;

PCT/US99/01642

- 21. A pharmaceutical composition comprising a fusion protein according to any one of claims 18-20 and a physiologically acceptable carrier.
- 22. A vaccine comprising a fusion protein according to any one of claims 18-20 and an immune response enhancer.
 - 23. The vaccine of claim 22 wherein the immune response enhancer is an adjuvant.

10

20

30

- 24. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient an effective amount of the pharmaceutical composition of claim 21.
- 25. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient an effective amount of the vaccine of claim 22.
- 26. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient a polynucleotide under conditions such that the polynucleotide enters a cell of the patient and is expressed therein, the polynucleotide having a sequence selected from the group consisting of:
 - (a) a sequence provided in SEQ ID NO: 102;
 - (b) sequences complementary to a sequence of SEQ ID NO: 102; and
 - (c) variants of the sequence of SEQ ID NO: 102.
- 27. A method for detecting lung cancer in a patient, comprising:
 - (a) contacting a biological sample obtained from the patient with a binding agent which is capable of binding to a polypeptide, the polypeptide comprising an immunogenic portion of a lung tumor protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of sequences provided in SEQ ID NO: 1-31, 49-

- (a) sequences recited in SEQ ID NO: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139, 143-149, 151-154 and 156-158;
- (b) the complements of nucleotide sequences recited in SEQ ID NO: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139, 143-149, 151-154 and 156-158; and
- (c) variants of the sequences of (a) and (b).
- 32. A method for inhibiting the development of lung cancer in a patient, comprising administering to the patient a therapeutically effective amount of a monoclonal antibody according to claim 31.
 - 33. The method of claim 32 wherein the monoclonal antibody is conjugated to a therapeutic agent.
 - 34. A method for detecting lung cancer in a patient comprising:
 - (a) obtaining a biological sample from the patient;
 - (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein at least one of the oligonucleotides is specific for a polynucleotide encoding a polypeptide comprising an immunogenic portion of a lung tumor protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of sequences recited in SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181, the complements of said sequences and variants thereof; and
 - (c) detecting in the sample a DNA sequence that amplifies in the presence of the oligonucleotide primers, thereby detecting lung cancer.
- 35. The method of claim 34, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a polynucleotide comprising a sequence selected from SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181.

15

20

provided in SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and - 126-181, the complements of said sequences and variants thereof.

- 44. A method for detecting lung cancer in a patient, comprising:
 - obtaining a biological sample from the patient; (a)
- contacting the biological sample with an oligonucleotide probe specific for a polynucleotide encoding a polypeptide comprising an immunogenic portion of a lung tumor protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of sequences recited in SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181, the complements of said nucleotide sequences and variants thereof; and
 - (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe, thereby detecting lung cancer in the patient.
 - 45. The method of claim 44 wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a polynucleotide having a nucleotide sequence selected from the group consisting of sequences recited in SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181, the complements of said nucleotide sequences and variants thereof.
 - A diagnostic kit comprising an oligonucleotide probe specific for a **46.** polynucleotide encoding a polypeptide comprising an immunogenic portion of a lung tumor protein or a variant thereof, said protein comprising an amino acid sequence encoded by a polynucleotide comprising a nucleotide sequence selected from the group consisting of sequences recited in SEQ ID NO: 1-31, 49-55, 63, 64, 66, 68-72, 78-80, 84-92, 102-110, 116-120 and 126-181, the complements of said sequences and variants thereof.
- The diagnostic kit of claim 46, wherein the oligonucleotide probe 47. comprises at least about 15 contiguous nucleotides of a polynucleotide having a nucleotide 25 sequence selected from the group consisting of sequences recited in SEQ ID NO: 1-31, 49-55,

10_.

pharmaceutically acceptable carrier.

- 55. A composition for the treatment of lung cancer in a patient, comprising T cells proliferated in the presence of a polynucleotide of claim 1, in combination with a pharmaceutically acceptable carrier.
 - 56. A method for treating lung cancer in a patient, comprising the steps of:
- (a) incubating antigen presenting cells in the presence of at least one polypeptide of claim 2; and
 - (b) administering to the patient the incubated antigen presenting cells.
 - 57. A method for treating lung cancer in a patient, comprising the steps of:
- (a) incubating antigen presenting cells in the presence of at least one polynucleotide of claim 1; and
 - (b) administering to the patient the incubated antigen presenting cells.
 - 58. The method of claims 54 or 55 wherein the antigen presenting cells are selected from the group consisting of dendritic cells and macrophage cells.
- 59. A composition for the treatment of lung cancer in a patient, comprising antigen presenting cells incubated in the presence of a polypeptide of claim 2, in combination with a pharmaceutically acceptable carrier.
- 60. A composition for the treatment of lung cancer in a patient, comprising antigen presenting cells incubated in the presence of a polynucleotide of claim 1, in combination with a pharmaceutically acceptable carrier.

SEQUENCE LISTING

```
<110> Corixa Corporation
      <120> COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR
            THEIR USE
      <130> 210121.447PC
      <140> PCT
      <141> 1999-01-28
      <160> 216
      <170> PatentIn Ver. 2.0
      <210> 1
      <211> 339
      <212> DNA
      <213> Homo sapiens
      <400> 1
      gtactcagac aggatagtca tcatgtagca caaagcamat cctgtttcta tacttgtagt 60
      ttgctctcac tcagtggcat ratcattact atacagtgta gaatgttrtt atgtagcata 120
gatgtggggt ctctagcca cagctctsta cctttgtcta gcactcctgt cctcatacct 180
      ragtggcctg tccatcagca tgtttctcat ctactttgct tgtccagtcc actgtggtcc 240
      tcccttgccc tctcccttat gtggcagagt ggaaccagct gtcctgagac ttgagttcaa 300
      catctggttc gcccatytgc atgtttgtgg tctgagtac
                                                                     339
      <210> 2
      <211> 698
    <212> DNA
      <213> Homo sapiens
      <400> 2
      gtactcagac cacgactgca ttttctccac tgctgacggg tctaatacca gctgcttccc 60
      tttcttggag gcagagctng tgaccttgag aaagtgacct gtgaccatca tgtgggtagt 120
      gagetgetge aaggtgteat gggageteee acaeteeatg caetttwaga tetgggaett 180
     gcaggcetca ractgecagg tgtagetege tecattttgg tagecatage gsttgttgga 240
      ggacaactgc aagttggcgt tcttctgaga agaaaaagaa tctgcaaaag atectgtggt 300
      tgaatcgggg gaacacggcc gattgacatc aaaaacgcgt ttcttagccc gggtgaccat 360
     yaatcatgtk gacgctccaa tcttggragg gaatcgaang rantcnccnc caaaacatrc 480
    stttcagraa cettttgare atcetettt tteegtrtee eggmaargee cyttteekg 540
     ggctttgaaa wyagcctsgt tgggttctta aattaccart ccacnwgttg gaattccccg 600
     ggccccctgc ccggktccaa ccaattttgg graaaacccc cncansccgt tkggantgcn 660
     acaachtggn ntttttchtt tcgtgntccc ctngaacc.
                                                                     698°
     <210> 3
     <211> 697
     <212> DNA
     <213> Homo sapiens
     <400> 3
```

gtactcagac ccccaacctc gaacagccag aagacaggtt gtctcctggg ccttggacac 60

```
agcongocag gocattgaag ganaagcaaa gacgaagcga accatototo tocattgtgg 120
gggccaagta gctgcantan ccttcagtcc cagttgcatt gggttaaaga gctcatacat 180
actatgtgtn aggggtacag aagcttttcc tcatagggca tgagctctcc nagagttgac 240
cttttgcctn aacttggggt ttctgtggtt cataaagttn ggatatgtat ttttttcaa 300
atggaanaaa atccgtattt ggcaaaaaga ctccaggggg atgatactgt ccttgccact 360
tacagtccaa angatnttcc ccaaagaata gacatttttt cctctcatca cttctggatg 420
caaaatcttt tattttttc ctttctcgca ccnccccaga ccccttnnag gttnaaccgc 480
ttcccatctc ccccattcca cacgatnttg aattngcann ncgttgntgg tcgggtcccn 540
nccgaaaggg tntttttatt cggggtnctg anttnnnaac cnctnagttg aatccgcggg 600
gcggccnngn gggttnnacc atgntgggga naactncccn ccgcgnttgg aatgccanag 660
ccttgaaant tttcttttgg tcgcccccn gagattc
<210> 4
<211> 712
<212> DNA
<213> Homo sapiens
<400>.4
gtactcagac aaccaatagg tgtgttyctc anatctgaaa cacaaaaaga ttctagctna 60
taatgttsaa tggttgaggg tttaagtgat cttggtatgt tngatttagc agcgatnggc 120
cgggtgcggt ggctcacgca tgtatcccag cactttggga ggccgaggca ggaggatcac 180
ctgaggtcag gagtttgaga ccagcctggc cgacatggtn aaaccccgtc tctactanga 240
atacanaaat tagcccgggc atagtggcgc gtgcctrtga cctcsgctac tttggggatt 300
ctcctgagga agaattgctt gaactcaggg aagtggargt ttgcagtgag cttaaatcaa 360
gccactggca ctcccagct gggktaacag agccamgact ctkgccgaaa aaaaaraama 420
cgacggagaa nmagntctgt tattccatgg gaaattkgaa tttccttcyt tkaaatatct 480
taaaatnggt cctcctwaaa aaagttcggc tggggcccgk tggctcacat tttkttaycc 540
cyccccttt tggggarggc caarggccgg kttgawtnnc ccttgagggg ccanaactcc 600
agnaaccrgn cccgggccar smgwkgkstr armccctttc cyyccmaraa aawwcsmaaa 660
wwttycccsc cygsykggct ggkasckgtt myyyyygmtm csyagcttgc tt 712
<210> 5
<211> 679
<212> DNA
<213> Homo sapiens
gtactcagac cacctcacat gcagggtnag aaacatggag tgtgcggcag catcctcctc 60
acatecettt gtgageaegg etgeteegga ataetgaeea tetgggetag eaegaeetaa 120
cagagggttc tgcaggatgt gctattttaa agcagetggg tgcaacttgt gaaaacggga 180
atctngaage agaacatgtn atcagegatg getgggattg gtggacagga ttgacaggag 240
tatttgagge tetaceagge etgtetacag gacagettea tegaagggae atttttaac 300
ctgttatttt anatnocaca tatnttttt aatgctnaag catacaggtt gaatttctgg 360
atograacta ctagtgactt ctgaggttta cagttngaat atgttctcnn aggtttatca 420
agtinitita tigatgaing graatciaca cototggaag cigingaatg igaaaaagat 480
nentneanct gaccagtttg nagggeacte tettetggna agnaateegn ccaaaaaaaa 540
tgtttcnagg gggcntgggg ggtttaaaaa aatgtttctn ttnccntaaa aatgtttacc 600
conctattga aaaaatgggg gtcgnggggg gcttnaaatc cccnanttnt gaatnttnta 660
tccggaanct tggtttccc
<210> 6
<211> 369
<212> DNA
<213> Homo sapiens
```

```
<400> 6
tcagtccagt catgggtcct ataagagaag tcactctgtg agtttccatg gaggaagaaa 60
aagcttcatt tctttaccct gcagcaacag cggagggagg gagagcctat cttctttgca 120
aattcattaa ctttgtggtt gaagggagca gcgtcngaaa ctgctttagc acagtgggag 180
gaaaacaaac agattcatct ccggaaacca aaggaaaggg tragtgggtt tttattagcc 240
agctgtatcc tagatggtca atttccagtg gatgaataca ccttacgtac gtttctcttg 300
cttcctacct nggcctgatc agctnggcac ttraatcatt ccgtnggggt wgctgtnaca 360
ctggactga
  <210> 7
<211> 264
<212> DNA
<213> Homo sapiens
<400> 7
tgctggatra gggatggggc acgggagcac agatmgactt taactgcccc cacgtintcm 60
aggaaaggat tacaggcgtg agccactgcg cccggcctct tctccacttt cataggttcc 120
agtetetggt tettettet eagtttgttg tttttgette ttaaatmatg gagatnagaa 180
tgaacactac actoggaato aggaagooot gootggogoo totgtoacot gtotagggo 240
ttcttctcac tgagtcatcc agca
<210> 8
                         <211> 280
7:
<213> Homo sapiens
                        医抗性病 医三角样 人名英格兰人英基格兰
                                  <400> 8
acctcaactg cccanaacan aactgttgta caagatttga ggatttaaca atatttcaca 60
tgaaatattt cagacctacg ngagggctta aagacnaatt aaatgagcac engtgtgccc 120
accgccccna ttaagaatta gagcaagcag tgaggtgaag cettgteett gettttaaca 180
tagaaagtga tccaaattca ccaaacttga cttnnggttt tgcagtgtgg cctcctgatt 240
ctagacnetg gegaaacatt tgatgggeaa aaaaaaaaa
<210> 9
<211> 449
<212> DNA
<213> Homo sapiens
                        San All Control of the Control
tcgtcaactc caggatggct ttgaaaatna atggacacag atctctcctg ttttgatrat 60
ntgcagtgct natgactggc tttgcagttn attttgattc aggcaacaga tgttcctttt 120
ggttccctgt ctcccatggg cgtcatttca tgttgtcctc tgccttcccc cagatattct 180
aagttcagga cacaagcttc tggcccatgc agagcagagg ccatgagggg tcacagcatg 240
ggtacgggag gaaacactgg gctnacccag atnctggact tgagtcttgc ctctgctgct 300
tgctgcacag cttctgtcat ggtgctaaac ctgtgacctg cctcacaggc ttagagcatg 360
cccgtagaag tactctnaac taaratgctt tccacaaatq agatggtttc atgaaaactt 420
Caaatagagg gcctgggcaa aaaaaaaaa
<210> 10
<211> 538
<212> DNA
<213> Homo sapiens
<400> 10
```

ttttttttt ttcccaaagg cctcaraaca ctagtcttct aattccaagc agaaagttac 60

-

4

```
atccgccggg atacatgcca cttggtttga taaatcaaaa tacagcatcc ttcagatccc 120
 tttgctgagc aatacaatta tttgtatatg ttactttttt ttctgtttgg ctnaaagatt 180
 tgatatgage tgaggaaaat gaageentta etgetatnag atetnateee tttecaceae 240
 ctttcaggga tnttggcact gcayatattc agaattcccc nnagtcgctn gtgataaaaa 300
 tgtcttcaga gatggcagaa tatgtttcct ttggtacatg ttcattaaaa atatacacgt 360
 geteactact gtggatatgt atgtnttgae egatnaeaca ggetgattta gggaagagat 420
 aaaagcacac ttngaattta ttagcctttc accnagacta anattctgaa attaagaatg 480
 tattccttgg tcaacaattt tcctcttctc ttagccctct tacattgtan tggactga 538
                                                                   an 一种型型 2000年 1997年 1997年
 <210> 11
                                                                      The state of the state of
 <211> 543
                                                                 1. 电线电路 建氯化磷酸 化氯化二甲基
 <212> DNA
                                                                  en and the expension for
 <213> Homo sapiens
                                                                  The light a grid to the more and a track and a second process to
                                                                1.5 五百分十二十分 各种 人工 等等 一个 数据 人名特尔 (1)
 <400> 11
 ttttttttt ttgcccacag ctgccatctt tgtgtgataa ggccaacctt ctatgggaat 60
caaccctcgc catcccagca aatcccctct ctcccttctc atgggagtgc cttgtattca 120
 tcaggcatct gggacttgat gtgggtntgg gatttgaaat cagagcacct nggtctctst 180
 caccattctn tcacttatta gctctnacct tgggtnaata cctgccttag tgtcntaggt 240
 acaatatgaa tattgtctat ttctcaggga ttgcaatgac nagtnnatna gtgcatgaga 300
 gggtaaaacc acagggtact ccgctcctcc naagaatgga gaattttttc tagaagccca 360
 nathigetty gaaggitgge cacenagage enhaatette tittatithe cactgaange 420
 ctaagaggna attctgaact catccccnna tgacctctcc cgaatmagaa tatctctggc 480
acttaccata ttttcttgcc ctcttccact tacnaaactc ctttattcct taacnggacg/540
 aaa
 <210> 12
 <211> 329
 <212> DNA
 <213> Homo sapiens
 <400> 12
cgatgacttg ggcagtgagt gggcctcctg ccaggtggca gggcacagct tagaccaaac 60
ccttggcctc cccctctgc agstacctct gaccaagaag gaaactagca agcctatgct 120
ggcaagacca taggtggggt gctgggaatc ctcggggccg gctggcaccc actcctggtg 180
ctcaagggag agaccactt gttcagatgc atrggcctca ggcggttcaa ggcrgtctta 240
gagccacaga gtcaaataaa aatcaatttt gagagaccac agcacctgct gctttgatcg 300
tgatgttcaa ggcaagttgc aagtcatcg
                                               North Artistance of the state of the state of the second
<211> 314
                                       。1960年1月6日,1月15日 1961年 - 1月1日 - 1月1日
<212> DNA
                                Contraction to the contraction of the contraction o
<213> Homo sapiens
                                                                                               <400> 13
cgatgacttg caccogggag ctgtgacagt ggcctggaag cagatggcag ccccgtcaag 60
gegggagtgg agaccaccaa accetecaaa cagagcaaca actagtaege ggecageage 120
tacctgagee tgacgeega geagtggaag teccaeagaa getaeagetg eeaggteacg 180
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttcata ggttcccnac: 240.
tetnacecca eccaeggag cetgganetg cangateceg ggggaagggt etetetecee 300
atcccaagtc atcg
                                                                                                                                                                       *314
<210> 14...
```

<210> 14 <211> 691 <212> DNA

```
<213> Homo sapiens
                                      <400> 14
  cgattacttg cacaatgcan attagaaccc aaatgaaggg tacaacccag atcttctggc 60
  ttccagttca gtgctgctgg gtttttctta ctaaaccaaa acaatkaaga gcatagaagg 120
  gaagagaaga ataaagtcta ttttggtctt tggtagcchg ggtaangaga atgctstcac 180
  tctacnagaa aacccnaagt gaacccggct aatcaggacc gtgcttggga agggagcagg 240
  ggcattacct ttcaacacca gaggttcttt gccttctctc tgcagggact cgargactat 300
  gtgaagtggc tgggarggca tcactcggct tggttcattg gtrttctcat cataaactat 360
  natttetttg gaaaaagate etettgaaag arteettgee tteeetacag gaaatcaagt 420
  ctaggacagt gatcttgccc ctgcttgcas tctccgccgg ctgatcttat csgscccagt 480
  tkatgtgsam cgctccttgg atrtkactct tgttttwctc cvaggaaggg gcytgcmagt 540
  convenate amssegecc ttaactccgg screetnamy notegectsc ratteteget 600
 ycytcttcyt ttgsccmggt tcktcnaaac cacttngttr aattccccgg sccgcctkgc 660
  nggtycaacc wttttgggaa mamcycccc c
          <210> 15
                                     <211> 355
  <213> Homo sapiens
                                                                                             a manga garapatan dari da kalendaran kalendaran musukan dibibibi
  <400> 15
                               acctgaactg tgtgttgaag agtgatgtcc tgctgcctgg agctcaagtc actactgatg 60
accetecta tetcceacae ctaettnect ccategatet gacteagace aatetetet 120
tcyacceteg getettacet ttgacnaagt etecegttga gagtactace gaaccaccag 180
 cagttcgagc ctctnaagag cgtctaagcg atggggatat atatttactg gagaatgggc 240
 tcaacctctt cctctgggtg ggagcaageg tccagcaggg tgttgtccag agccttttca 300
 gcgtctcctc cttcagtcag atcaccagtg gtntgagtgt tctgccagtt caggt
 <210> 16
  <211> 522
 <212> DNA
 <213> Homo sapiens
                                                                             <400> 16
                        化二氯化二羟二甲二烷二烷
                                                                                                  29 to 15 to 1
                                                                                * to the " * * * * *
 tcagtccagt gaggtggaag acttcgaggc tcgtgggagc cgcttctcca agtctgctga 60
 tgagagacag cgcatgctgg tgcagcgtan ggacgaactc ctccagcaag ctcgcagacg 120
tttcttgaac aaaagttctg aagatgatgc ggcctcagag agcttcctcc cctcggaagg 180
 tgcgtcctct gaccccgtga ccctncgtcg aangatgctg gctgccgccg cggaacggan 240
 gcttcagaag cagcagacct cctngcgctc ccttgccttc ctcagctgcc tcctgcgccc 300
 tgtgcccggc tgactggagg aggcctgtcc aattctgccc gccccatgga aaagcgggct 360
 tgactgcatt gccgctgtat naaagcatgt ggtcttacag tgttnggacn gctnatnaat 420
 ttnatcctnc tntgtaatac ttcctatgtg acatttctct tccccttgga aacactgcan 480
 attttaactg tgagtttgat ctcttctngt gttactggac tg
 <211> 317
                                  化分离性化 化二十二十二烷基 化自己 电电路 自身的 化二氯化物 经净额 黃旗 电电影 医电影管
                             and the control of th
 <212> DNA
 <213> Homo sapiens to the late of the same of the same
                                                                           <400> 17
gtgtcgcgaa ttcgcggtgg tgctaagaaa aggaagaaga agtcttacac cactcccaag 60
aaggataagc accagagaaa gaaggttcag ccggccgtcc tgaaatatta taaggtggat 120
gagaatggca aaattagttg ccttcgtcga gagtgcccct ctgatgaatg tggtgctggg 180
gtgtttatgg caagtcactt tgacagacat tattgtggca aatgttgtct gacccactgt 240
```

```
ttcaactaac cagaagacaa gtaactgtat gagttaatta aagacatgaa ctaaaaaaaa 300
  aaaaaaaaa actcgag
                                                                                                                                                           317
  <210> 18
  <211> 392
  <212> DNA
  <213> Homo sapiens
  <400> 18
  tggagatttc taatgaggtg aggaagttcc gtacattgac agaattgatc ctcgatgctc 60
  aggaacatgt taaaaatcct tacaaaggca aaaaactcaa gaaacaccca gacttcccca 120
  agaageeet gaceettat tteegettet teatggagaa gegggeeaag tatgegaaac 180
  tccaccctca gatgagcaac ctggacctga ccaagattct gtccaagaaa tacaaggagc 240
  gagcgaaacc tggcccgatt cagggaggat cacccccacc ttatccagaa tgccaagaat 360
  cggacatccc agagaagccc caagaccccc cg
                                                                                                                                                          392
  <210> 19
  <211> 2624
  <212> DNA
                                              <213> Homo sapiens
                                     THE SHOW IN THE RESERVE OF THE SHOW IN THE
                                                                             TONE ME TO TRANS ME WEST TO THE TONE TO T
  <400> 19
  gaaacagtga gaaggagatt cotgtgotca atgagotgoo agtooccatg gtggooccgct 60
  acattegeat aaaceeteag teetgette ataacgggag catetgeatg aggatggaga 120
  tettgggetg eccaetgeeg gateetaata actattatea eegaegtaat gagatgaeea 180
  ccacggatga cctggatttt aagcaccaca actattagga aatgcgccag ttgatgaagg 240
  ttgtcaatga aatgtgcccc aatattacca ggatttacaa cattggcaaa agccaccagg 300
 gcctgaaatt gtatgcggta gagatctctg accatcctgg ggaacatgaa gttggtgagc 360
  ccgagttcca ctacatcgca ggggcccacg gcaatgaggt tctgggacga gaactgctgc 420
  tgctgctgct gcacttcctc tgccaggaat actcggcgca gaacgcacgc atcgtccgct 480
  tggtggagga gactcgaatc cacattctac cctccctcaa tcctgatggc tatgagaagg 540
 cctatgaagg aggttccgag ttgggaggct ggtccctggg acgttggacc catgatggca 600
 tcgatatcaa caacaacttt ccggatttaa actcgctgct ctgggaggca gaggaccagc 660
 agaatgcccc aaggaaggtc cccaaccact acattgccat ccctgagtgg tttctgtctg 720
 agaatgccac agtggccaca gagaccagag ccgtcatcgc ctggatggag aagatcccgt 780
 ttgtgctggg aggcaaccta caggggggtg agctggtcgt ggcatacccc tatgacatgg 840
 tgcggtccct gtggäagacc caggagcaca ccccaacacc tgatgatcat gtgttccgct 900
 ggetggegta tteetaegee tecaeteace geeteatgae agatgeeagg aggegagtgt 960
gccacacgga agattttcag aaggaggagg gcaccgtcaa tggggcttcc tggcacacag 1020
 tggctggaag tctaaacgat ttcagctace tccatacaaa ctgctttgag ctgtccatct 1080
 acgtgggctg tgataaatac ccacacgaga gcgagctgcc ggaggaatag gagaataacc 1140
 gggagtetet gattgtgtte atggageagg tteategagg cateaaagge atagtgagag 1200
 atttacaagg gaaagggatt tcaaatgctg tcatctctgt ggaaggtgtt aaccatgaca 1260
 tccggacage cagegatggg gattactgge gtctactgaa ccctggcgaa tatgtggtca 1320
 cagccaaggc ggaaggcttt atcacttcca ccaagaactg catggttggc tatgatatgg 1380
 gagctactcg gtgtgacttc accctcacaa agaccaacct ggctaggata agagaaatta 1440
 tggagacatt tgggaagcag cctgtcagcc taccctccag gcgcctgaag ctgcggggac 1500
ggaaaaggcg gcagcgtggg tgaccctgtc ggacacttga gacatacccc agaccgtgca 1560
 aataaaaatc cactccagta gtaactctgt agcaggcttt ccctgttgtt ttgactgtaa 1620
ttcaagagac actcaggagc atacctgcat ggcttggctg accccaaagg ggagggctgg 1680
tggctcaggg tgttttgttt tttgtttttt gtttttcct ttgttctcat ttatccaaat 1740
accttgaaca gagcagcaga gaaaggccgg tggcagtgag ggaattaatt cagtgagtca 1800
gtctgagatt ctaaaaaggg tgcttgacca ctggccagga agggaaatca ggccttcccc 1860
catttgcgtg acattcaagc ttcccagtgc atttgcaagt ggcacagttg acattgcagc 1920
```

```
acccagggaa tcctttgccc cagatgttat catttgagat gctcttatgc agcctaagaa 1980
aatccatcct ctctggcccc aggggacaag ccaagctgct atgtacacac tcggtgttct 2040
attgacaata gaggcattta ttaccaagtg tgcatcgctg agtcctaaat cagctctgtt 2100
cctttttcca acaaagcttg tcttcctaag agcagacaga agtggagagc acccaagaat 2160
gagtgctggg cagcagaccc tgggggaggg ggcttgctat cccagaaagc ccctaaaccc 2220
tttgctgctc cattagccct ggggtgagga gagccagaca tgttaggagg ccagagcagt 2280
cagtcagggc atcttggaaa agaccttgaa ggaagcaaac cctgggttcc ttttgctcca 2340
gaatgtgaga gctccaagtt ggccccaatc aggaggggag taatgatgaa catacagacg 2400
gccacatctt gccaatcaag catcatctga tgaaaaagaa agcaatctta ggattacctg 2460
ggacacgtca gtctgggaga ggtggttgaa tcattgtgta agggaatagt gtatctaatc 2520
tgtgttgatc ctgctgcctt gttgacctgg agagaatgaa acaaacaac acataaacaa 2580
ataaagcaaa tggtaagatt aaaaaaaaaaa aaaaaaaact cgag
<210> 20
<211> 488
<212> DNA
<213> Homo sapiens
<400> 20
ctttcaaccc gcgctcgccg gctccagccc cgcgcgcccc caccccttgc cctcccggcg 60
gctccgcagg gtgaggtggc tttgaccccg ggttgcccgg ccagcacgac cgaggaggtg 120
gctggacagc tggaggatga acggagaagc cgactgcccc acagacctgg aaatggccgc 180
ccccagaggc caagaccgtt ggtcccagga agacatgctg actttgctgg aatgcatgaa 240
gaacaacett ceatecaatg acageteeca gtteaaaace acceaacae acatggaceg 300
ggaaaaagtt gcattgaaag acttttctgg agacatgtgc aagctcaaat gggtcgagat 360
Ctctaatgag gtgaggaagt tccgtacatt gacagaattg atcctcgata ctcaggaaca 420
tgtttaaaat ccttacaaag gcaaaaaatc aagaaacacc ccgacttccc cgagaaagcc 480
cctaaccc
<210> 21
<211> 391
<212> DNA
<213> Homo sapiens
<400> 21
atggaattgt ggttttctct ttgggatcaa tggtctcaga aattccagag aagaaagctg 60
tggcgattgc tgatgctttg ggcaaaatcc ctcagacagt cctgtggcgg tacactggaa 120
CCCgaccate gaatettgcg aacaacacga tacttgttca gtggctacce caaaacgate 180
tgcttggtca cccaatgacc cgtgccttta tcacccatgc tagttcccat ggtgttaatg 240
aaagcatatg caatggcgtt cccatggtga tgataccctt atttggtgat cagatggaca 300
atgcaaagcg cagggagact aagggagctg gagtgaccct gaatgttctg gagatgactt 360
ctgaagatet agaagatget etgaagagea g
<210> 22
<211> 1320
<212> DNA
<213> Homo sapiens
<400> 22
aatctgctgg gaatttcttg ggttgacagc tcttggatcc ctattttgaa cagtggtagt 60
gtcctggatt actttcaga aagaagtaat cctttttatg acagaacatg taataatgaa 120
gtggtcaaaa tgcagaggct aacattagaa cacttgaatc agatggttgg aatcgagtac 180
atcettttge atgeteaaga geeeattett tteateatte ggaageaaca geggeagtee 240
cctgcccaag ttatcccact agctgattac tatatcattg ctggagtgat ctatcaggca 300
ccagactigg gatcagttat aaactctaga gtgcttactg cagtgcatgg tattcagtca 360
```

```
gcttttgatg aagctatgtc atactgtcga tatcatcctt ccaaagggta ttggtggcac 420
ttcaaagatc atgaagagca agataaagtc agacctaaag ccaaaaggaa agaagaacca 480
agetetattt tteagagaea aegtgtggat getttaettt tagaeeteag acaaaaattt 540
ccacccaaat ttgtgcagct aaagcctgga gaaaagcctg ttccagtgga tcaaacaaag 600
aaagaggcag aacctatacc agaaactgta aaacctgagg agaaggagac cacaaagaat 660
gtacaacaga cagtgagtgc taaaggcccc cctgaaaaac ggatgagact tcagtgagta 720
ctggacaaaa gagaagcctg gaagactcct catgctagtt atcatacctc agtactgtgg 780
ctcttgaget ttgaagtact ttattgtaac cttcttattt gtatggaatg cgcttatttt 840
ttgaaaggat attaggccgg atgtggtggc tcacgcctgt aatcccagca ctttgggagg 900
ccatggcggg tggatcactt gaggtcagaa gttcaagacc agcctgacca atatggtgaa 960
accccgtctc tactaaaaat acaaaaatta gccgggcgtg gtggcgggcg cccatagtcc 1020
cagctactcg ggaggctgag acaggagact tgcttgaacc cgggaggtgg aggttgccct 1080
gagctgatca tcctgctgtt gcactccagc ttgggcgaaa gagcgagact ttgtctctat 1140
aaagaaggaa agatattatt cccatcatga tttcttgtga atatttgtaa tatgttttt 1200
gtaacctttc ctttcccgga cttgagcaac ctacacactc acatgtttaa tggtagatat 1260
<210> 23
                     <211> 633
<212> DNA
                               <213> Homo sapiens
                                345
                                人名英巴里尔 医牙上皮 医隐藏 帶
<400> 23
                    CONTRACTOR OF
ctaagggcag tgaaggtgaa aaccetetea eggteecagg gagggagaag gaaggeatge 60
tgatgggggt taagccgggg gaggacgcat cggggcctgc tgaagacctt gtgagaagat 120
ctgagaaaga tactgcagct gttgtctcca gacagggcag ctccctgaac ctctttgaag 180
atgtgcagat cacagaacca gaagctgage cagagtecaa gtetgaaccg agacctecaa 240
tttcctctcc gagggctccc cagaccagag ctgtcaagcc ccgacttcat cctgtgaagc 300
caatgaatge caeggeeace aaggttgeta actgeagett gggaactgee accateateg 360
gtgagaactt gaacaatgag gtcatgatga agaaatacag cccctcggac cctgcatttg 420
catatgegea getgaeceae gatgagetga tteagetggt ceteaaacag aaggaaacga 480
taágcaágaa ggagttccag gtccgcgagc tggaagacta cattgacaac ctgctcgtca 540
gggtcatgga agaaaccccc aatatcctcc gcatcccgac tcaggttggc aaaaaagcag 600
gaaagatgta aattagcaga aaaaaaactc gag
<210> 24
<211> 1328
                      化分类性 电连接 医水体 医神经神经 人名英格兰人姓氏人名英语
<213> Homo sapiens
           TO THE OBJECT OF THE PROPERTY OF THE PARTY.
graaacgctc tcggaattat ggcggcggtg gatatccgag acaatctgct gggaatttct 60
tgggttgaca gctcttggat ccctattttg aacagtggta gtgtcctgga ttactttca 120
gaaagaagta atcetttta tgacagaaca tgtaataatg aagtggtcaa aatgcagagg 180
ctaacattag aacacttgaa tcagatggtt ggaatcgagt acatcctttt gcatgctcaa 240
gagcccattc ttttcatcat tcggaagcaa cagcggcagt cccctgccca agttatccca 300
ctagctgatt actatatcat tgctggagtg atctatcagg caccagactt gggatcagtt 360
ataaactcta gagtgcttac tgcagtgcat ggtattcagt cagcttttga tgaagctatg 420
tcatactgtc gatatcatcc ttccaaaggg tattggtggc acttcaaaga tcatgaagag 480
caagataaag tcagacctaa agccaaaagg aaagaagaac caagctctat ttttcagaga 540
caacgtgtgg atgctttact tttagacctc agacaaaaaa tttccaccca aatttgtgca 600
gtggatcaaa caaagaaaga ggcagaacct ataccagaaa ctgtaaaacc tgaggagaag 660
```

gagaccacaa agaatgtaca acagacagtg agtgctaaag gcccccctga aaaacggatg 720 agacttcagt gagtactgga caaaagagaa gcctggaaga ctcctcatgc tagttatcat 780

acctcagtac tgtggctctt gagctttgaa gtactttatt gtaaccttct tatttgtatg 840

```
gaatgcgctt attttttga aaggatatta ggccggatgt ggtggctcac gcctgtaatc 900
ccagcacttt gggaggccat ggcgggtgga tcacttgagg tcagaagttc aagaccagcc 960
tgaccaatat ggtgaaaccc cgtctctact aaaaatacaa aaattagccg ggcgtggtgg 1020
cgggcgccca tagtcccagc tactcgggag gctgagacag gagacttgct tgaacccggg 1080
aggtggaggt tgccctgagc tgattatcat gctgttgcac tccagcttgg gcgacagagc 1140
gagactttgt ctcaaaaaag aagaaaagat attattccca tcatgatttc ttgtgaatat 1200
ttgtgatatg tcttctgtaa cctttcctct cccggacttg agcaacctac acactcacat 1260
gtttactggt agatatgttt aaaagcaaaa taaaggtatt tgtataaaaa aaaaaaaaa 1320
                                                                  1328
aaactcga
<210> 25
<211> 1758
<212> DNA
<213> Homo sapiens
<400> 25
gtttttttt tttttttt aaagagttgc aacaattcat ctttatttct tattttcctc 60
tggagatgca gaatttggta tatttcaccc caagtatatt tgggatagtt ggctcctcgc 120
tgggtcagga tggctgggtg ccttctccc tggcatggtt ctcttctctg cagggcgagg 180
ggcagggagc tagtaaaacc tcgcaatgac agccgcaatg gcagacccaa tggagcccag 240
gatgaacttg gtcaatccgg agagtccagt tgctcccagt gactgcagag tagccacaag 300
gctgcccgag gcaactccac ccccattggc aatggccgcc gcggacatca tcttggctgc 360
tatggaggac gaggcgattc ccgccgcagt gaagcccatg gcactgagtg gcggcggtgg 420
atatccgaga caatctgctg ggaatttctt gggttgacag ctcttggatc cctattttga 480
acagtggtag tgtcctggat tacttttcag aaagaagtaa tcctttttat gacagaacat 540
gtaataatga agtggtcaaa atgcagaggc taacattaga acacttgaat cagatggttg 600
gaatcgagta catccttttg catgctcaag agcccattct tttcatcatt cggaagcaac 660
ageggeagte ecetgeecaa gttateecae tagetgatta etatateatt getggagtga 720
tctatcaggc accagacttg ggatcagtta taaactctag agtgcttact gcagtgcatg 780
gtattcagtc agcttttgat gaagctatgt catactgtcg atatcatcct tccaaagggt 840
attggtggca cttcaaagat catgaagagc aagataaagt cagacctaaa gccaaaagga 900
aagaagaacc aagctctatt tttcagagac aacgtgtgga tgctttactt ttagacctca 960
gacaaaaatt tccacccaaa tttgtgcage taaageetgg agaaaageet gttecagtgg 1020
atcaaacaaa gaaagaggca gaacctatac cagaaactgt aaaacctgag gagaaggaga 1080
ccacaaagaa tgtacaacag acagtgagtg ctaaaggccc ccctgaaaaa cggatgagac 1140
ttcagtgagt actggacaaa agagaagcct ggaagactcc tcatgctagt tatcatacct 1200
cagtactgtg gctcttgagc tttgaagtac tttattgtaa ccttcttatt tgtatggaat 1260
gcgcttattt tttgaaagga tattaggccg gatgtggtgg ctcacgcctg taatcccagc 1320
actttgggag gccatggcgg gtggatcact tgaggtcaga agttcaagac cagcctgacc 1380
aatatggtga aaccccgtct ctactaaaaa tacaaaaatt agccgggcgt ggtggcgggc 1440
gcccatagtc ccagctactc gggaggctga gacaggagac ttgcttgaac ccgggaggtg 1500
gaggttgccc tgagctgatt atcatgctgt tgcactccag cttgggcgac agagcgagac 1560
tttgtctcaa aaaagaagaa aagatattat tcccatcatg atttcttgtg aatatttgtt 1620
atatgtcttc tgttaccttt cctccccgg aattgagcaa cctacacact cacatgttta 1680
ctggtagata tgtttaaaag caaataaagg tattggtata tattgcttca aaaaaaaaa 1740
                                                                  1758
aaaaaaaaa aactcgag
<210> 26
<211> 493
<212> DNA
<213> Homo sapiens
<400> 26
gaggcgagcg gcagggcctg gtggcgagag cgcggctgtc actgcgcccg agcatcccag 60
agettteega geggaegage eggeegtgee gggeateece ageetegeta eeetegeage 120
```

```
acacgtcgag ccccgcacag gcaagggtcc ggaacttagc ccaaagcacg tttcccctgg 180
 cagcgcagga gacgcccggc cgcgcgccgg cgcacgcccc cctctcctcc tttgttccgg 240
 gggtcggcgg ccgctctcct gccagcgtcg ggatctcggc cccgggaggc gggccgtcgg 300
 gcgcagccgc gaagattccg ttggaactga cgcagagccg agtgcagaag atctgggtgc 360
 ccgtggacca caggccctcg ttgcccagat cctgtgggcc aaagctgacc aactcccccg 420
 ccgtcttcgt catggtgggc:ctccccgcc cggggcaaga cctacttctc cacgaaagct 480
                                                                   493
tactcgctgc ctc
 <210> 27
 <211> 1331
 <212> DNA
 <213> Homo sapiens
 <400> 27
 ggtggatatc cgagacaatc tgctgggaat ttcttgggtt gacagctctt ggatccctat 60
 tttgaacagt ggtagtgtcc tggattactt ttcagaaaga agtaatcctt tttatgacag 120
 aacatgtaat aatgaagtgg tcaaaatgca gaggctaaca ttagaacact tgaatcagat 180
 ggttggaatc gagtacatcc ttttgcatgc tcaagagccc attctttca tcattcggaa 240
 gcaacagcgg cagtcccctg cccaagttat cccactagct gattactata tcattgctgg 300
 agtgatctat caggcaccag acttgggatc agttataaac tctagagtgc ttactgcagt 360
 gcatggtatt cagtcagctt ttgatgaagc tatgtcatac tgtcgatatc atccttccaa 420
 agggtattgg tggcacttca aagatcatga agagcaagat aaagtcagac ctaaagccaa 480
aaggaaagaa gaaccaagct ctattttca gagacaacgt gtggatgctt tacttttaga 540
 cctcagacaa aaatttccac ccaaatttgt gcagctaaag cctggagaaa agcctgttcc 600
 agtggatcaa acaaagaaag aggcagaacc tataccagaa actgtaaaac ctgaggagaa 660
ggagaccaca aagaatgtac aacagacagt gagtgctaaa ggcccccctg aaaaacggat 720
 gagacttcag tgagtactgg acaaaagaga agcctggaag actcctcatg ctagttatca 780
 tacctcagta ctgtggctct tgagctttga agtactttat tgtaaccttc ttatttgtat 840
 ggaatgcgct tatttttga aaggatatta ggccggatgt ggtggctcac gcctgtaatc 900
ccagcacttt gggaggccat ggcgggtgga tcacttgagg tcagaagttc aagaccagcc 960
 tgaccaatat ggtgaaaccc cgtctctact aaaaatacaa aaattagccg ggcgtggtgg 1020
 cgggcgccca tagtcccagc tactcgggag gctgagacag gagacttgct tgaacccggg 1080
 aggragaggt racctgage regarratear gergregeae recagerrag gegacagage 1140
 gagactttgt ctcaaaaaaa gaagaaaaga tattattccc atcatgattt cttgtgaata 1200
 tttgttatat gtcttctgta acctttcctc tcccggactt gagcaaccta cacactcaca 1260
 tgtttactgg tagatatgtt taaaagcaaa ataaaggtat tggtataaaa aaaaaaaaa 1320
                                                                   1331
 aaaaactcga g
 <210> 28
 <211> 1333
 <212> DNA
 <213> Homo sapiens
 the second of the second
 <400> 28
 cggcggtgga tatccgagac aatctgctgg gaatttcttg ggttgacagc tcttggatcc 60
 ctattttgaa cagtggtagt gtcctggatt acttttcaga aagaagtaat cctttttatg 120
 acagaacatg taataatgaa gtggtcaaaa tgcagaggct aacattagaa cacttgaatc 180
 agatggttgg aatcgagtac atccttttgc atgctcaaga gcccattctt ttcatcattc 240
 ggaagcaaca gcggcagtcc cctgcccaag ttatcccact agctgattac tatatcattg 300
 ctggagtgat ctatcaggca ccagacttgg gatcagttat aaactctaga gtgcttactg 360
 cagtgcatgg tattcagtca gcttttgatg aagctatgtc atactgtcga tatcatcctt 420-
 ccaaagggta ttggtggcac ttcaaagatc atgaagagca agataaagtc agacctaaag 480
 ccaaaaggaa agaagaacca agctctattt ttcagagaca acgtgtggat gctttacttt 540
 tagacctcag acaaaaattt ccacccaaat ttgtgcagct aaagcctgga gaaaagcctg 600
 ttccagtgga tcaaacaaag aaagaggcag aacctatacc agaaactgta aaacctgagg 660
```

```
agaaggagac cacaaagaat gtacaacaga cagtgagtgc taaaggcccc cctgaaaaac 720
ggatgagact tcagtgagta ctggacaaaa gagaagcctg gaagactcct catgctagtt 780
atcatacctc agtactgtgg ctcttgagct ttgaagtact ttattgtaac cttcttattt 840
gtatggaatg cgcttatttt ttgaaaggat attaggccgg atgtggtggc tcacgcctgt 900
aatcccagca ctttgggagg ccatggcggg tggatcactt gaggtcagaa gttcaagacc 960
agcetgacca atatggtgaa acceegtete tactaaaaat acaaaaatta geegggegtg 1020
gtggcggcg cccatagtcc cagctactcg ggaggctgag acaggagact tgcttgaacc 1080
cgggaggtgg aggttgccct gagctgatta tcatgctgtt gcactccagc ttgggcgaca 1140
gagcgagact ttgtctcaaa aaagaagaaa agatattatt cccatcatga tttcttgtga 1200
atatttgtga tatgtcttct gtaacctttc ctctcccgga cttgagcaac ctacacactc 1260
acatgtttac tggtagatat gtttaaaagc aaaataaagg tatttgtata aaaaaaaaa 1320
aaaaaaactc gag
<210> 29
<211> 813
<212> DNA
<213> Homo sapiens
<400> 29
ctgagctgca cttcagcgaa ttcacctcgg ctgtggctga catgaagaac tccgtggcgg 60
accgagacaa cagccccagc tcctgtgctg gcctcttcat tgcttcacac atcgggtttg 120
actggcccgg ggtctgggtc cacctggaca tcgctgctcc agtgcatgct ggcgagcgag 180
ccacaggett tggggtgget etectactgg etettttgg ccgtgcetce gaggacccge 240
tgctgaacct ggtatccccg ctggactgtg aggtggatgc ccaggaaggc gacaacatgg 300
ggcgtgactc caagagacgg aggctcgtgt gagggctact tcccagctgg tgacacaggg: 360
ttccttacct cattttgcac tgactgattt taagcaattg aaagattaac taactcttaa 420
gatgagtttg gcttctcctt ctgtgcccag tggtgacagg agtgagccat tcttctcta 480
gaagcagett aggggettgg tggggtetgg agaaaattgt cacagacece ataggtetee 540
atotgtaago totgtocott gtoctocaco otggtottta gagocacoto aggtoaccot 600
ctgtagtgag tgtacttcct gacccaggcc cttgctcaag ctggggctcc ctggggtgtc 660
taaccagccc tgggtagatg tgactggctg ttagggaccc cattctgtga agcaggagac 720
cctcacagct cccaccaacc cccagttcac ttgaagttga attaaatatg gccacaacat 780
aaaaaaaaa aaaaaaaaa aaaaaaactc gag
<210> 30
<211> 1316
<212> DNA
<213> Homo sapiens
<400> 30 ·
caggegeeca greatggeec aagagacage accacegret ggeecagret caaggggrea 60
cagtccaatc atagaaaaga tggaaaaaag gacatgtgcc ctgtgccctg aaggccacga 120
gtggagtcaa atatactttt caccatcagg aaatatagtt gctcatgaaa actgtttgct 180
gtattcatca ggactggtgg agtgtgagac tcttgatcta cgtaatacaa ttagaaactt 240
tgatgtcaaa tctgtaaaga aagagatctg gagaggaaga agattgaaat gctcattctg 300
taacaaagga ggcgccaccg tggggtgtga tttatggttc tgtaagaaga gttaccacta 360
tgtctgtgcc aaaaaggacc aagcaattct tcaagttgat ggaaaccatg gaacttacaa 420
attattttgc ccagaacatt ctccagaaca agaagaggcc actgaaagtg ctgatgaccc 480
aagcatgaag aagaagag gaaaaaacaa acgcctctca tcaggccctc ctgcacagcc 540
aaaaacgatg aaatgtagta acgccaaaag acatatgaca gaagagcctc atggtcacac 600
agatgcagct gtcaaatctc cttttcttaa gaaatgccag gaagcaggac ttcttactga 660
actatttgaa cacatactag aaaatatgga ttcagttcat ggaagacttg tggatgagac 720
tgcctcagag tcggactatg aagggatcga gaccttactg tttgactgtg gattatttaa 780
agacacacta agaaaattcc aagaagtaat caagagtaaa gcttgtgaat gggaagaaag 840
gcaaaggcag atgaagcagc agettgagge aettgeagae ttacaacaaa gettgtgete 900
```

```
attrcaagaa aatggggacc tggactgctc aagttctaca tcaggatcct tgctacctcc 960
tgaggaccac cagtaaaagc tgttcctcag gaaaactgga tggggcctcc atgttctcca 1020
aggatcgagg aagtcttcct gcctaccctg cccaccccag tcaagggcag caacaccaga 1080
gctttgctca gccttaaatg gaatcttaga gctttctctt gcttctgcta ctcctacaga 1140
tggcctcatc atggtctcca ctcagtatta ataactccat cagcatagag caaactcaac 1200
actgtgcatt gcacactgtt accatgggtt tatgctcact atcatatcac attgccaata 1260
<210> 31
<211> 1355
<212> DNA
<213> Homo sapiens
                                                         <400> 31
eggeggtgga tateegagae aatetgetgg gaatttettg ggttgaeage tettggatee:60
ctattttgaa cagtggtagt gtcctggatt acttttcaga aagaagtaat cctttttatg 120
acagaacatg taataatgaa gtggtcaaaa tgcagaggct aacattagaa cacttgaatc 180
agatggttgg aatcgagtac atccttttgc atgctcaaga gcccattctt ttcatcattc 240
ggaagcaaca gcggcagtcc cctgcccaag ttatcccact agctgattac tatatcattg 300
ctggagtgat ctatcaggca ccagacttgg gatcagttat aaactctaga gtgcttactg 360
cagtgcatgg tattcagtca gcttttgatg aagctatgtc atactgtcga tatcatcctt 420
ccaaagggta ttggtggcac ttcaaagatc atgaagagca agataaagtc agacctaaag 480
ccaaaaggaa agaagaacca agctctattt ttcagagaca acgtgtggat gctttacttt 540
tagacctcag acaaaaattt ccacccaaat ttgtgcagct aaagcctgga gaaaagcctg 600
ttccagtgga tcaaacaaag aaagaggcag aacctatacc agaaactgta aaacctgagg 660
agaaggagac cacaaagaat gtacaacaga cagtgagtgc taaaggcccc cctgaaaaac 720
ggatgagact tcagtgagta ctggacaaaa gagaagcctg gaagactcct catgctagtt 780
atcatacctc agtactgtgg ctcttgagct ttgaagtact ttattgtaac cttcttattt 840
gtatggaatg cgcttatttt ttgaaaggat attaggccgg atgtggtggc tcacgcctgt 900
aatcccagca ctttgggagg ccatggcggg tggatcactt gaggtcagaa gttcaagacc 960
agcctgacca atatggtgaa accccgtctc tactaaaaat acaaaaatta gccgggcgtg 1020
gtggcggcg cccatagtcc cagctactcg ggaggctgag acaggagact tgcttgaacc 1080
cgggaggtgg aggttgcct gagctgatta tcatgctgtt gcactccagc ttgggcgaca 1140
gaacgagact ttgtctcaaa aaaagaagaa aagatattat tcccatcatg atttcttgtg 1200
aatatttgtt atatgtcttc tggtaacctt tcctctcccg gacttgaagc aacctcacac 1260
actcacatgt ttactggtag atatgtttta aaagcaaaat aaaggtattt gtttttccaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaac tcgag
<210> 32
<211> 80
<212> PRT
<213> Homo sapiens
<400> 32
Val Ser Arg Ile Arg Gly Gly Ala Lys Lys Arg Lys Lys Lys Ser Tyr
                                    10
                                                 15 million 15 million 10 million
Thr Thr Pro Lys Lys Asp Lys His Gln Arg Lys Lys Val Gln Pro Ala 🗆 🚟
           · 20 ·
                                                25
Val Leu Lys Tyr Tyr Lys Val Asp Glu Asn Gly Lys Ile Ser Cys Leu
               40
                                               45
Arg Arg Glu Cys Pro Ser Asp Glu Cys Gly Ala Gly Val Phe Met Ala
```

55 ·

60

Ser His Phe Asp Arg His	Tyr Cys Gly	Lys Cys Cys	Leu Thr His Cys
70	-		——————————————————————————————————————
			·
The second secon			•
ng filiphone ka ta n mengan mengan berangan berangan			
	the same of the same		
Strain Section 1987	and the second		· · · · · · · · · · · · · · · · · · ·
	•		
<210> 33			
<211> 130			•
<212> PRT			
	•		
<213> Homo sapiens			
•		•	
<400> 33			
Glu Ile Ser Asn Glu Val	Arg Lys Phe	Arg Thr Leu	Thr Glu Leu Ile
. 1		_	
•			- · · · ·
	· ·		• .
Leu Asp Ala Gln Glu His	_		– – .
1. (14) 1. July 10 18 18 120 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	. JASAN 25 2 25		TO BE 30,00, and magazine of
James The same of the same of the same			·
Lys Lys His Pro Asp Phe	•		·
			_
2 (4) 1 (4) (4) (4) (4) (4) (4) (4) (4) (4) (4)			· · · · · · · · · · · · · · · · · · ·
一分享 自然人口的人的 医皮肤坏坏			
Phe Phe Met Glu Lys Arg	Ala Lys Tyr	Ala Lys Leu	His Pro Gln Met
191. 1 4 50 20t			•
	_		
	.* .		
Ser Asn Leu Asp Leu Thr	-		. —
3.65 (\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		75	
Pro Glu Lys Lys Lys Met		· ·	
		_	-
		•	
Thr Gly Val Arg Ala Lys	_		•
48 1 100 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	105	A	SEC 110 1 1 10 10 10 10 10 10 10 10 10 10 1
Control of the state of the seguination			
Pro Tyr Pro Glu Cys Gln		•	
			_
115	120		1/25 (1) (2) (2) (1) (1) (2) (4) (4) (4) (4) (4)
•			
Pro Pro			
130			5 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
130			
<210> 34			
<211> 506	-		; ;
<212> PRT 1122 1 AT 119- 114	7 - 1 - 2 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	· · · · · · · · · · · · · · · · · · ·	Burgar Burgar Burgar Baran
SALAS FRI	and the second s		
<213> Homo sapiens			
<213> Homo sapiens	* \$25		
<213> Homo sapiens	* \$25		
<213> Homo sapiens <400> 34			
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile		Asn Glu Leu	Pro Val Pro Met
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5	Pro Val Leu	Asn Glu Leu 10	Pro Val Pro Met 15
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5	Pro Val Leu	Asn Glu Leu 10	Pro Val Pro Met
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5	Pro Val Leu	Asn Glu Leu 10	Pro Val Pro Met 15
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5 Val Ala Arg Tyr Ile Arg	Pro Val Leu	Asn Glu Leu 10	Pro Val Pro Met 15 Phe Asp Asn Gly
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5 Val Ala Arg Tyr Ile Arg 20	Pro Val Leu I Ile Asn Pro (Asn Glu Leu 10 Gln Ser Trp	Pro Val Pro Met 15 Phe Asp Asn Gly 30
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5 Val Ala Arg Tyr Ile Arg 20	Pro Val Leu I Ile Asn Pro (25	Asn Glu Leu 10 Gln Ser Trp	Pro Val Pro Met 15 Phe Asp Asn Gly 30
<213> Homo sapiens <400> 34 Asn Ser Glu Lys Glu Ile 1 5 Val Ala Arg Tyr Ile Arg 20	Pro Val Leu I Ile Asn Pro (25	Asn Glu Leu 10 Gln Ser Trp	Pro Val Pro Met 15 Phe Asp Asn Gly 30

2.17

1 11 1

		35					40					45			
Asn	Asn 50	Tyr	Tyr	His	Arg	Arg 55	Asn	Glu	Met	Thr	Thr		Asp	Asp	Leu
Asp 65	Phe	Lys	His	His	Asn 70		Lys	Glu	Met	Arg 75	Gln	Leu	Met		Val 80
Val	Asn	Glu	Met	Cys 85	Pro	Asn	Ile	Thr	Arg 90	Ile				95	Lys -
Ser	His	Gln	Gly 100	Leu	Lys	Leu	Tyr	Ala 105	Val	Glu	Ile		110		Pro
Gly	Glu	His 115	Glu	Val	Gly	Glu	Pro 120	Glu	Phe	His	Tyr	125	Ala		
His	Gly 130	Asn	Glu	Val	Leu	Gly 135	Arg	Glư	Leu	Leu	Leu 140	Leu	Leû	Leu	His
145				. ,	150		Ala	7.2		155		. ?	gilt sa	A (e	160
	,· .	· .		165	1 %-		.*		170			· .		175	## 5.87
			180	· ,	e, *		Gly	185			٠.	· 	190	€ z.	jer yjel
		195						<u>. = ,</u>	<u></u>	ķ	مين د داد.	205			
	210					215					220	-			Arg
225					230					235				<u>.</u> .	Glu- 240
				245					250				-	255	Glů
		•	260				:*	265	٠			٤.	270		Va1
		275	•				280		•			285			Glu
	290					295			-	•	300				Ser
305					310				-	315	• •			•	Cys 320
His	Thr	Glu	Asp	Phe-	Gln	Lys	Glu	Glu	Gly 330	Thr	Val	Asn	Gly	Ala 335	Ser

Trp His Thr Val Ala Gly Ser Leu Asn Asp Phe Ser Tyr Leu His Thr 340 **350**. Asn Cys Phe Glu Leu Ser Ile Tyr Val Gly Cys Asp Lys Tyr Pro His 355 360 365 Glu Ser Glu Leu Pro Glu Glu Trp Glu Asn Asn Arg Glu Ser Leu Ile 375 Val Phe Met Glu Gln Val His Arg Gly Ile Lys Gly Ile Val Arg Asp 390 385 Leu Gln Gly Lys Gly Ile Ser Asn Ala Val Ile Ser Val Glu Gly Val 405 410 Asn His Asp Ile Arg Thr Ala Ser Asp Gly Asp Tyr Trp Arg Leu Leu 430 425...-420 Asn Pro Gly Glu Tyr Val Val Thr Ala Lys Ala Glu Gly Phe Ile Thr 445 Ser Thr Lys Asn Cys Met Val Gly Tyr Asp Met Gly Ala Thr Arg Cys 450 grant and the 455 state of the 460 ft. Asp Phe Thr Leu Thr Lys Thr Asn Leu Ala Arg Ile Arg Glu Ile Met 470 475 465 Callery A. Commercial Glu Thr Phe Gly Lys Gln Pro Val Ser Leu Pro Ser Arg Arg Leu Lys Leu Arg Gly Arg Lys Arg Arg Gln Arg Gly <210> 35 <211> 96... <212> PRT <213> Homo sapiens <400> 35 Met Asn Gly Glu Ala Asp Cys Pro Thr Asp Leu Glu Met Ala Pro 10 5 1 Arg Gly Gln Asp Arg Trp Ser Gln Glu Asp Met Leu Thr Leu Leu Glu . 30 25 . 20 Cys Met Lys Asn Asn Leu Pro Ser Asn Asp Ser Ser Gln Phe Lys Thr Thr Gln Thr His Met Asp Arg Glu Lys Val Ala Leu Lys Asp Phe Ser

55

70

Gly Asp Met Cys Lys Leu Lys Trp Val Glu Ile Ser Asn Glu Val Arg

50

65

60 ·

75

80

```
Lys Phe Arg Thr Leu Thr Glu Leu Ile Leu Asp Thr Gln Glu His Val
                 85
                                      90
                                                          95
```

<210> 36...

<211>, 129

<212> PRT

<213> Homo sapiens

8 139 W

Gly Ile Val Val Phe Ser Leu Gly Ser Met Val Ser Glu Ile Pro Glu 1 10

Lys Lys Ala Val Ala Ile Ala Asp Ala Leu Gly Lys Ile Pro Gln Thr 20

Control of the second Val Leu Trp Arg Tyr Thr Gly Thr Arg Pro Ser Asn Leu Ala Asn Asn 35 40

Thr Ile Leu Val Gln Trp Leu Pro Gln Asn Asp Leu Leu Gly His Pro 50 60

Met Thr Arg Ala Phe Ile Thr His Ala Ser Ser His Gly Val Asn Glu 65 70

the boundary of the second of Ser Ile Cys Asn Gly Val Pro Met Val Met Ile Pro Leu Phe Gly Asp 85 90

Gln Met Asp Asn Ala Lys Arg Arg Glu Thr Lys Gly Ala Gly Val Thr 100 105 110

Leu Asn Val Leu Glu Met Thr Ser Glu Asp Leu Glu Asp Ala Leu Lys 115 120

Ser

<210> 37

<211> 238

<212> PRT

<213> Homo sapiens

<400> 37

Asn Leu Leu Gly Ile Ser Trp Val Asp Ser Ser Trp Ile Pro Ile Leu 10

Asn Ser Gly Ser Val Leu Asp Tyr Phe Ser Glu Arg Ser Asn Pro Phe 20 25 30

Tyr Asp Arg Thr Cys Asn Asn Glu Val Val Lys Met Gln Arg Leu Thr 35

Leu Glu His Leu Asn Gln Met Val Gly Ile Glu Tyr Ile Leu Leu His 50 55 60

Ala Gln Glu Pro Ile Leu Phe Ile Ile Arg Lys Gln Gln Arg Gln Ser . Pro Ala Gln Val Ile Pro Leu Ala Asp Tyr Tyr Ile Ile Ala Gly Val Ile Tyr Gln Ala Pro Asp Leu Gly Ser Val Ile Asn Ser Arg Val Leu Thr Ala Val His Gly Ile Gln Ser Ala Phe Asp Glu Ala Met Ser Tyr Cys Arg Tyr His Pro Ser Lys Gly Tyr Trp Trp His Phe Lys Asp His Glu Glu Gln Asp Lys Val Arg Pro Lys Ala Lys Arg Lys Glu Glu Pro ···· 155 **150** Ser Ser Ile Phe Gln Arg Gln Arg Val Asp Ala Leu Leu Leu Asp Leu Arg Gln Lys Phe Pro Pro Lys Phe Val Gln Leu Lys Pro Gly Glu Lys Pro Val Pro Val Asp Gln Thr Lys Lys Glu Ala Glu Pro Ile Pro Glu Thr Val Lys Pro Glu Glu Lys Glu Thr Thr Lys Asn Val Gln Gln Thr · 220 Val Ser Ala Lys Gly Pro Pro Glu Lys Arg Met Arg Leu Gln <210> 38 <211> 202 <212> PRT <213> Homo sapiens <400> 38 Lys Gly Ser Glu Gly Glu Asn Pro Leu Thr Val Pro Gly Arg Glu Lys Glu Gly Met Leu Met Gly Val Lys Pro Gly Glu Asp Ala Ser Gly Pro Ala Glu Asp Leu Val Arg Arg Ser Glu Lys Asp Thr Ala Ala Val Val Ser Arg Gln Gly Ser Ser Leu Asn Leu Phe Glu Asp Val Gln Ile Thr Glu Pro Glu Ala Glu Pro Glu Ser Lys Ser Glu Pro Arg Pro Pro Ile

Ser Ser Pro Arg Ala Pro Gln Thr Arg Ala Val Lys Pro Arg Leu His
90 95

Pro Val Lys Pro Met Asn Ala Thr Ala Thr Lys Val Ala Asn Cys Ser 100 105 110

Leu Gly Thr Ala Thr Ile Ile Gly Glu Asn Leu Asn Asn Glu Val Met
115 120 125

Met Lys Lys Tyr Ser Pro Ser Asp Pro Ala Phe Ala Tyr Ala Gln Leu 130 135 140

Thr His Asp Glu Leu Ile Gln Leu Val Leu Lys Gln Lys Glu Thr Ile 145 150 155 160

Ser Lys Lys Glu Phe Gln Val Arg Glu Leu Glu Asp Tyr Ile Asp Asn 165 170 175

Leu Leu Val Arg Val Met Glu Glu Thr Pro Asn Ile Leu Arg Ile Pro 180 185 190

Thr Gln Val Gly Lys Lys Ala Gly Lys Met
195 200

<210> 39

<211> 243

<212> PRT

<213> Homo sapiens

<400> 39

Val Asn Ala Leu Gly Ile Met Ala Ala Val Asp Ile Arg Asp Asn Leu 1 5 10 15

Leu Gly Ile Ser Trp Val Asp Ser Ser Trp Ile Pro Ile Leu Asn Ser 20 25 30

Gly Ser Val Leu Asp Tyr Phe Ser Glu Arg Ser Asn Pro Phe Tyr Asp
35 40 45

Arg Thr Cys Asn Asn Glu Val Val Lys Met Gln Arg Leu Thr Leu Glu
50 55 60

His Leu Asn Gln Met Val Gly Ile Glu Tyr Ile Leu Leu His Ala Gln
65 70 75 80

Glu Pro Ile Leu Phe Ile Ile Arg Lys Gln Gln Arg Gln Ser Pro Ala 85 90 95

Gln Val Ile Pro Leu Ala Asp Tyr Tyr Ile Ile Ala Gly Val Ile Tyr 100 105 110

Gln Ala Pro Asp Leu Gly Ser Val Ile Asn Ser Arg Val Leu Thr Ala 115 120 125

.Va]	13	s Gl O	y Il	e Gl	n Sei	135		As _l	p Gl	u Ala	14	• *	т Тут	Cys	Arg	
Tyr 145		s Pr	o Se	r Ly	s Gl ₃ 150		Trp	Tr	o Hi	s Phe 15		s Ası) His	Glu	Glu 160	e 1 - 12 se
Glr	As _l	р Іу	ș Va	1 Arg		Lys	Ala	Lys	170	_	g Glu	ı Glu	Pro	Ser 175	Ser	
Ile	Phe	e Gl	n Arg	g Glr O	n Arg	y Val	Asp	Ala 185		ı Lev	ı Lev	ı Ası	190	•••	Gln;	i suri
Lys	Ile	19	r Thi	Glr	ı Ile	Cys	Ala 200	Val	. Asp	Gln	Thr	Lys 205		Glu	Ala	i sai
Glu	210	o Ile	e Pro	Glu	1 Thr	Val 215	Lys	Pro	Gl u	ı, Glu	Lys 220	-	: Thr	Thr	Lys	
Asn 225	Va]	Glr	ı Glr	Thr	Val 230		Ala	Lys	Gly	Pro 235		G1u	Lys	Arg	Met	i di wi
Arg	Leu	Glr	1	•		•	≈ , i.				· .	; ·3	\$ 1 · 1			
<21 <21	0> 4 1> 2 2> P 3> H	45 RT	sapi	ens				٠	-						1 2 4 1 2 4 2 2 2 2 1 2 1	
	0> 4 Ala		Asp	Ile	Arg	Asp	Asn	•			Ile	Ser	Trp	_ :	Asp	
Ser	Ser	Trp	Ile 20		Ile	Leu	Asn	, ,	Gly		Val				Phe	
Ser	Glu	Arg 35	Ser	· '	Pro		Tyr 40	Asp				Asn		Glu	Val	
Val	Lys 50	Met	Gln	Arg	Leu		Leu				•	,		Val	Gly	· •.
Ile 65	Glu	Tyr	Ile	Leu	Leu 70		•	Gln	Glu		Ile			Ile		
Arg	Lys	Gln	Gln	Arg 85	Gln	Ser	Pro	Ala	Gln 90	-	-		Leu	Ala		ا د میاک
lyr	Tyr	Ilė	Ile 100	Ala	Gly	Val	•	Tyr 105		Ala	Pro			Gly		
7al						,						'		.:		

Phe Asp Glu Ala Met Ser Tyr Cys Arg Tyr His Pro Ser Lys Gly Tyr 140 135 130 Trp Trp His Phe Lys Asp His Glu Glu Gln Asp Lys Val Arg Pro Lys 160 150 155 145 Ala Lys Arg Lys Glu Glu Pro Ser Ser Ile Phe Gln Arg Gln Arg Val 170 175 165 Asp Ala Leu Leu Asp Leu Arg Gln Lys Phe Pro Pro Lys Phe Val 190 185 180 Gln Leu Lys Pro Gly Glu Lys Pro Val Pro Val Asp Gln Thr Lys Lys 205 195 200 Glu Ala Glu Pro Ile Pro Glu Thr Val Lys Pro Glu Glu Lys Glu Thr 220 210 215 Thr Lys Asn Val Gln Gln Thr Val Ser Ala Lys Gly Pro Pro Glu Lys 225 230 Arg Met Arg Leu Gln 245 <210> 41 <211> 163 <212> PRT <213> Homo sapiens <400> 41 Gly Glu Arg Gln Gly Leu Val Ala Arg Ala Arg Leu Ser Leu Arg Pro 10 5 Ser Ile Pro Glu Leu Ser Glu Arg Thr Ser Arg Pro Cys Arg Ala Ser 20 25 Pro Ala Ser Leu Pro Ser Gln His Thr Ser Ser Pro Ala Gln Ala Arg 35 40 Val Arg Asn Leu Ala Gln Ser Thr Phe Pro Leu Ala Ala Gln Glu Thr 55 50 and the state of Pro Gly Arg Ala Pro Ala His Ala Pro Leu Ser Ser Phe Val Pro Gly 70 Val Gly Gly Arg Ser Pro Ala Ser Val Gly Ile Ser Ala Pro Gly Gly -177 Gly Pro Ser Gly Ala Ala Ala Lys Ile Pro Leu Glu Leu Thr Gln Ser 105 100 Arg Val Gln Lys Ile Trp Val Pro Val Asp His Arg Pro Ser Leu Pro 120 125 115 Arg Ser Cys Gly Pro Lys Leu Thr Asn Ser Pro Ala Val Phe Val Met

135 130 Val Gly Leu Pro Arg Pro Gly Gln Asp Leu Leu Leu His Glu Ser Leu 150 145 160 Leu Ala Ala <210> 42 <211> 243 <212> PRT <213> Homo sapiens <400> 42 Val Asp Ile Arg Asp Asn Leu Leu Gly Ile Ser Trp Val Asp Ser Ser 15 Trp Ile Pro Ile Leu Asn Ser Gly Ser Val Leu Asp Tyr Phe Ser Glu . 20 30 Arg Ser Asn Pro Phe Tyr Asp Arg Thr Cys Asn Asn Glu Val Lys 35 40 Met Gln Arg Leu Thr Leu Glu His Leu Asn Gln Met Val Gly Ile Glu 50 55 60 Tyr Ile Leu Leu His Ala Gln Glu Pro Ile Leu Phe Ile Ile Arg Lys 65 70 80 Gln Gln Arg Gln Ser Pro Ala Gln Val Ile Pro Leu Ala Asp Tyr Tyr 🕔 85 90 Ile Ile Ala Gly Val Ile Tyr Gln Ala Pro Asp Leu Gly Ser Val Ile * 100 105 110 Asn Ser Arg Val Leu Thr Ala Val His Gly Ile Gln Ser Ala Phe Asp 115 Glu Ala Met Ser Tyr Cys Arg Tyr His Pro Ser Lys Gly Tyr Trp Trp 130 Jan 19 19 19 135 His Phe Lys Asp His Glu Glu Gln Asp Lys Val Arg Pro Lys Ala Lys 155 145 160 Arg Lys Glu Glu Pro Ser Ser Ile Phe Gln Arg Gln Arg Val Asp Ala 165 170 Leu Leu Leu Asp Leu Arg Gln Lys Phe Pro Pro Lys Phe Val Gln Leu 180 190 Lys Pro Gly Glu Lys Pro Val Pro Val Asp Gln Thr Lys Lys Glu Ala 200 195 205 Glu Pro Ile Pro Glu Thr Val Lys Pro Glu Glu Lys Glu Thr Thr Lys 215 220

Asn Val Gln Gln Thr Val Ser Ala Lys Gly Pro Pro Glu Lys Arg Met 225 230 235 240

Arg Leu Gln

<210> 43

<211> 244

<212> PRT

<213> Homo sapiens

<400> 43

Ala Val Asp Ile Arg Asp Asn Leu Leu Gly Ile Ser Trp Val Asp Ser

1 10 15

Ser Trp Ile Pro Ile Leu Asn Ser Gly Ser Val Leu Asp Tyr Phe Ser 25__ 30

Glu Arg Ser Asn Pro Phe Tyr Asp Arg Thr Cys Asn Asn Glu Val Val

40
45

Lys Met Gln Arg Leu Thr Leu Glu His Leu Asn Gln Met Val Gly Ile
50 60

Glu Tyr Ile Leu Leu His Ala Gln Glu Pro Ile Leu Phe Ile Ile Arg 65 70 75 75 80

Lys Gln Gln Arg Gln Ser Pro Ala Gln Val Ile Pro Leu Ala Asp Tyr
85 90 95

Tyr Ile Ile Ala Gly Val Ile Tyr Gln Ala Pro Asp Leu Gly Ser Val 100 105: 110

Ile Asn Ser Arg Val Leu Thr Ala Val His Gly Ile Gln Ser Ala Phe 115 120 125

Asp Glu Ala Met Ser Tyr Cys Arg Tyr His Pro Ser Lys Gly Tyr Trp

130
135
140

Trp His Phe Lys Asp His Glu Glu Gln Asp Lys Val Arg Pro Lys Ala 145

Lys Arg Lys Glu Glu Pro Ser Ser Ile Phe Gln Arg Gln Arg Val Asp

Ala Leu Leu Leu Asp Leu Arg Gln Lys Phe Pro Pro Lys Phe Val Gln
180 185 185 185 190 190 190

Leu Lys Pro Gly Glu Lys Pro Val Pro Val Asp Gln Thr Lys Lys Glu
195 200 205

Ala Glu Pro Ile Pro Glu Thr Val Lys Pro Glu Glu Lys Glu Thr Thr 210 220

. . .

Lys Asn Val Gln Gln Thr Val Ser Ala Lys Gly Pro Pro Glu Lys Arg 225 230 235 240

Met Arg Leu Gln

<210> 44

<211> 109

<212> PRT

<213> Homo sapiens

<400> 44

Glu Leu His Phe Ser Glu Phe Thr Ser Ala Val Ala Asp Met Lys Asn 1 5 10 15

Ser Val Ala Asp Arg Asp Asn Ser Pro Ser Ser Cys Ala Gly Leu Phe 20 25 30

Ile Ala Ser His Ile Gly Phe Asp Trp Pro Gly Val Trp Val His Leu
35 40 45

Asp Ile Ala Ala Pro Val His Ala Gly Glu Arg Ala Thr Gly Phe Gly 50 55 60

Val Ala Leu Leu Leu Ala Leu Phe Gly Arg Ala Ser Glu Asp Pro Leu 65 70 75 80

Leu Asn Leu Val Ser Pro Leu Asp Cys Glu Val Asp Ala Gln Glu Gly
85 90 95

Asp Asn Met Gly Arg Asp Ser Lys Arg Arg Arg Leu Val 100 105

<210> 45

<211> 324

<212> PRT

<213> Homo sapiens

Arg Arg Pro Val Met Ala Gln Glu Thr Ala Pro Pro Cys Gly Pro Val
1 5 10 15

Ser Arg Gly Asp Ser Pro Ile Ile Glu Lys Met Glu Lys Arg Thr Cys
20 25 30

Ala Leu Cys Pro Glu Gly His Glu Trp Ser Gln Ile Tyr Phe Ser Pro
35 40 45

Ser Gly Asn Ile Val Ala His Glu Asn Cys Leu Leu Tyr Ser Ser Gly 50 55 60

Leu Val Glu Cys Glu Thr Leu Asp Leu Arg Asn Thr Ile Arg Asn Phe 65 70 75 80

PCT/US99/01642 WO 99/38973

Asp Val Lys Ser Val Lys Lys Glu Ile Trp Arg Gly Arg Arg Leu Lys 85 90 95

Cys Ser Phe Cys Asn Lys Gly Gly Ala Thr Val Gly Cys Asp Leu Trp 100 105 110

Phe Cys Lys Lys Ser Tyr His Tyr Val Cys Ala Lys Lys Asp Gln Ala 115 120 125

医肾髓 建氯化氯化氯化甲磺酸甲基甲基化二甲基 Ile Leu Gln Val Asp Gly Asn His Gly Thr Tyr Lys Leu Phe Cys Pro 130 135

图 "大狗,"他一个"快吃"。\$P\$ (1) Glu His Ser Pro Glu Glu Glu Glu Ala Thr Glu Ser Ala Asp Asp Pro 145 150 155 160

人名 化无色色色 医多色色 医多色 医髓 化二十二烷 医二氯磺胺 医二氯磺胺二氯磺胺二氯 Ser Met Lys Lys Arg Gly Lys Asn Lys Arg Leu Ser Ser Gly Pro 165

- 第4 1 1 1 2 A 4 4 4 + 1 1 1 Pro Ala Gln Pro Lys Thr Met Lys Cys Ser Asn Ala Lys Arg His Met 180 185 190

on the state of the contract o Thr Glu Glu Pro His Gly His Thr Asp Ala Ala Val Lys Ser Pro Phe 195 200 ~

Leu Lys Lys Cys Gln Glu Ala Gly Leu Leu Thr Glu Leu Phe Glu His 210 215 220

2017、1217年,12日本中国,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,1917年,19 Ile Leu Glu Asn Met Asp Ser Val His Gly Arg Leu Val Asp Glu Thr 225 230 235 240

(1997) (1998) (1997) (1997) (1997) Ala Ser Glu Ser Asp Tyr Glu Gly Ile Glu Thr Leu Leu Phe Asp Cys 250

on the first of the beat as to the way have been as the first of the Gly Leu Phe Lys Asp Thr Leu Arg Lys Phe Gln Glu Val Ile Lys Ser 260 265 270

Lys Ala Cys Glu Trp Glu Glu Arg Gln Arg Gln Met Lys Gln Gln Leu 280 **275**.

大大 化氯基二硫磺二酚 化二酚基宁 人名德 法证据

不过 化磺胺二甲基二甲二甲磺胺 的复数重新 化玻璃 人名德里克 化多次 电线性 海绵 医骨孔 Glu Ala Leu Ala Asp Leu Gln Gln Ser Leu Cys Ser Phe Gln Glu Asn 290 295 300

化成化 经保险 机机 网络大小 化氯酚 建铁铁 鐵鐵 电电影 化二甲烷酸 化氯化合物 Gly Asp Leu Asp Cys Ser Ser Ser Thr Ser Gly Ser Leu Leu Pro Pro 305 310 315 320

Glu Asp His Gln

<210> 46

<211> 244

<212> PRT

<213> Homo sapiens

<400> 46

Ala Val Asp Ile Arg Asp Asn Leu Leu Gly Ile Ser Trp Val Asp Ser

1				5					10		÷			15	
Ser	Trp	Ile	Pro 20	Ile	Leu	Asn	Ser	Gly 25	Ser	Val	Leu	Asp	Tyr 30	Phe	Ser
Glu		Ser 35	Asn	Pro	Phe	Tyr	Asp 40	Arg	Thr	Cys	Asn	Asn 45	Glu	Val	Val
Lys	Met 50	Gln	Arg	Leu	Thr	Leu 55	Glu	His	Leu	Asn	Gln 60	Met	Val	Gly	Ile
Glu 65	Tyr	Ile	Leu	Leu	His 70	Ala	Gln	Glu	Pro		Leu		Ile		
Lys	Gln	Gln	Arg	Gln 85	Ser	Pro	Ala		Val 90				-	Asp 95	
Tyr	Ile	Ile	Ala 100		Val	Ile	Tyr	Gln 105		Pro	Asp	Leu	Gly 110		V al
•	i	115	•			÷	120			· _ ``	· 4 66.	125			
	130		Met	2		135			•		140	` ::	:		
145		•	Lys		150				•	155	v in v Vi i	, · · · · <u>·</u>	· · · · · · · · · · · · · · · · · · ·		160
				165	. ;		.: 1		170	e - '	,	• • •		175	· , :
	:	· · · .	Leu 180		•			185			- ^.		190		·.
	. 44	195	Gly			: :	200	*. -		÷. •	•	205			:
Ala	Glu 210	-	Ile	Pro		Thr. 215		Lys	Pro	Glu	Glu 220		Glu	Thr	Thr
Lys 225	Asn	Val	Gln		Thr 230				Lys				Glu		Arg 240
Met	Arg	Leu	Gln					-			,			-	

<210> 47

<211> 14

<212> DNA <213> Homo sapiens

<400> 47 ttttttttt ttag

N7

```
<210> 48
    <211> 10
    <212> DNA
   <213> Homo sapiens
   <400> 48
   cttcaacctc
    <210> 49
   <211> 496
   <212> DNA
   <213> Homo sapiens
   <400> 49
   gcaccatgta ccgagcactt cggctcctcg cgcgctcgcg tcccctcgtg cgggctccag: 60
ccgcagcctt agcttcggct cccggcttgg gtggcgcggccgtccctcg ttttggcctc-120
   cgaacgcggc tcgaatggca agccaaaatt ccttccggat agaatatgat acctttggtg 180
  aactaaaggt gccaaatgat aagtattatg gcgcccagac cgtgagatct acgatgaact 240
   ttaagattgg aggtgtgaca gaacgcatgc caaccccagt tattaaagct tttggcatct 300
   tgaagegage ggeegetgaa gtaaaceagg attatggtet tgateeaaag attgetaatg 360
   caataatgaa ggcagcagat gaggtagctg aaggtaaatt aaatgatcat tttcctctcg 420
   tggtatggca gactggatca ggaactcaga caaatatgaa tgtaaatgaa gtcattagcc 480
   aatagagcaa ttgaaa
                                                                                                                      柯特 化硫酸氢异
   <210> 50
   <211> 499
   <212> DNA
   <213> Homo sapiens
  agaaaaagtc tatgtttgca gaaatacaga tccaagacaa agacaggatg ggcactgctg: 60
   gaaaagttat taaatgcaaa gcagctgtgc tttgggagca gaagcaaccc ttctccattg 120
   aggaaataga agttgccca ccaaagacta aagaagttcg cattaagatt ttggccacag 180
   gaatetgteg cacagatgae catgtgataa aaggaacaat ggtgteeaag ttteeagtga 240
   ttgtgggaca tgaggcaact gggattgtag agagcattgg agaaggagtg actacagtga 300
  aaccaggtga caaagtcatc cctctcttc tgccacaatg tagagaatgc aatgcttgtc 360
   gcaacccaga tggcaacctt tgcattagga gcgatattac tggtcgtgga gtactggctg 420
  atggcaccac cagatttaca tgcaagggcg aaccagtcca ccacttcatg aacaccagta 480
catttaccga gtacacagt
TIPE CONTRACTOR AND A
                                                     ing the transfer of the property of the control of 
<210> 51
                                                              <211> 887
                                                         the second of the second
 <212> DNA
   <213> Homo sapiens
  <400> 51.
  gagtetgage agaaaggaaa ageageettg geageeacgt tagaggaata eaaageeaca 60
  gtggccagtg accagataga gatgaatcgc ctgaaggctc agctggagaa tgaaaagcag 120
  aaagtggcag agctgtattc tatccataac tctggagaca aatctgatat tcaggacctc 180
  ctggagagtg tcaggctgga caaagaaaaa gcagagactt tggctagtag cttgcaggaa 240
  gatctggctc atacccgaaa tgatgccaat cgattacagg atgccattgc taaggtagag 300
 gatgaatacc, gagcetteca agaagaaget aagaaacaaa ttgaagattt gaatatgacg 360
 ttagaaaaat taagatcaga cctggatgaa aaagaaacag aaaggagtga catgaaagaa 420
 accatetttg aacttgaaga tgaagtagaa caacategtg etgtgaaact teatgacaac 480
  ctcattattt ctgatctaga gaatacagtt aaaaaactcc aggaccaaaa gcacgacatg 540
```

```
gaaagagaaa taaagacact ccacagaaga cttcgggaag aatctgcgga atggcggcag 600
tttcaggctg atctccagac tgcagtagtc attgcaaatg acattaaatc tgaagcccaa 660
gaggagattg gtgatctaaa gcgccggtta catgaggctc aagaaaaaaa tgagaaactc 720
acaaaagaat tggaggaaat aaagtcacgc aagcaagagg aggagcgagg cgggtataca 780
attacatgaa tgccgttgag agagatttgg cagccttaag gcagggaatg ggactgagta 840
gaaggtcctc gacttcctca gagccaactc ctacagtaaa aaccctc
                                                                    887
 <210> 52
 <211> 491
 <212> DNA
<213> Homo sapiens
<400> 52
ggcacgagct tttccaaaaa tcatgctgct cctttctcta aagttcttac attttataga 60
aaggaacett teaetettga ggeetactae ageteteete aggattigee etateeagat 120
cctgctatag ctcagttttc agttcagaaa gtcactccte agtctgatgg ctccagttca 180
aaagtgaaag tcaaagttcg agtaaatgtc catggcattt tcagtgtgtc cagtgcatet 240
ttagtggagg ttcacaagtc tgaggaaaat gaggagccaa tggaaacaga tcagaatgca 300
aaggaggaag agaagatgca agtggaccag gaggaaccac atgttgaaga gcaacagcag 360
cagacaccag gcagaaaata aggcagagtc tgaagaaatg gagacctctc aagctggate 420
caaggataaa aagatggacc aaccacccca agccaagaag gcaaaagtga agaccagtac 480
tgtggacctg g
<210> 53
                                                            <211> 787
                                                            手尖掛 医多型囊菌
<212> DNA
<213> Homo sapiens
                                                            Charles of Elizabeth
<400> 53
aagcagttga gtaggcagaa aaaagaacct cttcattaag gattaaaatg tataggccag 60
cacgtgtaac ttcgacttca agatttctga atccatatgt agtatgtttc attgtcgttg 120
caggggtagt gateetggea greaceatag etetaettgt tractttta getttegate 180
aaaaatetta ettetatagg ageagtette aacteetaaa tgttgaatat aatagteagt 240
taaattcacc agctacacag gaatacagga ctttgagtgg aagaattgaa tctctgatta 300
Ctaaaacatt caaagaatca aatttaagaa atcagttcat cagagctcat gttgccaaac 360
tgaggcaaga tggtagtggt gtgagagcgg atgttgtcat gaaatttcaa ttcactagaa 420
ataacaatgg agcatcaatg aaaagcagaa ttgagtctgt tttacgacaa atgctgaata 480
actctggaaa cctggaaata aacccttcaa ctgagataac atcacttact gaccaggctg 540
cagcaaattg gcttattaat gaatgtgggg ccggtccaga cctaataaca ttgtctgagc 600
agagaateet tggaggeact gaggetgagg agggaagetg geegtggeaa gteagtetge 660
ggctcaataa tgcccaccac tgtggaggca gcctgatcaa taacatgtgg atcctgacag 720
cagctcactg cttcagaagc aactctaatc ctcgtgactg gattgccacg tctggtattt 780
                                                          7 (1980) 1 1 1 1 1 787
ccacaac
                                                       ్రార్, బ్యాబడ్స్ ఇద్కోట్రార్
<210> 54
<211> 386
<212> DNA
<213> Homo sapiens
                         The state of the second second second
<400> 54
                                                    一个人,这一位,"你一样的过程就是这个人。"
ggcattttca gtgtgtccag tgcatcttta gtggaggttc acaagtctga ggaaaatgag 60
gagccaatgg aaacagatca gaatgcaaag gaggaagaga agatgcaagt ggaccaggag 120
gaaccacatg ttgaagagca acagcagcag acaccagcag aaaataaggc agagtctgaa 180
gaaatggaga ceteteaage tggatecaag gataaaaaga tggaceaace acceeaagee 240
aagaaggcaa aagtgaagac cagtactgtg gacctgccaa tcgagaatca gctattatgg 300
```

```
cagatagaca gagagatgct caacttgtac attgaaaatg agggtaagat gatcatgcag 360
                                                                 386
gataaactgg agaaggagcg gaatga
<210> 55
<211> 1462
<212> DNA
<213> Homo sapiens
<400> 55
aagcagttga gtaggcagaa aaaagaacct cttcattaag gattaaaatg tataggccag 60
cacgtgtaac ttcgacttca agatttctga atccatatgt agtatgtttc attgtcgtcg 120
caggggtagt gatectggea gteaceatag etetaettgt ttaettttta gettttgate 180
aaaaatctta cttttatagg agcagttttc aactcctaaa tgttgaatat aatagtcagt 240
taaattcacc agctacacag gaatacagga ctttgagtgg aagaattgaa tctctgatta 300
ctaaaacatt caaagaatca aatttaagaa atcagttcat cagagctcat gttgccaaac 360
tgaggcaaga tggtagtggt gtgagagcgg atgttgtcat gaaatttcaa ttcactagaa 420
ataacaatgg agcatcaatg aaaagcagaa ttgagtctgt tttacgacaa atgctgaata 480
actctggaaa cctggaaata aacccttcaa ctgagataac atcacttact gaccaggctg 540
cagcaaattg gcttattaat gaatgtgggg ccggtccaga cctaataaca ttgtctgagc 600
agagaateet tggaggeact gaggetgagg agggaagetg geegtggeaa gteagtetge 660
ggctcaataa tgcccaccac tgtggaggca gcctgatcaa taacatgtgg atcctgacag 720
cageteactg etteagaage aactetaate etegtgaetg gattgecaeg tetggtattt 780
ccacaacatt tcctaaacta agaatgagag taagaaatat tttaattcat aacaattata 840
aatctgcaac tcatgaaaat gacattgcac ttgtgagact tgagaacagt gtcaccttta 900
ccaaagatat ccatagtgtg tgtctcccag ctgctaccca gaatattcca cctggctcta 960
ctgcttatgt aacaggatgg ggcgctcaag aatatgctgg ccacacagtt ccagagctaa 1020
ggcaaggaca ggtcagaata ataagtaatg atgtatgtaa tgcaccacat agttataatg 1080
gagccatctt gtctggaatg ctgtgtgctg gagtacctca aggtggagtg gacgcatgtc 1140
agggtgactc tggtggccca ctagtacaag aagactcacg gcggctttgg tttattgtgg 1200
ggatagtaag ctggggagat cagtgtggcc tgccggataa gccaggagtg tatactcgag 1260
tgacagcata cattgactgg attaggcaac aaactgggat ctagtgcaac aagtgcatcc 1320
ctgttgcaaa gtctgtatgc aggtgtgcct gtcttaaatt ccaaagcttt acatttcaac 1380
tgaaaaagaa actagaaatg tcctaattta acatcttgtt acataaatat ggtttaacaa 1440
                                                                1462
aaaaaaaaa aaaaaactcg ag
<210> 56
<212> PRT
<213> Homo sapiens
<400> 56
Thr Met Tyr Arg Ala Leu Arg Leu Leu Ala Arg Ser Arg Pro Leu Val
                                        15
                                    10
Arg Ala Pro Ala Ala Ala Leu Ala Ser Ala Pro Gly Leu Gly Gly Ala
                 25
Ala Val Pro Ser Phe Trp Pro Pro Asn Ala Ala Arg Met Ala Ser Gln
                            40 45
Asn Ser Phe Arg Ile Glu Tyr Asp Thr Phe Gly Glu Leu Lys Val Pro
     50
Asn Asp Lys Tyr Tyr Gly Ala Gln Thr Val Arg Ser Thr Met Asn Phe
                                        75
                     70
```

ាចស្ថានស្ថាន និង ប្រជាពីសម្រេច 🚓 ខេត្ត ខែក្រុម ខែក្រុម ខេត្ត ខេត្ត ប្រាស្ត្រីបំបាន 🛦 ខេត្តស្ថា 😘 ប្រុ

Lys Ile Gly Gly Val Thr Glu Arg Met Pro Thr Pro Val Ile Lys Ala 85 90 95

Phe Gly Ile Leu Lys Arg Ala Ala Ala Glu Val Asn Gln Asp Tyr Gly
100 105 110

Leu Asp Pro Lys Ile Ala Asn Ala Ile Met Lys Ala Ala Asp Glu Val 115 120 125

Ala Glu Gly Lys Leu Asn Asp His Phe Pro Leu Val Val Trp Gln Thr 130 135 140

Gly Ser Gly Thr Gln Thr Asn Met Asn Val Asn Glu Val Ile Ser 145 150 155

<210> 57

<211> 165

<212> PRT

<213> Homo sapiens

<400> 57

Lys Lys Ser Met Phe Ala Glu Ile Gln Ile Gln Asp Lys Asp Arg Met

1 5 10 15

Gly Thr Ala Gly Lys Val Ile Lys Cys Lys Ala Ala Val Leu Trp Glu 20 25 30

Gln Lys Gln Pro Phe Ser Ile Glu Glu Ile Glu Val Ala Pro Pro Lys
35 40 45

Thr Lys Glu Val Arg Ile Lys Ile Leu Ala Thr Gly Ile Cys Arg Thr

Asp Asp His Val Ile Lys Gly Thr Met Val Ser Lys Phe Pro Val Ile 65 70 75 80

Val Gly His Glu Ala Thr Gly Ile Val Glu Ser Ile Gly Glu Gly Val
85 90 95

Thr Thr Val Lys Pro Gly Asp Lys Val Ile Pro Leu Phe Leu Pro Gln
100 105 110

Cys Arg Glu Cys Asn Ala Cys Arg Asn Pro Asp Gly Asn Leu Cys Ile 115 120 125

Arg Ser Asp Ile Thr Gly Arg Gly Val Leu Ala Asp Gly Thr Thr Arg 130 135 140

Phe Thr Cys Lys Gly Glu Pro Val His His Phe Met Asn Thr Ser Thr 145 150 155 160

Phe Thr Glu Tyr Thr

165

<21	10> 5	58													
<21	1> 2	259													
<21	.2> I	PRT					•	-							· <u>.</u>
<21	.3> · I	omo	sapi	èns									•		
<40	0> 5	8	,			-									
			, Glr	Larc	Gly	r Tare	. Ala	בות .	. T.O.	. או	. או			<i>-> 1</i>	
1	. Dei	. 610	. G.I.	r mya	GIY	шус	, AIG	AIG	10		Alc	TILL	reu		
					, 			. ,.							1, 17
175					•		10 03.				**				_
TÄT	ъуs	MIC			. Ald	Sei	Asp			GIU	met	Asn			гу
			. 20		•.			25		٠.		_	- 30		
71-														-•	
MIG	GII			ASI	GIU	гу	Gln		vaı	AT9	GIU		. –	Ser	116
		35					40					45			
111.0	3													٠.	
nis			GIA	Asp	Lys		Asp	TIE	_GIN	Asp			GIU	Ser	-Vai
·	50					. 55		••	-		60		•	÷	
N							A								
		Asp) rys	GIU			Glu	Inr	Leu		Ser	Ser	Leu	Gln	
65				•	7 0					75					80
Nan							4 · · · ·								
Asp	rea	Ald	nis			ASII	Asp	Ala		Arg	Leu	GIN	Asp		Tie
	٠.	•		85		, .			90					95	
בות	Lazo	Wal.					.								
ATG	ту	vai	. G1u		GIU	IYL	Arg		Phe	GIR	GIU			гÀг	Lys
								105				•	110	_	
Gln.	T10						The								
. GIII	TIG	115		, ren	ASII	mec	Thr		GIU	тÀЗ	rea		Ser	Asp	Leu
		115	•				120					125	···		
Agn	Glu	Tare	Glv												
тър	130		Giu	TIIL	. Gru	135	Ser	ASP	Mec	пÄг		THE	TIE	Pilė	GIU
	130					133					140		•		
T.eu	Glu	Aen	Glu	V=1.	Gliv	Gln	His	7~~	71-	1751	Taro	Lou	ui a	n an	Aan
145	010	nop	GIU	Val	150	GIII	1113	ALG		155	пуъ	ьец	urs	-	
143			_	•	150					133					160
T.eu	Tla	Tla	Ser	Acn	T.Ou	G3.r	Asn	Thr	Wal	Tara	Tara		C1 n		CIn
LCu	.116	116	Ser	165		Gtu	MSII	TIIL	170	nys	тХЗ	rea		_	
						م م		·	•			·- f-		175	-
Tare	Hie	λen	Mor	Gli	Ara	Gl.	. (i) Ile	Tare	Thr.	Lou	Uic	1	% ⊕ \\ - X ~~~	Ton	" 7 ~~~
Dy 3	1113	nap	180	GIU	MLG	Gin	116		TILL	neu	urs	Arg		ren	Arg
			100		. ,		· ·	185					190		
Glu	Gliv	Cor	71-				~								
GIU	Gru			GIU	пр	Arg	Gln	Pile	GIII	Ala	Asp		GTÚ	THE	Ala
		195					200					205		•	
17-7			•		•		• 1 1								
val							Lys			•		GIU	Glu	TTE	Gly
	210										220		•		
3	* -	-		_	` <i></i> .	•••	:	· ; .,			. f(S	₹ <u> </u>			. · · · · · · · · · · · · · · · · · · ·
	ьeu	гÀЗ	Arg	Arg		His	Glu	ALa	GIn		гàг	Asn	Glu	Lys	_
225					230					235					240
							· ·								
Inr	LVS	GLu	Len	G111	GIn	Tle	Lvs	Ser	Arg	LVS	Glp	Glu	Glu	Glu.	Ara

Gly Gly Tyr

<210> 59

<211> 125

<212> PRT

<213> Homo sapiens

and the state of the state of the state of

₹400> 59

Gly Thr Ser Phe Ser Lys Asn His Ala Ala Pro Phe Ser Lys Val Leu
1 15

Thr Phe Tyr Arg Lys Glu Pro Phe Thr Leu Glu Ala Tyr Tyr Ser Ser 20 25 30

Pro Gln Asp Leu Pro Tyr Pro Asp Pro Ala Ile Ala Gln Phe Ser Val

Gln Lys Val Thr Pro Gln Ser Asp Gly Ser Ser Ser Lys Val Lys Val
50 60

Lys Val Arg Val Asn Val His Gly Tle Phe Ser Val Ser Ser Ala Ser 65

Leu Val Glu Val His Lys Ser Glu Glu Asn Glu Glu Pro Met Glu Thr
90 95

Asp Gln Asn Ala Lys Glu Glu Glu Lys Met Gln Val Asp Gln Glu Glu 100 105 110

Pro His Val Glu Glu Gln Gln Gln Gln Thr Pro Gly Arg
115 120 125

<210> 60

<211> 246@44 ... \ 1964 @4 ...

<212> PRT

<213> Homo sapiens

<400> 60 PM

Tyr Val Val Cys Phe Ile Val Val Ala Gly Val Val Ile Leu Ala Val 20 25 30

Thr Ile Ala Leu Leu Val Tyr Phe Leu Ala Phe Asp Gln Lys Ser Tyr 35 40 45

Phe Tyr Arg Ser Ser Phe Gln Leu Leu Asn Val Glu Tyr Asn Ser Gln
50 55 60

Leu Asn Ser Pro Ala Thr Gln Glu Tyr Arg Thr Leu Ser Gly Arg Ile
65 70 75 80

Glu Ser Leu Ile Thr Lys Thr Phe Lys Glu Ser Asn Leu Arg Asn Gln
85 90 95

Phe Ile Arg Ala His Val Ala Lys Leu Arg Gln Asp Gly Ser Gly Val

Arg Ala Asp Val Val Met Lys Phe Gln Phe Thr Arg Asn Asn Gly
115 120 125

Ala Ser Met Lys Ser Arg Ile Glu Ser Val Leu Arg Gln Met Leu Asn 130 135 140

Asn Ser Gly Asn Leu Glu Ile Asn Pro Ser Thr Glu Ile Thr Ser Leu 145 150 155 160

Thr Asp Gln Ala Ala Asn Trp Leu Ile Asn Glu Cys Gly Ala Gly
165 170 175

Pro Asp Leu Ile Thr Leu Ser Glu Gln Arg Ile Leu Gly Gly Thr Glu 180 185 190

Ala Glu Glu Gly Ser Trp Pro Trp Gln Val Ser Leu Arg Leu Asn Asn 195 200 205

Ala His His Cys Gly Gly Ser Leu Ile Asn Asn Met Trp Ile Leu Thr 210 220

Ala Ala His Cys Phe Arg Ser Asn Ser Asn Pro Arg Asp Trp Ile Ala 225 230 235 240

Thr Ser Gly Ile Ser Thr 245

<210> 61

<211> 128

<212> PRT

<213> Homo sapiens

<400> 61

Gly Ile Phe Ser Val Ser Ser Ala Ser Leu Val Glu Val His Lys Ser 1 5 10 15

Glu Glu Asn Glu Glu Pro Met Glu Thr Asp Gln Asn Ala Lys Glu Glu
20 25 30

Glu Lys Met Gln Val Asp Gln Glu Glu Pro His Val Glu Glu Gln Gln 35 40 45

Gln Gln Thr Pro Ala Glu Asn Lys Ala Glu Ser Glu Glu Met Glu Thr
50 55 60

Ser Gln Ala Gly Ser Lys Asp Lys Lys Met Asp Gln Pro Pro Gln Ala 65 70 75 80

Lys Lys Ala Lys Val Lys Thr Ser Thr Val Asp Leu Pro Ile Glu Asn

Gln Leu Leu Trp Gln Ile Asp Arg Glu Met Leu Asn Leu Tyr Ile Glu 100 105 110

Asn Glu Gly Lys Met Ile Met Gln Asp Lys Leu Glu Lys Glu Arg Asn 115 120 125

<210> 62

<211> 418

<212> PRT

<213> Homo sapiens

<400> 62

Met Tyr Arg Pro Ala Arg Val Thr Ser Thr Ser Arg Phe Leu Asn Pro 1 5 10 15

Tyr Val Val Cys Phe Ile Val Val Ala Gly Val Val Ile Leu Ala Val

Thr Ile Ala Leu Leu Val Tyr Phe Leu Ala Phe Asp Gln Lys Ser Tyr 35 40 45

Phe Tyr Arg Ser Ser Phe Gln Leu Leu Asn Val Glu Tyr Asn Ser Gln 50 55

Leu Asn Ser Pro Ala Thr Gln Glu Tyr Arg Thr Leu Ser Gly Arg Ile
65 70 75 80

Glu Ser Leu Ile Thr Lys Thr Phe Lys Glu Ser Asn Leu Arg Asn Gln
85 90 95

Phe Ile Arg Ala His Val Ala Lys Leu Arg Gln Asp Gly Ser Gly Val

Arg Ala Asp Val Val Met Lys Phe Gln Phe Thr Arg Asn Asn Asn Gly
115 120 125

Ala Ser Met Lys Ser Arg Ile Glu Ser Val Leu Arg Gln Met Leu Asn 130 135 140

Asn Ser Gly Asn Leu Glu Ile Asn Pro Ser Thr Glu Ile Thr Ser Leu 145 150 155 160

Thr Asp Gln Ala Ala Asn Trp Leu Ile Asn Glu Cys Gly Ala Gly
165 170 175

Pro Asp Leu Ile Thr Leu Ser Glu Gln Arg Ile Leu Gly Gly Thr Glu
180 185 190

Ala Glu Glu Gly Ser Trp Pro Trp Gln Val Ser Leu Arg Leu Asn Asn 195 200 205

Ala His His Cys Gly Gly Ser Leu Ile Asn Asn Met Trp Ile Leu Thr

															_
	210)			:	215	;				220	٠.			-
Al 22	a Ala 5	His	Cys	Phe	Arg		Asn	Ser	Asn	Pro 235	_	Asp	Trp	Ile	Ala 240
Th	r Ser	Gly	Ile	Ser	Thr		Phe	Pro	-		Arg	Met	Arg		Arg
As	n Ile	Leu	Ile	245 His		Asn	Tvr	Lvs	250 Ser		Thr	His	Glu	255 Asn	
			260		4-2-2-		-1-	265					270		
11	e Ala	Leu 275		Arg	Leu	Glu	Asn 280		Val	Thr	Phe	Thr 285	-	Asp	Ile
ні	s Ser 290		Cys	Leu	Pro	Ala 295		Thr	Gln		Ile 300		Pro	Gly	Ser
Th:	r Ala 5	Tyr	Val	Thr	Gly 310	Trp	Gly	Aļa	_Gln	Glu 315	Tyr	Ala	Gly	His	Thr 320
Va:	l Pro	Glu	Leu	Arg 325	Gln	Gly	Gln	Val	Arg 330	Ile	Ile	Ser	Asn	Asp 335	
Cy:	s Asn	Ala	Pro 340	His	Ser	Tyr	Asn	Gly 345	Ala	Ile	Leu	Ser	Gly 350	Meť	Leu
Cys	s Ala	Gly 355		Pro	Gln	Gly	Gly 360	Val	Asp	Ala	Cys	G1n 365	_	Asp	Sér
Gly	7 Gly 370	Pro	Leu	Val	Gln	Glu 375	Asp	Ser	Arg	Arg	Leu 380	Trp:	Phe	Ile	Val
Gl _y 385	/ Ile	Val	Ser	Ţŗp	Gly 390	Asp	Gln	Cys 、	-	Leu 395	Pro	Asp	Lys	Pro	Gly 400
Va]	Tyr	Thr	Arg	Val 405	Thr	Ala	Tyr	Ile	Asp 410	Trp	Ile	Arg	Gln	Gln 415	Thr
Gly	, Ile											•			,
											•				

<210> 63 <211> 776 <212> DNA <213> Homo sapiens

<400> 63

cacagatggt gatagaggaa tecatettge agteagataa ageeeteact gatagagaa 60 aggeagtage agtggategg gecaagaagg aggeagetga gaaggaacag gaactttaa 120 aacagaaatt acaggagcag ceageaacag atggaggete aagataagag tegeaaggaa 180 aactageeaa etgaaggaga agetgeagat ggagagagaa cacetaetga gagageagat 240 tatgatgttg gageacaege agaaggteea aaatgattgg etteatgaag gatttaagaa 300 gaagtatgag gagatgaatg eagagataag teaatttaaa egtatgattg atactacaaa 360 aaatgatgat acteeetgga ttgeacgaae ettggacaae ettgeegatg agetaactge 420 aatattget geteetgeta aattaattgg teatggtgte aaaggtgtga geteaetett 480

```
taaaaaagcat aagctcccct tttaaggata ttatagattg tacatatatg ctttggacta 540
tttttgatct gtatgttttt cattttcatt cagcaagttt ttttttttt tcagagtctt 600
actctgttgc ccaggctgga gtacagtggt gcaatctcag ctcactgcaa cctctgcctc 660
ctgggttcaa gagattcacc tgcctcagcc ccctagtagc tgggattata ggtgtacacc 720
accacaccca gctaattttt gtattttag tagagatggg gtttcactat gttggc
 <210> 64
 <211> 160
<212> DNA
 <213> Homo sapiens
                                        1. Dec 1986 1993 1993
<400> 64
gcagcgctct cggttgcagt acccactgga aggacttagg cgctcgcgtg gacaccgcaa 60
geceteagt ageeteggee caagaggeet getttecaet egetageece geeggggte 120
cgtgtcctgt ctcggtggcc ggacccgggc ccgagcccga
                                                                   160
<210> 65
<211> 72
<212> PRT
<213> Homo sapiens
<400> 65
Leu Ser Ala Met Gly Phe Thr Ala Ala Gly Ile Ala Ser Ser Ile
  1
                                     10
                                                         15
Ala Ala Lys Met Met Ser Ala Ala Ala Ile Ala Asn Gly Gly Gly Val
             20 3.5.
                                 25
                                                     30
Ala Ser Gly Ser Leu Val Ala Thr Leu Gln Ser Leu Gly Ala Thr Gly
         35
                                                 45
Leu Ser Gly Leu Thr Lys Phe Ile Leu Gly Ser Ile Gly Ser Ala Ile
     · 50
                        55
Ala Ala Val Ile Ala Arg Phe Tyr
<210>.66
<211> 2581
<212> DNA
<213> Homo sapiens
<400> 66
ctttcaaccc gcgctcgccg gctccagccc cgcgcgcccc caccccttgc cctcccggcg 60
gctccgcagg gtgaggtggc tttgaccccg ggttgcccgg ccagcacgac cgaggaggtg 120
gctggacage tggaggatga acggagaage cgactgcccc acagacetgg aaatggccgc 180
ccccaaagge caagacegtt ggtcccagga agacatgctg actttgctgg aatgcatgaa 240
gaacaacctt ccatccaatg acagctccaa gttcaaaacc accgaatcac acatggactg 300
ggaaaaagta gcatttaaag acttttctgg agacatgtgc aagctcaaat gggtggagat 360
ttctaatgag gtgaggaagt tccgtacatt gacagaattg atcctcgatg ctcaggaaca 420
tgttaaaaat ccttacaaag gcaaaaaact caagaaacac ccagacttcc caaagaagcc 480
cctgacccct tattccgct tcttcatgga gaagcgggcc aagtatgcga aactccaccc 540
tgagatgage aacctggace taaccaagat tetgteeaag aaatacaagg agetteegga 600
gaagaagaag atgaaatata ttcaggactt ccagagagag aaacaggagt tcgagcgaaa 660
```

```
cctggcccga ttcagggagg atcaccccga cctaatccag aatgccaaga aatcggacat 720
cccagagaag cccaaaaccc cccagcagct gtggtacacc cacgagaaga aggtgtatct 780
caaagtgcgg ccagatgcca ctacgaagga ggtgaaggac tccctgggga agcagtggtc 840
tcagctctcg gacaaaaaga ggctgaaatg gattcataag gccctggagc agcggaagga 900
gtacgaggag atcatgagag actatatcca gaagcaccca gagctgaaca tcagtgagga 960
gggtatcacc aagtccaccc tcaccaaggc cgaacgccag ctcaaggaca agtttgacgg 1020
gegacecace aagecacete egaacageta etegetgtae tgegeagage teatggeeaa 1080
catgaaggac gtgcccagca cagagcgcat ggtgctgtgc agccagcagt ggaagctgct 1140
gtcccagaag gagaaggacg cctatcacaa gaagtgtgat cagaaaaaga aagattacga 1200
ggtggagetg etecgtttee tegagageet geetgaggag gageageage gggtettggg 1260
ggaagagaag atgctgaaca tcaacaagaa gcaggccacc agccccgcct ccaagaagcc 1320
agcccaggaa gggggcaagg gcggctccga gaagcccaag cggcccgtgt cggccatgtt 1380
catetteteg gaggagaaac ggeggeaget geaggaggag eggeetgage teteegagag 1440
cgagetgace egeetgetgg ecegaatgtg gaacgacetg tetgagaaga agaaggeeaa 1500
gtacaaggee egagaggegg egeteaagge teagteggag aggaageeeg geggggageg 1560
cgaggaacgg ggcaagctgc ccgagtcccc caaaagagct gaggagatct ggcaacagag 1620
cgttatcggc gactacctgg cccgcttcaa gaatgaccgg gtgaaggcct tgaaagccat 1680
ggaaatgacc tggaataaca tggaaaagaa ggagaaactg atgtggatta agaaggcagc 1740
cgaagaccaa aagcgatatg agagagagct gagtgagatg cgggcacctc cagctgctac 1800
aaattettee aagaagatga aatteeaggg agaaceeaag aageeteeca tgaacggtta 1860
ccagaagttc tcccaggagc tgctgtccaa tggggagctg aaccacctgc cgctgaagga 1920
gcgcatggtg gagatcggca gtcgctggca gcgcatctcc cagagccaga aggagcacta 1980
caaaaagetg geegaggage ageaaaagea gtacaaggtg caeetggace tetgggttaa 2040
gagcctgtct ccccaggacc gtgcagcata taaagagtac atctccaata aacgtaagag 2100
catgaccaag ctgcgaggcc caaaccccaa atccagccgg actactctgc agtccaagtc 2160
ggagtccgag gaggatgatg aagaggatga ggatgacgag gacgaggatg aagaagagga 2220
agatgatgag aatggggact cetetgaaga tggeggegae teetetgagt eeageagega 2280
ggacgagagc gaggatgggg atgagaatga agaggatgac gaggacgaag acgacgacga 2340
ggatgacgat gaggatgaag ataatgagte egagggeage ageteeaget ceteett 2400
aggggactcc tcagactttg actccaactg aggcttagcc ccaccccagg ggagccaggg 2460
agageceagg agetecete eccaactgae eacetttgtt tetteceeat gttetgteee 2520
ttgccccct ggcctcccc actttctttc tttctttaaa aaaaaaaaa aaaaactcga 2580
                                                                  2581
<210> 67
<211> 764
<212> PRT
<213> Homo sapiens
```

<400> 67

Met Asn Gly Glu Ala Asp Cys Pro Thr Asp Leu Glu Met Ala Ala Pro 1 5 10 15

Lys Gly Gln Asp Arg Trp Ser Gln Glu Asp Met Leu Thr Leu Leu Glu 20 25 30

Cys Met Lys Asn Asn Leu Pro Ser Asn Asp Ser Ser Lys Phe Lys Thr 35 40 45

Thr Glu Ser His Met Asp Trp Glu Lys Val Ala Phe Lys Asp Phe Ser 50 55 60

Gly Asp Met Cys Lys Leu Lys Trp Val Glu Ile Ser Asn Glu Val Arg 65 70 75 80

Lys Phe Arg Thr Leu Thr Glu Leu Ile Leu Asp Ala Gln Glu His Val Lys Asn Pro Tyr Lys Gly Lys Lys Leu Lys Lys His Pro Asp Phe Pro 100 105 110 Lys Lys Pro Leu Thr Pro Tyr Phe Arg Phe Phe Met Glu Lys Arg Ala Lys Tyr Ala Lys Leu His Pro Glu Met Ser Asn Leu Asp Leu Thr Lys 135 Ile Leu Ser Lys Lys Tyr Lys Glu Leu Pro Glu Lys Lys Lys Met Lys Tyr Ile Gln Asp Phe Gln Arg Glu Lys Gln Glu Phe Glu Arg Asn Leu 165 Ala Arg Phe Arg Glu Asp His Pro Asp Leu Ile Gln Asn Ala Lys Lys 180 Ser Asp Ile Pro Glu Lys Pro Lys Thr Pro Gln Gln Leu Trp Tyr 200 His Glu Lys Lys Val Tyr Leu Lys Val Arg Pro Asp Ala Thr Thr Lys 210 Glu Val Lys Asp Ser Leu Gly Lys Gln Trp Ser Gln Leu Ser Asp Lys 225 230 Lys Arg Leu Lys Trp Ile His Lys Ala Leu Glu Gln Arg Lys Glu Tyr 250 255 245 Glu Glu Ile Met Arg Asp Tyr Ile Gln Lys His Pro Glu Leu Asn Ile 260 265 270 Ser Glu Glu Gly Ile Thr Lys Ser Thr Leu Thr Lys Ala Glu Arg Gln **275** 280 285 Leu Lys Asp Lys Phe Asp Gly Arg Pro Thr Lys Pro Pro Pro Asn Ser 290 Tyr Ser Leu Tyr Cys Ala Glu Leu Met Ala Asn Met Lys Asp Val Pro 305 310 315 320 Ser Thr Glu Arg Met Val Leu Cys Ser Gln Gln Trp Lys Leu Leu Ser Gln Lys Glu Lys Asp Ala Tyr His Lys Lys Cys Asp Gln Lys Lys 340 345 Asp Tyr Glu Val Glu Leu Leu Arg Phe Leu Glu Ser Leu Pro Glu Glu 355 360

Glu Gln Gln Arg Val Leu Gly Glu Glu Lys Met Leu Asn Ile Asn Lys

380 🎋 375 370 Lys Gln Ala Thr Ser Pro Ala Ser Lys Lys Pro Ala Gln Glu Gly Gly 395 400 390 385 Lys Gly Gly Ser Glu Lys Pro Lys Arg Pro Val Ser Ala Met Phe Ile 410 405 That 64's Phe Ser Glu Glu Lys Arg Gln Leu Gln Glu Glu Arg Pro Glu Leu 420 Ser Glu Ser Glu Leu Thr Arg Leu Leu Ala Arg Met Trp Asn Asp Leu 1964 1966 440 198 19 19 1445 WAS WAS 1964 1965 Ser Glu Lys Lys Lys Ala Lys Tyr Lys Ala Arg Glu Ala Ala Leu Lys 450 Ala Gln Ser Glu Arg Lys Pro Gly Gly Glu Arg Glu Glu Arg Gly Lys 465 470 475 Leu Pro Glu Ser Pro Lys Arg Ala Glu Glu Ile Trp Gln Gln Ser Val 490 485 Ile Gly Asp Tyr Leu Ala Arg Phe Lys Asn Asp Arg Val Lys Ala Leu 510 505 500 ். நடந்த இசையை இண்டுகள் இருக்கும் மாகும் கார்க்கும் மாகும் மாகும் இருக்கும் இருக்கும் இருக்கும் இருக்கும் இருக Lys Ala Met Glu Met Thr Trp Asn Asn Met Glu Lys Lys Glu Lys Leu 59g 1 mg. 515fg by a deposit of \$20 mm - 2 fg 2 525gm - 1 fg 25gm - 1 Met Trp Ile Lys Lys Ala Ala Glu Asp Gln Lys Arg Tyr Glu Arg Glu 1986 - 530 Sept. 2 State of 535 Sept. Sept. 12 July 540 C. Sept. 4 The County of the Asset of the Leu Ser Glu Met Arg Ala Pro Pro Ala Ala Thr Asn Ser Ser Lys Lys 550 555 545 Met Lys Phe Gln Gly Glu Pro Lys Lys Pro Pro Met Asn Gly Tyr Gln 570 565 Lys Phe Ser Gln Glu Leu Leu Ser Asn Gly Glu Leu Asn His Leu Pro 590 585 580 我们看了一块,一点,_{我们}是一种"我们的"的**这种"**"这一个"有一个"的话,她的一点,他们在这个一点的"我们"的一样。。 Leu Lys Glu Arg Met Val Glus Ile Gly Ser Arg Trp Gln Arg Ile Ser 14. The mass 595 by the analysis of the 600 miles of the country 605 miles with the first of Gln Ser Gln Lys Glu His Tyr Lys Lys Leu Ala Glu Glu Gln Gln Lys 610 615 620 Gln Tyr Lys Val His Leu Asp Leu Trp Val Lys Ser Leu Ser Pro Gln 635 625 630 and the state of the state of the Asp Arg Ala Ala Tyr Lys Glu Tyr Ile Ser Asn Lys Arg Lys Ser Met 655 650 645 Thr Lys Leu Arg Gly Pro Asn Pro Lys Ser Ser Arg Thr Thr Leu Gln 665 670 660

```
Ser Lys Ser Glu Ser Glu Glu Asp Asp Glu Glu Asp Glu Asp Glu
                                             685
       675
                          680
Asp Glu Asp Glu Glu Glu Glu Asp Asp Glu Asn Gly Asp Ser Ser Glu
                       695
                                         700
    690
Asp Gly Gly Asp Ser Ser Glu Ser Ser Ser Glu Asp Glu Ser Glu Asp
                                                         720
                                      715
705
                   710
Gly Asp Glu Asn Glu Glu Asp Asp Glu Asp Glu Asp Asp Glu Asp
               725
                                  730
            人名英巴克森姓氏 网络人名马克 海绵药 医抗原性
Asp Asp Glu Asp Glu Asp Asn Glu Ser Glu Gly Ser Ser Ser Ser
                              745
                                                 750
           740
          Ser Ser Leu Gly Asp Ser Ser Asp Phe Asp Ser Asn
       755
                          760
<210> 68
<211> 434
<212> DNA
<213> Homo sapiens
              化二氯化二甲酰胺 经货币 机压力 化二氯
<400> 68
ctaagatgct ggatgctgaa gacatcgtcg gaactgcccg gccagatgag aaagccatta 60
tgacttatgt gtctagcttc tatcatgcct tctctggagc ccagaaggca gaaacagcag 120
ccaatcgcat ctgcaaagtg ttggcggtca atcaagagaa cgagcagctt atggaagact 180
atgagaagct ggccagtgat ctgttggagt ggatccgccg caccatccca tggctggaga 240
atcgggtgcc tgagaacacc atgcatgcca tgcagcagaa gctggaggac ttccgagact 300
atagacgcct gcacaagccg cccaaggtgc aggagaagtg ccagctggag atcaacttta 360
acacgctgca gaccaaactg cggctcagca accggcctgc cttcatgccc tccgagggca 420
                                                             434
ggatggtctc ggat
<210> 69
<211> 244
<212> DNA
<213> Homo sapiens
     သည် သေ့သေးသည် သည်၏ သည်၍ အခေါ်သည် သ
<400> 69
aggcagcatg ctcgttgaga gtcatcacca ctccctaatc tcaagtacgc agggacacaa 60
acactgcgga aggccgcagg gtcctctgcc taggaaaacc agagaccttt gttcacttgt 120
ttatgtgctg accttccctc cactattgtc ctgtgaccct gccaaatccc cctttgtgag 180
244
                    14. C. W. #
<210> 70
<211> 437
<212> DNA
<213> Homo sapiens
<400> 70
ctgggacggg agcgtccagc gggactcgaa ccccagatgt gaaggcgttt ctggaaagtc 60
cttggtccct ggatccagcg tcggccagcc cagagcccgt gccgcacatc cttgcgtcct 120
```

```
ccaggcagtg ggaccccgcg agctgcacgt ccctgggcac ggacaagtgt gaggcactgt 180
tggggctgtg ccaggtgcgg ggtgggctgc ccctttctc agaaccttcc agcctggtgc 240
cgtggccccc aggccggagt cttcctaagg ctgtgaggcc acccctgtcc tggcctccgt 300
tctcgcagca gcagaccttg cccgtgatga gcggggaggc ccttggctgg ctgggccagg 360
ctggttccct ggccatgggg gctgcacctc tgggggagcc agccaaggag gaccccatgc 420
tggcgcagga agccggg
<210> 71
<211> 271
<212> DNA
<213> Homo sapiens
<400> 71
gcgcagagtt ctgtcgtcca ccatcgagtg aggaagagag cattggttcc cctgagatag 60
aagagatggc tctcttcagt gcccagtctc catacattaa cccgatcatc ccctttactg 120
gaccaatcca aggagggtg caggagggac ttcaggtgac cctccagggg actaccgaga 180
gttttgcaca aaagtttgtg gtgaactttt cagaacagct tcaatggaga tgacttggcc 240
ttccacttca accccggtta tgaggaagga g-
<210> 72
<211> 290
<212> DNA
<213> Homo sapiens
<400> 72
ccgagcccta cccggaggtc tccagaatcc ccaccgtcag gggatgcaac ggctccctgt 60
ctggtgccct ctcctgctgc gaggactcgg cccagggctc gggcccgccc aaggccccta 120
eggtggeega gggteeeage teetgeette ggeggaaegt gateagegag agggagegea 180
ggaagcggat gtcgttgagc tgtgagcgtc tgcgggccct gctgccccag ttcgatggcc 240
ggcgggagga catggcctcg gtcctggaga tgtctgttgc aattcctgcg
<210> 73
<211> 144
<212> PRT
<213> Homo sapiens
<400> 73
Lys Met Leu Asp Ala Glu Asp Ile Val Gly Thr Ala Arg Pro Asp Glu
  Lys Ala Ile Met Thr Tyr Val Ser Ser Phe Tyr His Ala Phe Ser Gly
       ·Ala Gln Lys Ala Glu Thr Ala Ala Asn Arg Ile Cys Lys Val Leu Ala
Val Asn Glu Asn Glu Gln Leu Met Glu Asp Tyr Glu Lys Leu Ala
   50 55
Ser Asp Leu Leu Glu Trp Ile Arg Arg Thr Ile Pro Trp Leu Glu Asn
    Arg Val Pro Glu Asn Thr Met His Ala Met Gln Gln Lys Leu Glu Asp
                  90
```

Phe Arg Asp Tyr Arg Arg Leu His Lys Pro Pro Lys Val Gln Glu Lys 105 100 Cys Gln Leu Glu Ile Asn Phe Asn Thr Leu Gln Thr Lys Leu Arg Leu 115 120 Ser Asn Arg Pro Ala Phe Met Pro Ser Glu Gly Arg Met Val Ser Asp 130 135 140 <210> 74 <211> 64 <212> PRT grangstate Cotton Silva <213> Homo sapiens <400> 74 Gly Ser Met Leu Val Glu Ser His His His Ser Leu Ile Ser Ser Thr - 10 5 Gln Gly His Lys His Cys Gly Arg Pro Gln Gly Pro Leu Pro Arg Lys 20 Thr Arg Asp Leu Cys Ser Leu Val Tyr Val Leu Thr Phe Pro Pro Leu **35** · Leu Ser Cys Asp Pro Ala Lys Ser Pro Phe Val Arg Asn Thr Gln Glu <210> 75 <211> 145 <212> PRT <213> Homo sapiens <400> 75 Gly Thr Gly Ala Ser Ser Gly Thr Arg Thr Pro Asp Val Lys Ala Phe Leu Glu Ser Pro Trp Ser Leu Asp Pro Ala Ser Ala Ser Pro Glu Pro Val Pro His Ile Leu Ala Ser Ser Arg Gln Trp Asp Pro Ala Ser Cys 40 45 Thr Ser Leu Gly Thr Asp Lys Cys Glu Ala Leu Leu Gly Leu Cys Gln 50 55 60 Val Arg Gly Gly Leu Pro Pro Phe Ser Glu Pro Ser Ser Leu Val Pro 65 75 80 Trp Pro Pro Gly Arg Ser Leu Pro Lys Ala Val Arg Pro Pro Leu Ser Trp Pro Pro Phe Ser Gln Gln Gln Thr Leu Pro Val Met Ser Gly Glu 100 105 110

Ala Leu Gly Trp Leu Gly Gln Ala Gly Ser Leu Ala Met Gly Ala Ala 120 125 115 Pro Leu Gly Glu Pro Ala Lys Glu Asp Pro Met Leu Ala Gln Glu Ala 140 . 135 130 Gly 145 <210> 76 **<211> 69** <212> PRT <213> Homo sapiens 亞 2 . ディー・ <400>g76: grade a compression of the compression of the participation of the compression Ala Glu Phe Cys Arg Pro Pro Ser Ser Glu Glu Glu Ser Ile Gly Ser か経過 (^表文句) こと extra constant (こうかつ constant) in the commence of the commenc Pro Glu Ile Glu Glu Met Ala Leu Phe Ser Ala Gln Ser Pro Tyr Ile 25 grant 20 miles 25 grant 20 grant 20 miles 25 grant 25 ರಾಜ್ಯ ಕಾರ್ಯದಲ್ಲಿ ಜನಕ ಅರ್ಜ್ಯ ಪ್ರಕ್ರಿಸಿ ಅರ್ಥದಲ್ಲಿ ಅಭಿಕೃತಿಗಳ ಪಟ್ಟಿಕೆಯಾಗಿದ್ದ ಅಧಿಕಾರಣಿಗೆ ಅಂತ ಭಾರತಗಳ ಬಿ. ಮಿಡಿ Asn Pro Ile Ile Pro Phe Thr Gly Pro Ile Gln Gly Gly Leu Gln Glu 40 min on makes the 1,450mg multiple of the col-35 Gly Leu Gln Val Thr Leu Gln Gly Thr Thr Glu Ser Phe Ala Gln Lys . 55 a dependent 60 to the group of a spring of the 50 Phe Val Val Asn Phe <210> 77 **<211> 96** <212> PRT .<213> Homo: sapiens grade and the contract of 7.7<400> 77.000 july of the straight of a linear green angles of the first times. Glu Pro Tyr Pro Glu Val Ser Arg Ile Pro Thr Val Arg Gly Cys Asn The state of the s ាលស្រាប់ ប្រាស្ត្រ សំខុងស្រុង សុំស្រុងស្រាម (ស្រាស្ត្រ កំណា) ស្រាប់ ប្រាស្ត្រសាស្ត្រី សុំស in the first terms of the second of the seco Gly Ser Leu Ser Gly Ala Leu Ser Cys Cys Glu Asp Ser Ala Gln Gly 30. 20 Ser Gly Pro Pro Lys Ala Pro Thr Val Ala Glu Gly Pro Ser Ser Cys 40 35 Leu Arg Arg Asn Val Ile Ser Glu Arg Glu Arg Arg Lys Arg Met Ser 60 50 55 Leu Ser Cys Glu Arg Leu Arg Ala Leu Leu Pro Gln Phe Asp Gly Arg 70 and the first of the second of Arg Glu Asp Met Ala Ser Val Leu Glu Met Ser Val Ala Ile Pro Ala

<210> 78 <211> 2076 <212> DNA <213> Homo sapiens

<400> 78

agaaaaagtc tatgtttgca gaaatacaga tccaagacaa agacaggatg ggcactgctg 60 gaaaagttat taaatgcaaa gcagctgtgc tttgggagca gaagcaaccc ttctccattg 120 aggaaataga agttgcccca ccaaagacta aagaagttcg cattaagatt ttggccacag 180 gaatctgtcg cacagatgac catgtgataa aaggaacaat ggtgtccaag tttccagtga 240 ttgtgggaca tgaggcaact gggattgtag agagcattgg agaaggagtg actacagtga 300 aaccaggtga caaagtcatc cctctcttc tgccacaatg tagagaatgc aatgcttgtc 360 gcaacccaga tggcaacctt tgcattagga gcgatattac tggtcgtgga gtactggctg 420 atggcaccac cagatttaca tgcaagggca aaccagtcca ccacttcatg aacaccagta 480 catttaccga gtacacagtg gtggatgaat cttctgttgc taagattgat gatgcagctc 540 ctcctgagaa agtctgttta attggctgtg ggttttccac tggatatggc gctgctgtta 600 aaactggcaa ggtcaaacct ggttccactt gcgtcgtctt tggcctgaga ggagttggcc 660 tgtcagtcat catgggctgt aagtcagctg gtgcatctag gatcattggg attgacctca 320 acaaagacaa atttgagaag gccatggctg taggtgccac tgagtgtatc agtcccaagg 780 actctaccaa acccatcagt gaggtgctgt cagaaatgac aggcaacaac gtgggataca 840 cctttgaagt tattgggcat cttgaaacca tgattgatgc cctggcatcc tgccacatga 900 actatgggac cagcgtggtt gtaggagttc ctccatcagc caagatgctc acctatgacc 960 cgatgttgct cttcactgga cgcacatgga agggatgtgt ctttggaggt ttgaaaagca 1020 gagatgatgt cccaaaacta gtgactgagt tcctggcaaa gaaatttgac ctggaccagt 1080 tgataactca tgtcttacca tttaaaaaaa tcagtgaagg atttgagctg ctcaattcag 1140 gacaaagcat tcgaacggtc ctgacgtttt gagatccaaa gtggcaggag gtctgtgttg 1200 tcatggtgaa ctggagtttc tcttgtgaga gttccctcat ctgaaatcat gtatctgtct 1260 cacaaataca agcataagta gaagatttgt tgaagacata gaacccttat aaagaattat 1320 taacctttat aaacatttaa agtcttgtga gcacctggga attagtataa taacaatgtt 1380 aatatttttg atttacattt tgtaaggcta taattgtatc ttttaagaaa acatacactt 1440 ggatttctat gttgaaatgg agatttttaa gagttttaac cagctgctgc agatatatat 1500 ctcaaaacag atatagcgta taaagatata gtaaatgcat ctcctagagt aatattcact 1560 taacacattg aaactattat tttttagatt tgaatataaa tgtatttttt aaacacttgt 1620 tatgagttaa cttggattac attttgaaat cagttcattc catgatgcat attactggat 1680 tagattaaga aagacagaaa agattaaggg acgggcacat ttttcaacga ttaagaatca 1740 tcattacata acttggtgaa actgaaaaag tatatcatat gggtacacaa ggctatttgc 1800 cagcatatat taatatttta gaaaatattc cttttgtaat actgaatata aacatagagc 1860 tagaatcata ttatcatact tatcataatg ttcaatttga tacagtagaa ttgcaagtcc 1920 ttaagtccct attcactgtg cttagtagtg actccattta ataaaaagtg tttttagttt 1980 ttaacaacta cactgatgta tttatatata tttataacat gttaaaaatt tttaaggaaa 2040 ttaaaaatta tataaaaaaa aaaaaaaaaa ctcgag 2076

<210> 79
<211> 2790
<212> DNA
<213> Homo sapiens

<400> 79

aagcagttga gtaggcagaa aaaagaacct cttcattaag gattaaaatg tataggccag 60 cacgtgtaac ttcgacttca agatttctga atccatatgt agtatgtttc attgtcgtcg 120 caggggtagt gatcctggca gtcaccatag ctctacttgt ttacttttta gcttttgatc 180 aaaaatctta cttttatagg agcagttttc aactcctaaa tgttgaatat aatagtcagt 240

```
taaattcacc agctacacag gaatacagga ctttgagtgg aagaattgaa tctctgatta 300
ctaaaacatt caaagaatca aatttaagaa atcagttcat cagagctcat gttgccaaac 360
tgaggcaaga tggtagtggt gtgagagcgg atgttgtcat gaaatttcaa ttcactagaa 420
ataacaatgg agcatcaatg aaaagcagaa ttgagtctgt tttacgacaa atgctgaata 480
actctggaaa cctggaaata aacccttcaa ctgagataac atcacttact gaccaggctg 540
cagcaaattg gcttattaat gaatgtgggg ccggtccaga cctaataaca ttgtctgagc 600
agagaateet tggaggeact gaggetgagg agggaagetg geegtggeaa gteagtetge 660
ggctcaataa tgcccaccac tgtggaggca gcctgatcaa taacatgtgg atcctgacag 720
cageteactg etteagaage aactetaate etegtgaetg gattgecaeg tetggtattt 780
ccacaacatt tcctaaacta agaatgagag taagaaatat tttaattcat aacaattata 840
aatctgcaac tcatgaaaat gacattgcac ttgtgagact tgagaacagt gtcaccttta 900
ccaaagatat ccatagtgtg tgtctcccag ctgctaccca gaatattcca cctggctcta 960
ctgcttatgt aacaggatgg ggcgctcaag aatatgctgg ccacacagtt ccagagctaa 1020
ggcaaggaca ggtcagaata ataagtaatg atgtatgtaa tgcaccacat agttataatg 1080
gagccatctt gtctggaatg ctgtgtgctg gagtacctca aggtggagtg gacgcatgtc 1140
agggtgactc tggtggccca ctagtacaag aagactcacg gcggetttgg tttattgtgg 1200
ggatagtaag ctggggagat cagtgtggcc tgccggataa gccaggagtg tatactcgag 1260
tgacagceta cettgactgg attaggcaac aaactgggat ctagtgcaac aagtgcatce 1320
ctgttgcaaa gtctgtatgc aggtgtgcct gtcttaaatt ccaaagcttt acatttcaac 1380
tgaaaaagaa actagaaatg tcctaattta acatcttgtt acataaatat ggtttaacaa 1440
acactgttta acctttcttt attattaaag gttttctatt ttctccagag aactatatga 1500
atgttgcata gtactgtggc tgtgtaacag aagaaacaca ctaaactaat tacaaagtta 1560
acaatttcat tacagttgtg ctaaatgccc gtagtgagaa gaacaggaac cttgagcatg 1620
tatagtagag gaacctgcac aggtctgatg ggtcagaggg gtcttctctg ggtttcactg 1680
aggatgagaa gtaagcaaac tgtggaaaca tgcaaaggaa aaagtgatag aataatattc 1740
aagacaaaaa gaacagtatg aggcaagaga aatagtatgt atttaaaatt tttggttact 1800-
caatatetta taettagtat gagteetaaa attaaaaatg tgaaaetgtt gtaetataeg: 1860
tataacctaa ccttaattat tctgtaagaa catgcttcca taggaaatag tggataattt 1920
tcagctattt aaggcaaaag ctaaaatagt tcactcctca actgagaccc aaagaattat 1980
agatatttt catgatgacc catgaaaaat atcactcatc tacataaagg agagactata 2040
tctattttat agagaagcta agaaatatac ctacacaaac ttgtcaggtg ctttacaact 2100
acatagtact ttttaacaac aaaataataa ttttaagaat gaaaaattta atcatcggga 2160
agaacgtccc actacagact tcctatcact ggcagttata tttttgagcg taaaagggtc 2220
gtcaaacgct aaatctaagt aatgaattga aagtttaaag agggggaaga gttggtttgc 2280
aaaggaaaag tttaaatagc ttaatatcaa tagaatgatc ctgaagacag aaaaaacttt 2340
gtcactcttc ctctctcatt ttctttctct ctctctcccc ttctcataca catgcctccc 2400
cgaccaaaga atataatgta aattaaatcc actaaaatgt aatggcatga aaatctctgt 2460
agtctgaatc actaatattc ctgagttttt atgagctcct agtacagcta aagtttgcct 2520
atgcatgatc atctatgcgt cagagettee teettetaca agetaactee etgcatetgg 2580
gcatcaggac tgctccatac atttgctgaa aacttcttgt atttcctgat gtaaaattgt 2640
gcaaacacct acaataaagc catctacttt tagggaaagg gagttgaaaa tgcaaccaac 2700
tcttggcgaa ctgtacaaac aaatctttgc tatactttat ttcaaataaa ttctttttga 2760
                                                                 2790
                                        aatgaaaaaaaaaaaaa aaaactcgag
```

<210> 80

<211> 1460

<212> DNA

<213> Homo sapiens

<400> 80

ctcaaagcag ttgagtaggc agaaaaaaga acctcttcat taaggattaa aatgtatagg 60 ccagcacgtg taacttcgac ttcaagattt ctgaatccat atgtagtatg tttcattgtc 120 gtcgcagggg tagtgatcct ggcagtcacc atagctctac ttgtttactt tttagctttt 180 gatcaaaaat cttactttta taggagcagt tttcaactcc taaatgttga atataatagt 240 cagttaaatt caccagctac acaggaatac aggactttga gtggaagaat tgaatctctg 300

attactaaaa cattcaaaga atcaaattta agaaatcagt tcatcagagc tcatgttgcc 360 aaactgaggc aagatggtag tggtgtgaga gcggatgttg tcatgaaatt tcaattcact 420 agaaataaca atggagcatc aatgaaaagc agaattgagt ctgttttacg acaaatgctg 480 aataactctg gaaacctgga aataaaccct tcaactgaga taacatcact tactgaccag 540 gctgcagcaa attggcttat taatgaatgt ggggccggtc cagacctaat aacattgtct 600 gagcagagaa teettggagg caetgagget gaggagggaa getggeegtg geaagteagt 660 etgeggetea ataatgeeea eeactgtgga ggeageetga teaataaeat gtggateetg 720 acagcagete actgetteag aagcaactet aateetegtg actggattge caegtetggt 780 atttccacaa catttcctaa actaagaatg agagtaagaa atatttaat tcataacaat 840 tataaatetg caacteatga aaatgacatt geacttgtga gaettgagaa cagtgteace 900 tttaccaaag atatccatag tgtgtgtctc ccagctgcta cccagaatat tccacctggc 960 tctactgctt atgtaacagg atggggggct caagaatatg ctggccacac agttccagag 1020 ctaaggcaag gacaggtcag aataataagt aatgatgtat gtaatgcacc acatagttat 1080 aatggagcca tettgtetgg aatgetgtgt getggagtae etcaaggtgg agtggaegea 1140 tgtcagggtg actctggtgg cccactagta caagaagact cacggegget ttggtttatt 1200 gtggggatag taagetgggg agateagtgt ggeetgeegg ataageeagg agtgtataet 1260 cgagtgacag cctaccttga ctggattagg caacaaactg ggatctagtg caacaagtgc 1320 atccctgttg caaagtetgt atgcaggtgt gcctgtetta aattecaaag etttacattt 1380 caactgaaaa agaaactaga aatgteetaa tttaacatet tgttacataa atatggttta 1440 *acaaaaaaaaaaaaa

and the second of the second of the second

A SECTION OF SECTION AND A SECTION OF SECTION AND A SECTION OF SECTION ASSESSMENT OF SECTION ASSESSMENT ASSESS

受ける しゅくしょ 自己を終し いんしゅわけ たいしょ はいしましょ

Met Phe Ala Glu Ile Gln Ile Gln Asp Lys Asp Arg Met Gly Thr Ala 10 15 ljekali **1**900. – og k*el* o

"望海"。在西洋的"我",这一个大学,这些作为一点,一个意识,这一个"我",不是是一个原则是一个不是一个

Gly Lys Val Ile Lys Cys Lys Ala Ala Val Leu Trp Glu Gln Lys Gln પાસની વધુ પુરા સાંગ 20 કે ્ 25 30

Pro Phe Ser Ile Glu Glu Ile Glu Val Ala Pro Pro Lys Thr Lys Glu 타용하다 가게 1대 ~<**/35**.40 기타 가수 가능하다 45

Val Arg Ile Lys Ile Leu Ala Thr Gly Ile Cys Arg Thr Asp Asp His 7888 - 50% - Korney Greek Startman (1995) - 550 - 560 - 1990 - 1990 - 1990 - 1990 - 1990 - 1990 - 1990 - 1990

- ప్రేశ్లు అన్నార్స్ కార్స్ కోర్టుకు కార్యా కొర్యాకుకోంది. కార్డ్ క్రామ్ కార్డ్ క్రామ్ కార్స్ కార్డ్ కార్డ్ కో ఇంక

Val Ile Lys Gly Thr Met Val Ser Lys Phe Pro Val Ile Val Gly His 節部 65 TT はため TT についけたい 70。 といいいはいし は、こうでの750 TT に見ずめれには、こはない 80⁵ 8点点に

india kan takan dan kembanan menalah berandan bahan pertamban bahan bahan bahan bahan mengerapa bija

Glu Ala Thr Gly Ile Val Glu Ser Ile Gly Glu Gly Val Thr Val Gly Glu Gly Val Thr Val 85

Lys Pro Gly Asp Lys Val Ile Pro Leu Phe Leu Pro Gln Cys Arg Glu 110 100 105

Cys Asn Ala Cys Arg Asn Pro Asp Gly Asn Leu Cys Ile Arg Ser Asp 115 120 125

Ile Thr Gly Arg Gly Val Leu Ala Asp Gly Thr Thr Arg Phe Thr Cys 140

Lys Gly Lys Pro Val His His Phe Met Asn Thr Ser Thr Phe Thr Glu

145		· ;			120		<i>.</i> ∙.			122		•			100	· •.
Tyr	Thr	Val.	Val	Asp 165	Glu	Ser	Ser	Val	Ala 170	Lys	Ile	Asp	Asp	Ala 175	Ala	,
Pro	Pro	Glu	Lys 180	Val	Cys	Leu	Ile	Gly 185	Суз	Gly	Phe	Ser	Thr 190	Gly	Tyr	
Gly	Ala	Ala 195	V al	Lys	Thr	Gly	Lys 200	Val	Lys	Pro	Gly	Ser 205	Thr	Cys	Val	erjj j
Val	Phe 210	Gly	Leu	Arg	Gly	Val 215	Gly	Leu	Ser	Val	11e 220	Met	Gly	Cys	Lys	ight. Sky
Ser 225	Ala	Gly	Ala	Ser	Arg 230	Ile	Ile pu	Gly	Ile	Asp 235	. Leu	Asn	Lys	Asp	Lys 240	iā.
Phe	Glu	Lys		Met 245	Ala	Val	Gly	Ala	Thr. 250	Glu	Cys	Ile	Ser,	Pro 255	Lys	. * % 7 - -
Asp	Ser	Thr	Lys 260	Pro	Ile	Ser	Glu	Val 265	Leu	Ser	Glu	Met	Thr 270	Gly	Asn	* 35.
Asn	Val:	Gly 275	Tyr	Thr	Phe	Glu	Val 280	Ile	Gly	His,	Leu	Glu 285	Thr	Met	Ile Boy	
Asp ·	Ala 290		Ala	Ser	Cys	His 295	Met	Asņ	Tyr	Gly	Thr 300	Ser	Val	Val	Val	net *:
305	Val.	Pro	Pro	Ser	Ala 310	Lys	Met	Leu	Thr	Tyr 315	Asp	Pro	Met	Leu	Leu 320	
Phe	Thr	Gly	Arg	Thr 325	Trp	Lys	Gly	Cys	Val 330	Phe	Gly	Gly	Leu	135	Ser	
Arg	Asp	Asp.	Val 340	Pro	Lys	Leu	Val	Thr. 345	Glu	Phe	Leu.	Ala	150	Lys	Phe	¥
Asp	Leu	Asp 355	Gln/	Leu.	Ile; pes	Thr	His 360	Val,	Leu	Pro	Phe	145 365	Lys	Ile,	Ser	5 1 G
Glu	Gly 370		Glu	Leu	Leu	Asn 375	Ser	Gly,	Gln	Ser	11e 380	Arg	Thr	Val	Leu	
Thr 385	Phe		. : .	. 1 174	i ~ - f			· · .	***	जन्म	العاد فيدي الماد العاد العاد الماد		wit.	- سی ^م -	14.7°	
<211	> 41	.8 ·														
<400 Met	> 82 Tyr	Arg	Pro	Ala	Arg	Val	Thr	Ser	Thr	ser_	Arg	Phe	Leu	Asn	Pro	

, 1	•. •			5	-	. : .	-		10		•	·		15	-
Tyr	Val	Val	Cys 20	Phe	Ile	V al	Val	Ala 25	Gly	Val	Val	Ile	Leu 30	Ala	Val
Thr	Ile	Ala 35	Leu	Leu	Val	Tyr	Phe 40	Leu	Ala	Phe	Asp	Gln 45	Lys	Ser	Tyr
Phe	Tyr 50	Arg	Ser	Ser	Phe	Gln 55	Leu	Leu	Asn	Val	Glu 60	Tyr	Asn	Ser	Gln
Leu 65	Asn	Ser	Pro	Ala	Thr 70	Gln	Glu	Tyr	Arg	Thr 75	Leu	Ser	Gly	Arg	11e 80
Glu	Ser	Leu	Ile	Thr 85	Lys	Thr	Phe	Lys	Glu 90	Ser	Asn	Leu	Arg	Asn 95	Gln
Phe	Ile	Arg	Alá 100	His	Val	Ala	Lys	Leu 105	Arg	Gln	Asp	Gly	Ser 110	Gly	Val
Arg	Ala	Asp 115	Val	Val	Met	Lys	Phe 120	Gln	Phe	Thr	Arg	Asn 125	Asn	Asn	Gly
Ala	Ser 130	Met	Lys	Ser	Arg	11e 135	Glu	Ser	V al	Leu	Arg 140	Gln	Met	Leu	Asn
Asn 145	Ser	Gly	Asn	Leu	Glu 150		Asn	Pro	Ser	Thr 155	-	Ilė	Thr		Leu 160
Thr	Asp	Gln	Ala	Ala 165	Ala	Asn	Trp	Leu	11e 170	Asn	Glu	Cys	Gly	Ala 175	GÎÿ
Pro	Asp	Leu	Ile 180	Thr	Leu	Ser	Glu	Gln 185	Arg	Ile	Leu	Gly	Gly 190	Thr	Glu
Ala	Glu	Glu 195	Gly	Ser	Tŕp	Pro	Trp 200	Gln	Val	Ser	Leu	Arg 205	Leu	Asn	Asn
Ala	His 210	His	Сув	Gly	Gly	Ser 215	Leu	Ile	Asn	Asn	Met 220	Trp	Ile	Leu	Thr
Ala 225	Ala	His	Суѕ	Phe	Arg 230	Ser	Asn	Ser	Asn	Pro 235	Arg	Asp	Trp	Ile	Ala 240
Thr	Ser	Gly	Ile	Ser 245	Thr	Thr	Phe	Pro	Lys 250	Leu	Arg	Met	Arg	Val 255	Arg
Asn	Ile	Leu	Ile 260	His	Asn	Asn	Tyr	Lys 265	Ser	Ala	Thr	His	Glu 270	Asn	Asp
Ile	Ala	Leu 275	V al	Arg	Leu	Glu	Asn 280	Ser	V al	Thr	Phe	Thr 285	Lys	Asp	Ile
His	Ser 290	Val	Cys	Leu	Pro	Ala 295	Ala	Thr	Gln	Asn	Ile 300	Pro	Pro	Gly	Ser

Thr Ala Tyr Val Thr Gly Trp Gly Ala Gln Glu Tyr Ala Gly His Thr 310 315 320 305 Val Pro Glu Leu Arg Gln Gly Gln Val Arg Ile Ile Ser Asn Asp Val 325 330 Cys Asn Ala Pro His Ser Tyr Asn Gly Ala Ile Leu Ser Gly Met Leu ...340 (See 2017) 1345° Cys Ala Gly Val Pro Gln Gly Gly Val Asp Ala Cys Gln Gly Asp Ser 360 355 Gly Gly Pro Leu Val Gln Glu Asp Ser Arg Arg Leu Trp Phe Ile Val 370 Gly Ile Val Ser Trp Gly Asp Gln Cys Gly Leu Pro Asp Lys Pro Gly 390 m 385 400 5 S. A. Val Tyr Thr Arg Val Thr Ala Tyr Leu Asp Trp Ile Arg Gln Gln Thr 410 17.50 Gly Ile <211> 418 <212> PRT <213> Homo sapiens <400> 83 Met Tyr Arg Pro Ala Arg Val Thr Ser Thr Ser Arg Phe Leu Asn Pro 5 a 0 1 1 10 15 Tyr Val Val Cys Phe Ile Val Val Ala Gly Val Val Ile Leu Ala Val Thr Ile Ala Leu Leu Val Tyr Phe Leu Ala Phe Asp Gln Lys Ser Tyr - 35 Phe Tyr Arg Ser Ser Phe Gln Leu Leu Asn Val Glu Tyr Asn Ser Gln 50 55 Leu Asn Ser Pro Ala Thr Gln Glu Tyr Arg Thr Leu Ser Gly Arg Ile 65 70 Glu Ser Leu Ile Thr Lys Thr Phe Lys Glu Ser Asn Leu Arg Asn Gln 85 Phe Ile Arg Ala His Val Ala Lys Leu Arg Gln Asp Gly Ser Gly Val 100 105 Arg Ala Asp Val Val Met Lys Phe Gln Phe Thr Arg Asn Asn Gly 120 125 115:

Ala Ser Met Lys Ser Arg Ile Glu Ser Val Leu Arg Gln Met Leu Asn Asn Ser Gly Asn Leu Glu Ile Asn Pro Ser Thr Glu Ile Thr Ser Leu Thr Asp Gln Ala Ala Asn Trp Leu Ile Asn Glu Cys Gly Ala Gly Pro Asp Leu Ile Thr Leu Ser Glu Gln Arg Ile Leu Gly Gly Thr Glu Ala Glu Glu Gly Ser Trp Pro Trp Gln Val Ser Leu Arg Leu Asn Asn Ala His His Cys Gly Gly Ser Leu Ile Asn Asn Met Trp Ile Leu Thr Ala Ala His Cys Phe Arg Ser Asn Ser Asn Pro Arg Asp Trp Ile Ala -Thr Ser Gly Ile Ser Thr Thr Phe Pro Lys Leu Arg Met Arg Val Arg Asn Ile Leu Ile His Asn Asn Tyr Lys Ser Ala Thr His Glu Asn Asp Ile Ala Leu Val Arg Leu Glu Asn Ser Val Thr Phe Thr Lys Asp Ile His Ser Val Cys Leu Pro Ala Ala Thr Gln Asn Ile Pro Pro Gly Ser Thr Ala Tyr Val Thr Gly Trp Gly Ala Gln Glu Tyr Ala Gly His Thr 310 315 Val Pro Glu Leu Arg Gln Gly Gln Val Arg Ile Ile Ser Asn Asp Val Cys Asn Ala Pro His Ser Tyr Asn Gly Ala Ile Leu Ser Gly Met Leu Cys Ala Gly Val Pro Gln Gly Gly Val Asp Ala Cys Gln Gly Asp Ser 🕬 Gly Gly Pro Leu Val Gln Glu Asp Ser Arg Arg Leu Trp Phe Ile Val Gly Ile Val Ser Trp Gly Asp Gln Cys Gly Leu Pro Asp Lys Pro Gly Val Tyr Thr Arg Val Thr Ala Tyr Leu Asp Trp Ile Arg Gln Gln Thr

```
Gly Ile
  <210> 84
  <211> 489
  <212> DNA
  <213> Homo sapiens
<400× 84
aaaagggtaa gcttgatgat taccaggaac gaatgaacaa aggggaaagg cttaatcaag 60
  atcagctgga tgccgtttct aagtaccagg aagtcacaaa taatttggag tttgcaaaag 120
 aattacagag gagtttcatg gcactaagtc aagatattca gaaaacaata aagaagacag 180
  cacgtcggga gcagcttatg agagaagaag ctgaacagaa acgtttaaaa actgtacttg 240
  agctacagta tgttttggac aaattgggag atgatgaagt gcggactgac ctgaaacaag 300
 gtttgaatgg agtgccaata ttgtccgaag aggagttgtc attgttggat gaattctata 360
 agctagtaga ccctgaacgg gacatgagct tgaggttgaa tgaacagtat gaacatgcct 420
 ccattcacct gtgggacctg ctggaaggga aggaaaaacc tgtatgtgga accacctata 480
  aagttctaa
 <210> 85
 <211> 304
 <212> DNA
 <213> Homo sapiens
     <400> 85
 gggacctgga ggaggccacg ctgcagcatg aagccacagc agccaccctg aggaagaagc 60
 acgcggacag cgtggccgag ctcggggagc agatcgacaa cctgcagcgg gtgaagcaga 120
 agctggagaa ggagaagagc gagatgaaga tggagatcga tgacctcgct tgtaacatgg 180
 aggtcatctc caaatctaag ggaaaccttg agaagatgtg ccgcacactg gaggaccaag 240
 tgagtgaget gaagaeeeag gaggaggaae ageagegget gateaatgaa etgaetgege 300
 agag
 <210> 86
 <211> 296 %
 <212> DNA ( )
 <213> Homo sapiens
 <400> 86
gaaaatcctt cctttgaatg ggaatctcca agcagttgaa ttgggcgaaa aaagaacctc 60
ttccttaagg attaaaatgt ttagggcaac acgtgttact tccacttcca gatttctgaa 120
 tccatatgtt gtatgtttcc ttgtcctccc aggggttgtg atcctggcag tccccatagc 180
 tctacttgtt tactttttag cttttgatca aaaatcttac ttttattgga gcaattttcc 240
actcccaaat gttgaatata atagtccgtt taattccccc gcttcaccgg gaattc
<210> 87
<211> 904
 <212> DNA
<213> Homo sapiens
<400> 87
gtgtccagga aacgattcat gaacataaca agcttgctgc aaattcagat catctcatgc 60
agattcaaaa atgtgagttg gtcttgatcc acacctaccc agttggtgaa gacagccttg 120
tatctgatcg ttctaaaaaa gagttgtccc cggttttaac cagtgaagtt catagtgttc 180
gtgcaggacg gcatcttgct accaaattga atattttagt acagcaacat tttgacttgg 240
cttcaactac tattacaaat attccaatga aggaagaaca gcatgctaac acatctgcca 300
attatgatgt ggagctactt catcacaaag atgcacatgt agatttcctg aaaagtggtg 360
```

```
attcgcatct aggtggcggc agtcgagaag gctcgtttaa agaaacaata acattaaagt 420
    ggtgtacacc aaggacaaat aacattgaat tacactattg tactggagct tatcggattt 480
    cacctgtaga tgtaaatagt agaccttcct cctgccttac taattttctt ctaaatggtc 540
    gttctgtttt attggaacaa ccacgaaagt caggttctaa agtcattagt catatgctta 600
    gtagccatgg aggagagatt tttttgcacg tccttagcag ttctcgatcc attctagaag 660
    atccaccttc aattagtgaa ggatgtggag gaagagttac agactaccgg attacagatt 720
    ttggtgaatt tatgagggga aaacagatta actccttttc tacaccccag atataaaatc 780
    gatggaagtc ttgaggtccc tttggaaccg agccaaaaga tcagttaaaa aaacataccc 840
    gttactggcc tatgatttca aaaacccacc atttttaaca tgcaagcggt agttccgtta 900
acca
                                                                                       可是一种原理的 1000 (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995) (1995)
    <210> 88
                                                                                           <211> 387
                                                                                         人名英格兰人姓氏克里特 人名英格兰 医神经神经病
    <212> DNA
                                                                                          <213> Homo sapiens
                                                                                 cgtctctccc ccagtttgcc gttcacccgg agcgctcggg acttgccgat agtggtgacg 60
    gcggcaacat gtctgtggct ttcgcggccc cgaggcagcg aggcaagggg gagatcactc 120
    ccgctgcgat tcagaagatg ttggatgaca ataaccatct tattcagtgt ataatggact 180
    ctcagaataa aggaaagacc tcagagtgtt ctcagtatca gcagatgttg cacacaaact 240
    tggtatacct tgctacaata gcagattcta atcaaaatat gcagtctctt ttaccagcac 300
    cacccacaca gaatatgcct atgggtcctg gagggatgaa tcagagcggg cctccccac 360
    ctccacgctc tcacaacatg ccttcaa
                                                                                                                                                                                                      . - }9₽387 -
                                                                                  我们还有一个<del>我们的,她不是一个一个</del>
    <210> 89
                                                                     <211> 481
                                                                               · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 · 1985 ·
<212> DNA
                                                                                 (1) A (1) 
 <213> Homo sapiens
  <400> 89
    tgttcttgga cctgcggtgc tatagagcag gctcttctag gttggcagtt gccatggaat 60
    ctggacccaa aatgttggcc cccgtttgcc tggtggaaaa taacaatgag cagctattgg 120
    tgaaccagca agctatacag attettgaaa agatttetea gecagtggtg gtggtggeca 180
    ttgtaggact gtaccgtaca gggaaatcct acttgatgaa ccatctggca ggacagaatc 240
    atggcttccc tctgggctcc acggtgcagt ctgaaaccaa gggcatctgg atgtggtgcg 300:
    tgccccaccc atccaagcca aaccacaccc tggtccttct ggacaccgaa ggtctgggcg 360
   atgtggaaaa gggtgaccct aagaatgact cctggatctt tgccctggct gtgctcctgt 420
   geageacett tgtetacaac ageatgagea ceateaacea ceaggeeetg gageagetge 480
                                                                                    The transfer of the Contract o
                                                                                  <210> 90
    <211> 491
   <212> DNA
   <213> Homo sapiens
   <400> 90
   tgaaaactgt tettggacet geggtgetat agageaggtt ggeagttgee atggaatetg 60
   gacccaaaat gttggcccc gtttgcctgg tggaaaataa caatgagcag ctattggtga: 120
   accagcaage tatacagatt cttgaaaaga tttctcagec agtggtggtg gtggccattg 180
   taggactgta ccgtacaggg aaatcctact tgatgaacca tctggcagga cagaatcatg 240
  getteeetet gggeteeaeg gtgeagtetg aaaccaaggg catetggatg tggtgegtge 300
   cccacccatc caagccaaac cacaccctgg tccttctgga caccgaaggt ctgggcgatg 360
   tggaaaaggg tgaccctaag aatgactcct ggatctttgc cctggctgtg ctcctgtgca 420
  gcacctttgt ctacaacagc atgagcacca tcaaccacca agccctggag cagctgcatt 480
```

```
atgtgacgga c
 <210> 91
 <211> 488
 <212> DNA
 <213> Homo sapiens
                    <400> 91
ttcgacagtc agccgcatct tcttttgcgt cgccagccga gccacatcgc tcagacacca 60
 tggggaaggt gaaggtcgga gtcaacggat ttggtcgtat tgggcgcctg gtcaccaggg 120
ctgcttttaa ctctggtaaa gtggatattg ttgccatcaa tgacccettc attgacctca 180
 actacatggt tracatgtte caatatgatt ccacccatgg caaattecat ggeaccgteg 240
aggctgagaa cgggaagctt gtcatcaatg gaaatcccat caccatcttc caggagcgag 300
atccctccaa aatcaagtgg ggcgatgctg gcgctgagta cgtcgtggag tccactggcg 360
tetteaceae catggagaag getggggete atttgcaggg gggagecaaa agggteatea 420
tctctgcccc tctgctgatg ccccatgttc gtcatgggtg tgaaccatga gaagtatgac 480
acagcctc
                                                         ** - 1488-
                                                        起 2 4 - 《美国影片
<210> 92
                                                        到你一个知题。
<211> 384
                                                 医环点 建铁铁 电磁磁性 化重氮基氯酸
<212> DNA
<213> Homo sapiens
<400> 92
gacagtcagc cgcatcttct tttgcgtcgc cagccgagcc acatcgctca gacaccatgg 60
ggąaggtgaa ggteggagte aaeggatttg gtegtattgg gegeetggte aeeagggetg 120
cttttaactc tggtaaagtg gatattgttg ccatcaatga ccccttcatt gacctcaact 180
acatggttta catgttccaa tatgattcca cccatggcaa attccatggc accgtcgagg 240
ctgagaacgg gaagettgte ateaatggaa ateceateae catettecag gagegagate 300
cctccaaaat caagtgggc gatactggcg ctgagtacgt cgtggagtcc actggcgtct 360
tcaccaccat ggagaaggct gggg
                                                                 384
<210> 93
<211> 162
<212> PRT
<213> Homo sapiens
                大型的 医工作 医乳腺 医乳化 经收款 人名英格兰 医大胆 医大胆 化二基 计设置 经销售 化螺纹
<400>, 93
Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg
  1
                                                        15
                                                      Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr
                                25 .
                                                    30
Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Che
         35
                             40
Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln
     50
                        55
                                                          Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu
 65
                    70
                                        75
                                                           80
Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp . . . .
                                    90
```

Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu 110 105 100 Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp Pro Glu Arg Asp Met 125 120 115 Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp 5. 130 h La 17 % 7 h 3 1 1 35 % 8 1 1 1 1 1 Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu <210> 94 <211> 100 <212> PRT <213> Homo sapiens <400> 94 Asp Leu Glu Glu Ala Thr Leu Gln His Glu Ala Thr Ala Ala Thr Leu the properties and the contract of the contract of the contract of the contract of Arg Lys Lys His Ala Asp Ser Val Ala Glu Leu Gly Glu Gln Ile Asp 20 7 7 7 22 25 25 25 25 25 Asn Leu Gln Arg Val Lys Gln Lys Leu Glu Lys Glu Lys Ser Glu Met 107 St. September 35. 11 2 July 20 10 10 10 10 10 140 140 1 11 11 11 -Lys Met Glu Ile Asp Asp Leu Ala Cys Asn Met Glu Val Ile Ser Lys 60 50 55 Ser Lys Gly Asn Leu Glu Lys Met Cys Arg Thr Leu Glu Asp Gln Val 70 Ser Glu Leu Lys Thr Gln Glu Glu Gln Gln Arg Leu Ile Asn Glu Leu Thr Ala Gln 1. 4.4 (4.11) 3.5 (4.5) 100 The second of the second of the second of the second <211>. 99 <212> PRT <400> 95 Lys Ile Leu Pro Leu Asn Gly Asn Leu Gln Ala Val Glu Leu Gly Glu **5** . 10 1 Lys Arg Thr Ser Ser Leu Arg Ile Lys Met Phe Arg Ala Thr Arg Val 20

Thr Ser Thr Ser Arg Phe Leu Asn Pro Tyr Val Val Cys Phe Leu Val

Leu Pro Gly Val Val Ile Leu Ala Val Pro Ile Ala Leu Leu Val Tyr
50 55 60

Phe Leu Ala Phe Asp Gln Lys Ser Tyr Phe Tyr Trp Ser Asn Phe Pro
65 70 75 80

Leu Pro Asn Val Glu Tyr Asn Ser Pro Phe Asn Ser Pro Ala Ser Pro 85 90 95

Gly Ile Pro

<210> 96

444

<211> 257

<212> PRT

<213> Homo sapiens

<400> 96

Val Gln Glu Thr Ile His Glu His Asn Lys Leu Ala Ala Asn Ser Asp 1 5 10 15

His Leu Met Gln Ile Gln Lys Cys Glu Leu Val Leu Ile His Thr Tyr
20 25 30

Pro Val Gly Glu Asp Ser Leu Val Ser Asp Arg Ser Lys Glu Leu
35 40 45

Ser Pro Val Leu Thr Ser Glu Val His Ser Val Arg Ala Gly Arg His
50 55 60

Leu Ala Thr Lys Leu Asn Ile Leu Val Gln Gln His Phe Asp Leu Ala
65 70 75 80

Ser Thr Thr Ile Thr Asn Ile Pro Met Lys Glu Glu Gln His Ala Asn
85 90 95

Thr Ser Ala Asn Tyr Asp Val Glu Leu Leu His His Lys Asp Ala His
100 105 110

Val Asp Phe Leu Lys Ser Gly Asp Ser His Leu Gly Gly Gly Ser Arg 115 120 125

Glu Gly Ser Phe Lys Glu Thr Ile Thr Leu Lys Trp Cys Thr Pro Arg 130 135 140

Thr Asn Asn Ile Glu Leu His Tyr Cys Thr Gly Ala Tyr Arg Ile Ser 145 150 155 160

Pro Val Asp Val Asn Ser Arg Pro Ser Ser Cys Leu Thr Asn Phe Leu 165 170 175 Leu Asn Gly Arg Ser Val Leu Leu Glu Gln Pro Arg Lys Ser Gly Ser 180 185 190

Lys Val Ile Ser His Met Leu Ser Ser His Gly Gly Glu Ile Phe Leu 195 200 205

His Val Leu Ser Ser Ser Arg Ser Ile Leu Glu Asp Pro Pro Ser Ile 210 215 220

Ser Glu Gly Cys Gly Gly Arg Val Thr Asp Tyr Arg Ile Thr Asp Phe 225 230 235 240

Gly Glu Phe Met Arg Gly Lys Gln Ile Asn Ser Phe Ser Thr Pro Gln 245 250 255

Ile

<210> 97

<211> 128

<212> PRT

<213> Homo sapiens

<400> 97

Ser Leu Pro Gln Phe Ala Val His Pro Glu Arg Ser Gly Leu Ala Asp 1 5 10 15

Ser Gly Asp Gly Gly Asn Met Ser Val Ala Phe Ala Ala Pro Arg Gln

Arg Gly Lys Gly Glu Ile Thr Pro Ala Ala Ile Gln Lys Met Leu Asp
35 40 45

Asp Asn Asn His Leu Ile Gln Cys Ile Met Asp Ser Gln Asn Lys Gly
50 55 60

Lys Thr Ser Glu Cys Ser Gln Tyr Gln Gln Met Leu His Thr Asn Leu 65 70 75 80

Val Tyr Leu Ala Thr Ile Ala Asp Ser Asn Gln Asn Met Gln Ser Leu
85 90 95

Leu Pro Ala Pro Pro Thr Gln Asn Met Pro Met Gly Pro Gly Gly Met
100 105 110

Asn Gln Ser Gly Pro Pro Pro Pro Pro Arg Ser His Asn Met Pro Ser 115 120 125

医内部性骨髓 医二甲酚 医克尔特氏 医皮肤 医皮肤 化二甲基酚

<210> 98

<211>'159

<212> PRT

<213> Homo sapiens

<400> 98

Phe Leu Asp Leu Arg Cys Tyr Arg Ala Gly Ser Ser Arg Leu Ala Val

Ala-Met Glu Ser Gly Pro Lys Met Leu Ala Pro Val Cys Leu Val Glu

Asn Asn Glu Gln Leu Leu Val Asn Gln Gln Ala Ile Gln Ile Leu
35 40 45

Glu Lys Ile Ser Gln Pro Val Val Val Val Ala Ile Val Gly Leu Tyr
50 55 60

Arg Thr Gly Lys Ser Tyr Leu Met Asn His Leu Ala Gly Gln Asn His 65 70 75

Gly Phe Pro Leu Gly Ser Thr Val Glm Ser Glu Thr Lys Gly Ile Trp 85 90 95

Met Trp Cys Val Pro His Pro Ser Lys Pro Asn His Thr Leu Val Leu
100 105

Leu Asp Thr Glu Gly Leu Gly Asp Val Glu Lys Gly Asp Pro Lys Asn 115 120

Asp Ser Trp Ile Phe Ala Leu Ala Val Leu Leu Cys Ser Thr Phe Val

Tyr Asn Ser Met Ser Thr Ile Asn His Gln Ala Leu Glu Gln Leu 145 150 155

<210> 99

<211> 147

<212> PRT

<213> Homo sapiens

<400> 99

Met Glu Ser Gly Pro Lys Met Leu Ala Pro Val Cys Leu Val Glu Asn

Asn Asn Glu Gln Leu Leu Val Asn Gln Gln Ala Ile Gln Ile Leu Glu 20 25 30

Lys Ile Ser Gln Pro Val Val Val Val Ala Ile Val Gly Leu Tyr Arg
35 40 45

Thr Gly Lys Ser Tyr Leu Met Asn His Leu Ala Gly Gln Asn His Gly
50 55 60

Phe Pro Leu Gly Ser Thr Val Gln Ser Glu Thr Lys Gly Ile Trp Met
65 70 75 80

Trp Cys Val Pro His Pro Ser Lys Pro Asn His Thr Leu Val Leu Leu

Asp Thr Glu Gly Leu Gly Asp Val Glu Lys Gly Asp Pro Lys Asn Asp 100 105 110

Ser Trp Ile Phe Ala Leu Ala Val Leu Leu Cys Ser Thr Phe Val Tyr 115 120 125

Asn Ser Met Ser Thr Ile Asn His Gln Ala Leu Glu Gln Leu His Tyr 130 135 140

Val Thr Asp 145

<210> 100

<211> 124

<212> PRT

<213> Homo sapiens

<400>a100 a lead of a lead of the lead of

Met Gly Lys Val Lys Val Gly Val Asn Gly Phe Gly Arg Ile Gly Arg
1 5 10 15

Leu Val Thr Arg Ala Ala Phe Asn Ser Gly Lys Val Asp Ile Val Ala 20 25 30

Ile Asn Asp Pro Phe Ile Asp Leu Asn Tyr Met Val Tyr Met Phe Gln
35 40 45

Gly Lys Leu Val Ile Asn Gly Asn Pro Ile Thr Ile Phe Gln Glu Arg
65 70 75 80

Asp Pro Ser Lys Ile Lys Trp Gly Asp Ala Gly Ala Glu Tyr Val Val 90 95

Glu Ser Thr Gly Val Phe Thr Thr Met Glu Lys Ala Gly Ala His Leu 100 105 110

±1.5 (1.15)

Gln Gly Gly Ala Lys Arg Val Ile Ile Ser Ala Pro 115 120

<210> 101

<211> 127

<212> PRT

<213> Homo sapiens

<400> 101

Gln Ser Ala Ala Ser Ser Phe Ala Ser Pro Ala Glu Pro His Arg Ser

1 10 15

```
Asp Thr Met Gly Lys Val Lys Val Gly Val Asn Gly Phe Gly Arg Ile
            · 20 .
                                25
                                                   30
Gly Arg Leu Val Thr Arg Ala Ala Phe Asn Ser Gly Lys Val Asp Ile
                            40
Val Ala Ile Asn Asp Pro Phe Ile Asp Leu Asn Tyr Met Val Tyr Met
                 55
                                   60.
     50
                "你们还有你说。""我们是这个事,你们们的一个好好,这是一个是不有数人是好的数
Phe Gln Tyr Asp Ser Thr His Gly Lys Phe His Gly Thr Val Glu Ala
      70 m
                                        75 ·
Glu Asn Gly Lys Leu Val Ile Asn Gly Asn Pro Ile Thr Ile Phe Gln
                 85
                                    90.
Glu Arg Asp Pro Ser Lys Ile Lys Trp Gly Asp Thr Gly Ala Glu Tyr
            100
                               105
                                                  110
Val Val Glu Ser Thr Gly Val Phe Thr Thr Met Glu Lys Ala Gly
        115
                           120
                                               125
<210> 102
<211> 1225 1 198 1 19 17 1 19 18 17 1
                               para ya see meretari jire
<212> DNA 60 4 7 64 50 6
                       200
<213> Homo sapiens
<400> 102
atggcggcgc ggtcgtcgtc gggggtggcg gcggcagagg gggcggcggc cctggcggca 60
gcggagacgg cagccgtgac ggtggcagcg gcggcgcggg acctgggcct gggggaatga 120
ggcggccgcg gcgggccagc ggcggagccg tgtagcggag aagctccccc tccctgcttc 180
cettggccga gccgggggg cgcgcgcacg cggccgtcca gagcgggctc cccaccctc 240
gactcctgcg acccgcaccg cacccccacc cgggcccgga ggatgatgaa gctcaagtcg 300
aaccagaccc gcacctacga cggcgacggc tacaagaagc gggccgcatg cctgtgtttc 360
cgcagcgaga gcgaggagga ggtgctactc gtgagcagta gtcgccatcc agacagatgg 420
attgtccctg gaggaggcat ggagcccgag gaggagccaa gtgtggcagc agttcgtgaa 480
gtctgtgagg aggctggagt aaaagggaca ttgggaagat tagttggaat ttttgagaac 540
caggagagga agcacaggac gtatgtctat gtgctcattg tcactgaagt gctggaagac 600
tgggaagatt cagttaacat tggaaggaag agggaatggt ttaaaataga agacgccata 660
aaagtgctgc agtatcacaa acccgtgcag gcatcatatt ttgaaacatt gaggcaaggc 720
tactcagcca acaatggcac cccagtcgtg gccaccacat actcggtttc tgctcagagc 780
tcgatgtcag gcatcagatg actgaagact tcctgtaaga gaaatggaaa ttggaaacta 840
gactgaagtg caaatettee eteteaceet ggetetttee aetteteaca ggeeteetet 900
ttcaaataag gcatggtggg cagcaaagaa agggtgtatt gataatgttg ctgtttggtg 960
```

ttaagtgatg gggctttttc ttctgttttt attgagggtg ggggttgggt gtgtaatttg:1020

aggecaacag cetteceetg cettggatte tgaagtgtte etgtttgtet tateetggee 1140

taagtacttt tgtgcatgat ctgtccctcc ctcttcccac ccctgcagtc ctctgaagag 1080

ctggccagac gttttctttg atttttaatt ttttttttt attaaaagat accagtatga 1200

<210> 103

<211> 741

<212> DNA

<213> Homo sapiens

gaaaaaaaa aaaaaaaaac tcgag

```
<400> 103
      agaaacctca atcggattca gcaaaggaat ggtgttatta tcactacata ccaaatgtta 60
      atcaataact ggcagcaact ttcaagcttt aggggccaag agtttgtgtg ggactatgtc 120
      atcctcgatg aagcacataa aataaaaacc tcatctacta agtcagcaat atgtgctcgt 180
      gctattcctg caagtaatcg cctcctcctc acaggaaccc caatccagaa taatttacaa 240
      gaactatggt ccctatttga ttttgcttgt caagggtccc tgctgggaac attaaaaact 300
      tttaagatgg agtatgaaaa tcctattact agagcaagag agaaggatgc taccccagga 360
      gaaaaagcct tgggatttaa aatatctgaa aacttaatgg caatcataaa accctatttt 420
      ctcaggagga ctaaagaaga cgtacagaag aaaaagtcaa gcaacccaga ggccagactt 480
      aatgaaaaga atccagatgt tgatgccatt tgtgaaatgc cttccctttc caggagaaat 540
      gatttaatta tttggatacg acttgtgcct ttacaagaag aaatatacag gaaatttgtg 600
      tctttagatc atatcaagga gttgctaatg gagacgcgct cacctttggc tgagctaggt 660
      gtcttaaaga agctgtgtga tcatcctagg ctgctgtctg cacgggcttg ttgtttgcta 720
                                                                                                                                                                                                                            741
       aatcttggga cattctctgc t
       <210> 104
     <211> 321
       <212> DNA
       <213> Homo sapiens
       <400> 104
      ttgctctgcg tcatcaaaga caccaaactg ctgtgctata aaagttccaa ggaccagcag 60
      cctcagatgg aactgccact ccaaggctgt aacattacgt acatcccgaa agacagcaaa 120
      aagaagaagc acgagctgaa gattactcag cagggcacgg acccgcttgt tctcgccgtc 180
      cagagcaagg aacaggccga gcagtggctg aaggtgatca aagaagccta cagtggttgt 240
       agtggcccg tggattcaga gtgtcctcct ccaccaagct ccccggtgca caaggcagaa 300
                                                                                                                                                                                                                            321
       ctggagaaga aactgtcttc a
       <210> 105
       <211> 389
       <212> DNA TO TO THE REST OF THE PARTY OF THE
       <213> Homo sapiens
                                             and the state of t
       <400> 105
                                             cagcactggc cacactataa aattcaggtt cagaaaaaca gggtaagtca cagacagcaa 60
      cgcttccagc atttattttc tttgcaccca tgggcaattt gagaaaattt acctttagaa 120
       cgaactctgt taaaggtaca gacagtacaa tactttttat tcagaaggtt tctgcataaa 180
      ggtgatagtc ttttgactta atatattatt gtctcctgcc ttgtgtttct ggaatgaatg 240
      aaggtcatta tttagaagat aatctgggtt gtatttgtgt cgtcagattg aattttcatt 300
      gcacatgcta cttaatgtct ttaccaaata ataacaaagg gaaagaaaac caaatataga 360
 tgtataataa ggaaaagctg gcctataga
 <210> 106
      <213> Homo sapiens
                                                                                       the state of the s
                                                                                                                          gccacatttg ccctggtcat agtttaaaca ccaggtcctg tgtcacatct ttttggtgcc 60
      acaagtatca ctccattgtt cagagagtaa tgtattagtt ctgcccaatt cattcttcac 120
      ttttatttct tccatttcat tagcatttat atcagctcaa gaagttaagg tragaaaatt 180
      ttccacttca aattttcagt acagaaatgt gctgtgatgt ttgacaagac tatttcatag 240
      taagtgagtt aatgtttatt ggcctctgct ctcctctgtg tcagacctag gaagcctgag 300
      gattacttag ttgttctgtc tctgggtcca caggcagaat ttggcccatc caaagactgg 360
      ccaagtgcca aaaaaaggcc tgattaggcc ctgaaattca gtgaaattct gcctgaagaa 420
```

```
acctcttatt gaatttgaaa accata:
    and the second section
  <210> 107
  <211> 467
  <212> DNA
  <213> Homo sapiens
 <400> 107
 cegeegetge egtegeette etgggattgg agtetegage tttettegtt egttegeegg 60
 cgggttcgcg cccttctcgc gcctcggggc tgcgaggctg gggaaggggt tggaggggc 120
 tgttgatcgc cgcgtttaag ttgcgctcgg ggcggccatg tcggccggcg aggtcgagcg 180
 cctagtgtcg gagctgagcg gcgggaccgg aggggatgag gaggaagagt ggctctatgg 240
 cgatgaagat gaagttgaaa ggccagaaga agaaaatgcc agtgctaatc ctccatctgg 300
 aattgaagat gaaactgctg aaaatggtgt accaaaaccg aaagtgactg agaccgaaga 360
 tgatagtgat agtgacagcg atgatgatga agatgatgtg catgtcacta taggagacat 420
 taaaacggga gcaccacagt atgggagtta tggtacagca cctgtaa
                                                                                                                                    467
                                                     <210> 108
 <211> 491
 <212> DNA
                                                  多一致,我一我一次一个多个
 <213> Homo sapiens
                     一点,我们的最后<sub>,我就是</sub>一点,你们还是这些女孩的,在老爷的人就看了一点,一点一笑,<mark>笑着</mark>,"我是说了我最多的的。"
gaaagataca acttccccaa cccaaacccg tttgtggagg acgacatgga taagaatgaa 60
 atcgcctctg ttgcgtaccg ttaccgcagg tggaagcttg gagatgatat tgaccttatt 120
gtccgttgtg agcacgatgg cgtcatgact ggagccaacg gggaagtgtc cttcatcaac 180
 atcaagacac tcaatgagtg ggattccagg cactgtaatg gcgttgactg gcgtcagaag 240
ctggactctc agcgagggc tgtcattgcc acggagctga agaacaacag ctacaagttg 300
gcccggtgga cctgctgtgc tttgctggct ggatctgagt acctcaagct tggttatgtg 360
tctcggtacc acgtgaaaga ctcctcacgc cacgtcatcc taggcaccca gcagttcaag 420
cctaatgagt ttgccagcca gatcaacctg agcgtggaga atgcctgagg cattttacgc 480
 tgcgtcattg a state of the contract of the cont
 <210> 109
<211> 489
 <212> DNA
 <213> Homo sapiens
<400> 109
ctcagatagt actgaaccct ttatcaacta tgttttttca gtctgacaac caaggcggct 60
actaagtgac taaggggcag gtagtataca gtgtggataa gcaggacaaa ggggtgattc 120
acatcccagg caggacagag caggagatca tgagatttca tcactcagga tggcttgtgå 180
tttattttat tttattcttt ttttttttg agatggagtc tcactcttgc ccaggctgga 240
gtgcagtggt gcgatcttgg ctcactgcaa; cctctgcctc ctgggttcaa qcagttctcc 300
tgcctcagcc tcccaagtag ctgggattac aggcgtccgc caccatgccc agccaatttt 360
tgtactttta gtagagatgg ggtttcacca tgttggccag gctggtctcg aactcctgac 420.
ctcaggtgat ccactcgcct cggcctccca aagtgctggg attataggca tgcgccacca 480
tgcccgggc
<210> 110
<211> 391
<212> DNA
<213> Homo sapiens
<400> 110
```

gcggagtccg ctggctgacc cgagcgctgg tctccgccgg gaaccctggg gcatggagag 60 gtctgagtac ctcggccgcg gcgcacgctg catcgcggag ccaggctgcc gctgtcccag 120 tggagttcca ggagcaccac ctgagtgagg tgcagaatat ggcatctgag gagaagctgg 180 agcaggtgct gagttccatg aaggagaaca aagtggccat cattggaaag attcataccc 240 cgatggagta taagggggag ctagcctcct atgatatgcg gctgaggcgt aagttggact 300 tatttgccaa cgtaatccat gtgaagtcac ttcctgggta tatgactcgg cacaacaatc 360 tagacctggt gatcattcga gagcagacag a <210> 111 <211> 172 <212> PRT <213> Homo sapiens <400> 111 Met Met Lys Leu Lys Ser Asn Gln Thr Arg Thr Tyr Asp Gly Asp Gly 10 Tyr Lys Lys Arg Ala Ala Cys Leu Cys Phe Arg Ser Glu Ser Glu Glu 30 25 20 Glu Val Leu Leu Val Ser Ser Ser Arg His Pro Asp Arg Trp Ile Val 35 40 45 Pro Gly Gly Met Glu Pro Glu Glu Glu Pro Ser Val Ala Ala Val 60 . 55 Arg Glu Val Cys Glu Glu Ala Gly Val Lys Gly Thr Leu Gly Arg Leu 75 · 通信 Val Gly Ile Phe Glu Asn Gln Glu Arg Lys His Arg Thr Tyr Val Tyr 90 30 to 10 to 10 to 10 85. (v) Val Leu Ile Val Thr Glu Val Leu Glu Asp Trp Glu Asp Ser Val Asn 110 105 100 Ile Gly Arg Lys Arg Glu Trp Phe Lys Ile Glu Asp Ala Ile Lys Val 125 115 120 Leu Gln Tyr His Lys Pro Val Gln Ala Ser Tyr Phe Glu Thr Leu Arg 140 135 130 Gln Gly Tyr Ser Ala Asn Asn Gly Thr Pro Val Val Ala Thr Thr Tyr 9 145 Burney Ser Val Ser Ala Gln Ser Ser Met Ser Gly Ile Arg 170 165 医大型性乳腺素素 电电子线 化二氯化氯化 电流线电流 <<210> 112 <211> 247 <212> PRT

<400> 112

<213> Homo sapiens

Arg Asn Leu Asn Arg Ile Gln Gln Arg Asn Gly Val Ile Ile Thr Thr

	1	•			5	;		•		10	;				15	.
	Tyr	Glr	Met	Leu 20		Asn	Asn	Trp	Gln 25		Leu	Ser	Ser	Phe 30	_	, Gly
	Gln	_Glu	Phe		Trp	Asp	Tyr	Val 40		Leu	Asp	Glu	Ala 45		Lys	Ile
	Lys	Thr 50	-	Ser	Thr	Lys	Ser 55		Ile	Cys	Ala	Arg 60		Ile	Pro	Ala
		Aşn Gê	Arg	Leu	Leu	Leu 70		Gly	Thr	Pro	Ile 75	Gln	Asn	Asn	Leu	Gln 80
	Glu	Leu	Trp	Ser	Leu 85		- A sp	্Phe ং	Ala	Cys 90	Gln	Gly	Ser	Leu	Leu 95	Gly
_	Thr	Leu	Lys	Thr 100		Lys	Met	Glu	Tyr 105	_	Asn	Pro	Ile	Thr 110	Arg	Ala
· ·	Arg	Glu	Lys 115		Ala	Thr	Pro	Gly 120	Glu	Lys	Ala	Leu	Gly 125	Phe	Lys	Ile
٠.	Ser	Glu 130		Leu	Met	Ala	Ile 135	Ile	Lys	Pro	•	Phe 140	Leu		Arg	Thr
								Lys								Leu 160
	Asn							Asp						Pro		-
	Ser	Arg	Arg	Asn 180	Asp	Leu	Ile ∵⊘	Ile Van	Trp 185	Ile	Arg	Leu	V al	Pro 190	Leu	Gln
	Glu							Val 200			_			_		Leu
	Leu							Leu V							Lys	Lys
								Leu								
:	Asn		_		Phe 245										· .	•
•	<210 <211	> 11 > 10	.3	nes.	n akk ann n	×÷()	· ·	Gar.	200	<u>.</u>		V.		an ga		·.·
•	<212	> PR	T		ns ~	engill Vit		Gir.								
		> 11 Leu		Val				The 1		Leu 1	Leu (Cys '	Tyr	Lys .	Ser	Ser

15 10 5 1 Lys Asp Gln Gln Pro Gln Met Glu Leu Pro Leu Gln Gly Cys Asn Ile ं30 ·25 20 Thr Tyr Ile Pro Lys Asp Ser Lys Lys Lys His Glu Leu Lys Ile 45 40 35 Thr Gln Gln Gly Thr Asp Pro Leu Val Leu Ala Val Gln Ser Lys Glu 55 50 Gln Ala Glu Gln Trp Leu Lys Val Ile Lys Glu Ala Tyr Ser Gly Cys 80 **7**5 70 · 65 Ser Gly Pro Val Asp Ser Glu Cys Pro Pro Pro Pro Ser Ser Pro Val 95 His Lys Ala Glu Leu Glu Lys Lys Leu Ser Ser 105 100 <210> 114 <211> 155 ajan akan demining neak ulin da <212> PRT <213> Homo sapiens The the surface of the transfer that the surface of the state of the surface of t Glu Arg Tyr Asn Phe Pro Asn Pro Asn Pro Phe Val Glu Asp Asp Met 1 Asp Lys Asn Glu Ile Ala Ser Val Ala Tyr Arg Tyr Arg Arg Trp Lys 25 20 Leu Gly Asp Asp Ile Asp Leu Ile Val Arg Cys Glu His Asp Gly Val 35 The self was arise in Met Thr Gly Ala Asn Gly Glu Val Ser Phe Ile Asn Ile Lys Thr Leu **55** ' 50 Asn Glu Trp Asp Ser Arg His Cys Asn Gly Val Asp Trp Arg Gln Lys 75 70 65 TO THE REPORT OF THE PROPERTY Leu Asp Ser Gln Arg Gly Ala Val Ile Ala Thr Glu Leu Lys Asn Asn 95 85 Ser Tyr Lys Leu Ala Arg Trp Thr Cys Cys Ala Leu Leu Ala Gly Ser 110 105 100 Glu Tyr Leu Lys Leu Gly Tyr Val Ser Arg Tyr His Val Lys Asp Ser 125 120 115 提供的 人名英克 Ser Arg His Val Ile Leu Gly Thr Gln Gln Phe Lys Pro Asn Glu Phe 140. 135 130 Ala Ser Gln Ile Asn Leu Ser Val Glu Asn Ala

145 150 155 <210> 115 <211> 129 <212> PRT <213> Homo sapiens <400> 115 Gly Val Arg Trp Leu Thr Arg Ala Leu Val Ser Ala Gly Asn Prog Gly 100 10 Ala Trp Arg Gly Leu Ser Thr Ser Ala Ala Ala His Ala Ala Ser Arg Ser Gln Ala Ala Val Pro Val Glu Phe Gln Glu His His Leu Ser 35 Glu Val Gln Asn Met Ala Ser Glu Glu Lys Leu Glu Gln Val Leu Ser Ser Met Lys Glu Asn Lys Val Ala Ile Ile Gly Lys Ile His Thr Pro 65 **75** Met Glu Tyr Lys Gly Glu Leu Ala Ser Tyr Asp Met Arg Leu Arg Arg 85 Lys Leu Asp Leu Phe Ala Asn Val Ile His Val Lys Ser Leu Pro Gly 100 Tyr Met Thr Arg His Asn Asn Leu Asp Leu Val Ile Ile Arg Glu Gln <210× 116 <211> 550 <212> DNA <213> Homo sapiens <400> 116 gaatteggea ceagecteag ageceeceag eeeggetace acceetgeg gaaaggtace 60 catctgcatt cctgcccgtc gggacctggt ggacagtcca gcctccttgg cctctagcct 120 tggctcaccg ctgcctagag ccaaggagct catcctgaat gaccttcccg ccagcactcc 180 tgcctccaaa tcctgtgact cctccccgcc ccaggacgct tccaccccca ggcccagctc 240 ggccagtcac ctctgccagc ttgctgccaa gccagcacct tccacggaca gcgtcgccct 300 gaggagecce etgactetgt ceagteett caccaegtee tteagectgg geteecacag 360 cacteteaac ggagacetet eegtgeeeag etectaegte ageeteeace tgteeecea 420 ggtcagcagc tctgtggtgt acggacgctc ccccgtgatg gcatttgagt ctcatccca 480

tetegaggg teateegtet ettecteet acceageate eetgggggaa ageeggeeta 540

<210> 117 <211> 154

ctccttccac

```
<212> DNA
<213> Homo sapiens
<400> 117
ttctgaggga aagccgagtg gagtgggcga cccggcggcg gtgacaatga gttttcttgg 60
aggetttttt ggteceattt gtgagattga tgttgeeett aatgatgggg aaaccaggaa 120
aatggcagaa atgaaaactg aggatggcaa agta
<210> 118
<211> 449
<212> DNA
<213> Homo sapiens
<400> 118
gaatteggea ceagggeeg cageegagt gtegeegeea tggettegee geagetetge 60
cgcgcgctgg tgtcggcgca atgggtggcg gaggcgctgc gggccccgcg cgctgggcag 120
cetetgeage tgetggaege etectggtae etgecgaage tggggegega egegegaege 180
gagttcgagg agcgccacat cccgggcgcc gctttcttcg acatcgacca gtgcagcgac 240
egeacetege cetacgacea catgetgeee ggggeegage atttegegga gtacgeagge 300
cgcctgggcg tgggcgcggc cacccacgtc gtgatctacg acgccagcga ccagggcctc 360
tactccgccc cgcgcgtctg gtggatgttc cgcgccttcg gccaccacgc cgtgtcactg 420
cttgatggcg gcctccgcca ctggctgcg
<210> 119
<211> 642
<212> DNA
<213> Homo sapiens
<400> 119
gaatteggea egageagtaa eeegaeegee getggtette getggaeaee atgaateaea 60
ctgtccaaac cttcttctct cctgtcaaca gtggccagcc ccccaactat gagatgctca 120
aggaggagca cgaggtggct gtgctggggg cgcccacaa ccctgctccc ccgacgtcca 180
ccgtgatcca catccgcage gagacetecg tgcccgacca tgtcgtctgg tecetgttca 240
acaccctctt catgaacccc tgctgcctgg gcttcatagc attcgcctac tccgtgaagt 300
ctagggacag gaagatggtt ggcgacgtga ccggggccca ggcctatgcc tccaccgcca 360
agtgcctgaa catctgggcc ctgattctgg gcatcctcat gaccattctg ctcatcgtca 420
teccagiget gaieticeag geetaiggat agaieaggag geateaeiga ggeeaggage 480
tetgeceatg acetgtatee caegtactee aacttecatt cetegecetg eceeeggage 540
cgagtcctgt atcagccctt tatcctcaca cgcttttcta caatggcatt caataaagtg 600
cacgtgtttc tggtgaaaaa aaaaaaaaaa aaaaaactcg ag
<210> 120
<211> 603
<212> DNA
<213> Homo sapiens
<400> 120
gaatteggea egageeacaa eageeactae gaetgeatee actggateea eggeeacee 60
gtcctccacc ccgggaacag ctcccctcc caaagtgctg accagcccgg ccaccacacc 120
catgtccacc atgtccacaa tccacacctc ctctactcca gagaccaccc acacctccac 180
agtgctgacc accacagcca ccatgacaag ggccaccaat tccacggcca caccctcctc 240
cactetgggg acgacecgga tecteactga getgaceaea acagecaeta caactgcage 300
cactggatec acggecacce tgteetecae eccagggace acctggatec teacagagee 360
gagcactata gecacegtga tggtgcccae eggttccaeg gecacegeet ectecaetet 420
gggaacaget cacacececa aagtggtgae caceatggee actatgeeca cagecactge 480
```

ctccacggtt cccagctcgt ccaccgtggg gaccacccgc acccctgcag tgctcccag 540 cagcetgeca acetteageg tgtecactgt gteeteetea gteeteacea ceetgagace 600 cac <210> 121 <211> 178 <212> PRT <213> Homo sapiens <400> 121 Ser Glu Pro Pro Ser Pro Ala Thr Thr Pro Cys Gly Lys Val Pro Ile . 10 Cys Ile Pro Ala Arg Arg Asp Leu Val Asp Ser Pro Ala Ser Leu Ala 20 30 Ser Ser Leu Gly Ser Pro Leu Pro Arg Ala Lys Glu Leu Ile Leu Asn 45 : -Asp Leu Pro Ala Ser Thr Pro Ala Ser Lys Ser Cys Asp Ser Ser Pro 50 55 60 Pro Gln Asp Ala Ser Thr Pro Arg Pro Ser Ser Ala Ser His Leu Cys 65 **75** . Gln Leu Ala Ala Lys Pro Ala Pro Ser Thr Asp Ser Val Ala Leu Arg Ser Pro Leu Thr Leu Ser Ser Pro Phe Thr Thr Ser Phe Ser Leu Gly ₂ 100 105 110 Ser His Ser Thr Leu Asn Gly Asp Leu Ser Val Pro Ser Ser Tyr Val 115 120 · 125 Ser Leu His Leu Ser Pro Gln Val Ser Ser Ser Val Val Tyr Gly Arg 130 135 140 Ser Pro Val Met Ala Phe Glu Ser His Pro His Leu Arg Gly Ser Ser 150 155 Val Ser Ser Ser Leu Pro Ser Ile Pro Gly Gly Lys Pro Ala Tyr Ser 165 170

Phe His

<210> 122 <211> 36 <212> PRT <213> Homo sapiens

<400> 122

Met Ser Phe Leu Gly Gly Phe Phe Gly Pro Ile Cys Glu Ile Asp Val 10

Ala Leu Asn Asp Gly Glu Thr Arg Lys Met Ala Glu Met Lys Thr Glu Asp Gly Lys Val 35 <210> 123 <211> 136 <212> PRT <213> Homo sapiens <400> 123 Met Ala Ser Pro Gln Leu Cys Arg Ala Leu Val Ser Ala Gln Trp Val Ala Glu Ala Leu Arg Ala Pro Arg Ala Gly Gln Pro Leu Gln Leu Leu 20 25 Asp Ala Ser Trp Tyr Leu Pro Lys Leu Gly Arg Asp Ala Arg Arg Glu 35 Phe Glu Glu Arg His Ile Pro Gly Ala Ala Phe Phe Asp Ile Asp Gln 50 Cys Ser Asp Arg Thr Ser Pro Tyr Asp His Met Leu Pro Gly Ala Glu **65** · 70 80 His Phe Ala Glu Tyr Ala Gly Arg Leu Gly Val Gly Ala Ala Thr His 85 Val Val Ile Tyr Asp Ala Ser Asp Gln Gly Leu Tyr Ser Ala Pro Arg 100 105 110 Val Trp Trp Met Phe Arg Ala Phe Gly His His Ala Val Ser Leu Leu 115 120 125 Asp Gly Gly Leu Arg His Trp Leu 135 130 <210> 124 . m <211> 133 <212> PRT <213> Homo sapiens <400> 124

Met Asn His Thr Val Gln Thr Phe Phe Ser Pro Val Asn Ser Gly Gln
1 5 10 15

Pro Pro Asn Tyr Glu Met Leu Lys Glu Glu His Glu Val Ala Val Leu 20 25 30

Gly Ala Pro His Asn Pro Ala Pro Pro Thr Ser Thr Val Ile His Ile
35 40 45

4.3

1.1.

Arg Ser Glu Thr Ser Val Pro Asp His Val Val Trp Ser Leu Phe Asn 55 Thr Leu Phe Met Asn Pro Cys Cys Leu Gly Phe Ile Ala Phe Ala Tyr ·65 -70 **75** Ser Val Lys Ser Arg Asp Arg Lys Met Val Gly Asp Val Thr Gly Ala 85 95 Gln Ala Tyr Ala Ser Thr Ala Lys Cys Leu Asn Ile Trp Ala Leu Ile 100 105 110 Leu Gly Ile Leu Met Thr Ile Leu Leu Ile Val Ile Pro Val Leu Ile 115 120 Phe Gln Ala Tyr Gly <210> 125 <211> 195 <212> PRT <213> Homo sapiens <400> 125 Thr Thr Ala Thr Thr Ala Ser Thr Gly Ser Thr Ala Thr Pro Ser 1 10 Ser Thr Pro Gly Thr Ala Pro Pro Pro Lys Val Leu Thr Ser Pro Ala 20 25 Thr Thr Pro Met Ser Thr Met Ser Thr Ile His Thr Ser Ser Thr Pro **35** 84,733 € 7 a Proposition design for the company of the company of the company of Glu Thr Thr His Thr Ser Thr Val Leu Thr Thr Thr Ala Thr Met Thr 55. Special contractions of the contraction of the Arg Ala Thr Asn Ser Thr Ala Thr Pro Ser Ser Thr Leu Gly Thr Thr THE PARTY OF THE CONTROL OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PARTY OF THE PAR Arg Ile Leu Thr Glu Leu Thr Thr Thr Ala Thr Thr Ala Ala Thr 85 90 Gly Ser Thr Ala Thr Leu Ser Ser Thr Pro Gly Thr Thr Trp Ile Leu 100 105 110 Angeler (1980) by still a Thr Glu Pro Ser Thr Ile Ala Thr Val Met Val Pro Thr Gly Ser Thr 115 120 **125** Abd 1 3 4 5 5 6 ತ್ತ ಪ್ರಶಸ್ತಿ ಎಲ್ಲ ಸ್ವರ್ಥ ಅನಿಷತ್ತ ಮಾತ್ರವಾಧಿ ಪ್ರಾಕ್ಷೀಕ್ ಕ್ಲಾಗ್ ಕಾರ್ಯಕ್ಷ ಶ್ರಾಕ್ಷ್ ಕ್ಲೀಗ್ ಕಾಡಿಕೆ ಕೇರ್ಗ್ರಾಹ್ Ala Thr Ala Ser Ser Thr Leu Gly Thr Ala His Thr Pro Lys Val Val 150 (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) (150) Thr Thr Met Ala Thr Met Pro Thr Ala Thr Ala Ser Thr Val Pro Ser 150 155

Ser Ser Thr Val Gly Thr Thr Arg Thr Pro Ala Val Leu Pro Ser Ser 165 170 175 Leu Pro Thr Phe Ser Val Ser Thr Val Ser Ser Ser Val Leu Thr Thr 180 185 190 Leu Arg Pro 195 <210> 126 <211> 509 <212> DNA <213> homo sapien <400> 126 gaattcggca cgagccaagt acccctgag gaatctgcag cctgcatctg agtacaccgt 60 atccctcgtg gccataaagg gcaaccaaga gagccccaaa gccactggag tctttaccac 120 actgcagcct gggagctcta ttccacctta caacaccgag gtgactgaga ccaccattgt 180 gatcacatgg acgcctgctc caagaattgg ttttaagctg ggtgtacgac caagccaggg 240 aggagaggca ccacgagaag tgacttcaga ctcaggaagc atcgttgtgt ccggcttgac 300 tccaggagta gaatacgtct acaccatcca agtcctgaga gatggacagg aaagagatgc 360 gccaattgta aacaaagtgg tgacaccatt gtctccacca acaacttgc atctggaggc 420 aaaccctgac actggagtgc tcacagtctc ctggagagga gcaccacccc agacattact 480 gggtatagaa ttaccacaac ccctacaaa 509 <210> 127 <211> 500 <212> DNA <213> homo sapien <400> 127 gaattcggca cgagccactg atgtccgggg agtcagccag gagcttgggg aagggaagcg 60 -- -> cgccccggg gccggtcccg gagggctcga tccgcatcta cagcatgagg ttctgccgt 120 ttgctgagag gacgcgtcta gtcctgaagg ccaagggaat caggcatgaa gtcatcaata 180 tcaacctgaa aaataagcct gagtggttct ttaagaaaaa tccctttggt ctggtgccag 240 ttctggaaaa cagtcagggt cagctgatct acgagtctgc catcacctgt gagtacctgg 300 atgaagcata cccagggaag aagctgttgc cggatgaccc ctatgagaaa gcttgccaga 360 agatgatett agagttgttt tetaaggtge cateettggt aggaagettt attagaagee 420 aaaataaaga agactatgct ggcctaaaag aagaatttcg taaagaattt accaagctag 480 aggaggttet gactaataag 500 <210> 128 <211> 500 <212> DNA <213> homo sapien <400> 128 agctttcctc tgctgccgct cggtcacgct tgtgcccgaa ggaggaaaca gtgacagacc 60 tggagactgc agttctctat ccttcacaca gctctttcac catgcctgga tcacttcctt 120 tgaatgcaga agcttgctgg ccaaaagatg tgggaattgt tgcccttgag atctattttc 180 Cttctcaata tgttgatcaa gcagagttgg aaaaatatga tggtgtagat gctggaaagt 240 ataccattgg cttgggccag gccaagatgg gcttctgcac agatagagaa gatattaact 300 ctctttgcat gactgtggtt cagaatctta tggagagaaa taacctttcc tatgattgca 360

<211> 357 <212> DNA

<213> homo sapien

		tentennann	atdagagtet	otosagacta i	420
ttgggcggct ggaagttgga					-
atttgatgca gctgtttgaa	gagtctggga	atacagatat	agaaggaatc	gacacaacta	480
atgcatgcta tggaggcaca		`	•		500
acycaeyeta eggaggaaaa		•	*2 · ·		
		•			
<210> 129		18 1 22			
<211> 497					•
<212> DNA	Act to the second	· · ·			
	A 3		•		
<213> homo sapi	En		· •		
•	•	•			
<400> 129					
gaattcggca cgagcagagg	tctccagagc	cttctctctc	ctgtgcaaaa	tggcaactct	60
taaggaaaaa ctcattgcac	cagttggga	agaagaggca	acagttccaa	acaataagat	120
					180
cactgtagtg ggtgttggac					
tctggctgat gaacttgctc	ttgtggatgt	tttggaagat	aagcttaaag	gagaaatgat	240
ggatctgcag catgggagct	tatttcttca	gacacctaaa	attgtggcag	ataaagatta	300
ttctgtgacc gccaattcta					360
					420
ggagagtcgg ctcaatctgg	Lycayayaaa	Lyccaacyce			
gatcgtcaag tacagtcctg	attgcatcat	aattgtggtt	tccaacccag	cggacactet	480
tacgtatgtt acctgga		en de la companya de La companya de la co	1	ANTIBURE DES	497
				ام این از این	
<210> \130	是100mm				
			•	*	
<211> 383 <212> DNA	10 6 100	taget# ≥€	14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
<212> DNA				•	
<213> homo sapi	en		· \$1. \		•
				•	•
<400> 130			2.4.		
gaatteggea egagggeege	aactaccaac	tagatecect	accactatca	ccaccatggc	60
gaacteggea egagggeege	ggctgctgac		steerester.	gegegetate	120
tccgcaccgc cccgcgcccg					
gctgcccgtc cgcgcggcca					180
gcgggtgccc gaggcgcggc	ccaacagcat	ggtggtggaa	caccccgagt	tcctcaaggc	240
agggaaggag cctggcctgc	agatetggcg	tgtggagaaa	gttcgatctg	gtggcccgtg	300
cccaccaacc tttatggaga	cttcttcacg	ggcgacgcct	acqtcatcct	gaagacagtg	360
				• •	383
— cagcttaaga acggaaaatc	LLG			propagation of	
·					•
<210> 131	•		•	3 8 B	٠.
<211> 509				1 53	
<212> DNA	•	•	7.4.		
<213> homo sapi	en .			***	
<213> 110110 8ap1	CII		 Signer - General III 		
<400> 131	•		*- ****.	以传条头	
gaatteggea egagagteag	ccgcatcttc	ttttgcgtcg	ccagccgagc	cacatcgctc	60
agacaccatg gggaaggtga	aggtcggagt	caacggattt	ggtcgtattg	ggcgcctggt	120
caccagggct gcttttaact	ctaataaaat	ggarattett	gccatcaatg	accccttcat	180
Linguis Commission (1980)	Leggeadage	3346466466	2000000000	aartccatoo	240
tgacctcaac tacatggttt	acatgttcca	acatgattee	acccatggca	aaccccacyy	
caccetcaag ectgagaace	ggaagcttgt	catcaatgga	aatcccatca	ccatcttcca	300
ggagcgagat ccctccaaaa	tcaagtgggg	cgatgctggc	gctgagtacg	tcgtggagtc	360
cactggccgt cttcaccacc	atogagaagg	ctagaactca	tttgcaggg	ggagccaaaa	420
Tackyceye cereactace				atasacata	480
gggtcatcat ctctgccccc		Coccatget	caccacagge	Aragaccaca	
agaagtatga caacagcctc	aagatcatc		1.5		509
•					
<210> 132					
<211> 357	•	•	A STATE OF STATE	** · · ·	•
E/113 33/					

) 5 0 % / 0 % /

<400> 132	· Programme Artifaction	· · · · · ·		· •
	rta daccacadet	ccacaccato	gactggacct	. 60
gaatteggea egagtaagaa gaageeee				60
ggaggatect ettettggtg geageage				
aatctgggtc tgagttgaag aagcctgg				180
gacacatctt cagtatctat ggtttgaa	•			240
agtggatggg atggatcaaa gtcgacac	•			300
gacgatttgt cttctccctg gacacctc	tg tcagcacggc	atatctgcag	atcagca	357
			•	
<210> 133			raen. Men artik	
<211> 468	and the second	in the	1.4 - 1410 7	
2111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
ાં. જુલાલાં જ ચૂંચા છે. માટે માટે જે લિંદિયા મુક્કોનું ને લેવીનો			and the second of the second o	
<400> 133	The Market State of the Control of t	and the second s	and the second s	
gaatteggea egaggegeee egaacegt	cc tcctqctqct	ctcqqcqqcc	ctggccctga	60
ccgagacctg ggccggctcc cactccat		والمراجع والم والمراجع والمراجع والمراجع والمراجع والمراجع والمراجع والمراج		120
gccgcgggga gccccgcttc atctcagt		C		180
tcgacagcga cgccgcgagt ccgagaga			i de la companya de	240
ggccggagta ttgggaccgg aacacaca			· -,	300
agageetgeg gaacetgege ggetaeta				360
agagcatgta cggctgcgac gtggggcc			cataaccagt	420
acgcctacga cggcaaggat tacatcgc	cc tgaacgagga	ccracacr		468
		era st. iona i a		•
<210> 134				
<211> 214	•	34 2	42.	•
<212> DNA		400 - 488 <u>0</u> 400	30 25 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
<213> homo sapien		1 - 1 - <u>\$140</u> 7782 1,-11.	1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985	
<4UU> 134				
gaatteggea egagetgegt cetgetga	gc tctgttctct	ccagcacctc	ccaacccact	60
agtgcctggt tctcttgctc caccagga	ac aagccaccat	gtctcgccag	tcaagtgtgt	120
ccttccggag cgggggcagt cgtagctt	ca gcaccgcctc	tgccatcacc	ccgtctgtct	180
cccgcaccag cttcacctcc gtgtcccg	gt ccgg	4.1 %.	• • • • • • • • • • • • • • • • • • • •	214
				•
<210> 135		•		
<211> 355	•		•	
<212> DNA	•			
<213> homo sapien		I to Similar William		
<400> 135				
ファー・コール イン・ストー はっさい アー・コーナ えいさかい またんり 有し しごりん コープリー・ブ	te decateddec	atatastaca	tagacagaga	. 60
gaatteggea egaggtgaac aggaceeg				120
aagggcgccg ggtctgtgtt ccgcgcgc	the state of the s			
cgcgccgtgg atttcgctga gcggcacg				180
cacgacccgg gccgcgcgc gcccctcg		in the contract of the		. 240
aagaagcgga cggagctgtt cattgccg				300
tgcggcaaga aggcccagct caacattg	gc aatgtgctcc	ctgtgggcac	catgo	· 355
		; :	22 22 22	
<210> 136			S. San	•
<211> 242	φ, λ	•		
<212> DNA		.	. 4	
<213> homo sapien			en Maria de Caracteria de C Caracteria de Caracteria d	• •
•			•	
<400> 136			•	_
gaatteggea egagecaget cetaaceg	ca aataateeac		ct cccgaggt	60
•				120
gcccggattg cagacggagt ctccttca	ce cagigitida	-22cacccaa	arrandrac	,120

entere. Poster

			•			
	agtggtgtga tctcggctcg	ctacaacatc	cacctcccag	cagcctgcct	tggcctccca	180
	aagtgccgag attgcagctc					240
	at		•			242
	- 36	•				
	220 227	•	10.175			
	<210> 137	the section A				
•	<211> 424				The state of the state of	
	<212> DNA		Commence of the second	1987年1月1日 - 188	19 To 100	
	<213> homo sapi	.en		•		
	•	-			•	
	<400> 137					,
	gaattcggca cgagcccaga	tcccgaggtc	cgacagcgcc	cggcccagat	cccacqcct	60
	gccaggagca agccgagagc					120
						180
	ttcgacccga gccccgcgcc					240
	gccggccatg gagaccccgt			-		
	cactccgctg tcgcccaccc					300
	caatgatcgc ttggcggtct	••			· •	360
	gctgcgcctt cgcatcaccg	agtctgaaga	ggtggtcagc	cgcgaggtgt	ccggcatcaa	420:
	ggcc		e e s ame e per e sa		1 - MATERIA (1977)	424
	SWIFT TO THE PERSON					·.
	<210> 138		e de la companya della companya della companya de la companya della companya dell			
*	<211> 448			n der er ryd i Gregoriae	ri Turka kan dan sangan sangan	·
	<211> 448			i de la compania de La compania de la co	1943) - 1	•
	<212> DNA <213> homo sapi	en		and the state of t		
	: CEEDS HOMO DUPE					
`	<400> 138		•			
	-	ttecacaaa	coastcagas.	atoteatect	CACCCCCC	60
	gaattcggca cgagcctgtg					120
	agacttacct gtcctactca	CCGalligaa	gattcaatat	accaayacce	caacaacaa	180
	tgaatggcat gattcagtga					240
	ggagctctgc caggtagaag					
	aagacaggct tttcagattg	-				300
	actattatac aagttggctg					360
	agtcaatgaa tggtggaaaa	ctctattcca	atgcatatct	gaatgattta	gcaggctgca	420
	tcaaaacatt gcgctactgt	gcaggttg	Kalangan panggalahan	Company of the St	4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	448
					The state of the state of	
•	<210> 139					
	<211> 510				Section 1	
	<212> DNA					
	<213> homo sapi					
٠.						
	<400> 139				to the said of the	
-		tacaacreac	ggagaaggga	atggagaaag	tragraagta	60
	gaattcggca cgaggttccg					120
	ccccaaggag ctgcgcaagt					180
	gtgccagcgc cggacccgtt					
	tgctgcaact acatcacaga					240
	caggagtaac ctggatgagg		•			300
	cccagagage tggctgtgga					360
	tacgaagete atgaatatat					420
	gagcatgtcg gacaagaaag					480
	ggacttcttc atcgacctgc	ggctacccta	en e	and the second section of the second		510
	च्च का तका स्वास्त्राप्त सुवार सुवार है. -				entre det en la companya de la comp La companya de la co	
	<210> 140	**				
	<210> 140	•		-	and the second	•
. ,	<211> 360	•				
	<212> DNA		the state of the state of		" in the second of the	-
	<213> homo sapi	en	•	-		
				• .	. N	

-

					··	•
	<400> 140	•	•			-
	gaattcggca cgagcggtaa	ctaccccggc	tgcgcacagc	teggegetee	ttcccgctcc	60
	ctcacacacc ggcctcagcc	cgcaccggca	gtagaagatg	gtgaaagaaa	caacttacta	120
	cgatgttttg ggggtcaaac	ccaatgctac	tcaggaagaa	ttgaaaaagg	cttataggaa	180
	actggctttg aagtaccatc	ctgataagaa	cccaaatgaa	ggagagaagt	ttaaacagat	240
	ttctcaagct tacgaagttc				•	300
	agaacaggca attaaagagg			-		360
						
	<210> 141					
	<211> 483			•		
	<212> DNA	1. 1. 1. 1.			**:	
•	<213> homo sapie	en				
				P 424 1 12		
	<400> 141		$(-\infty,-\infty,-\infty) = (-\infty,-\infty)$			
	gaatteggea egagageaga	ggctgatctt	toctogaaaa	cagerggaag	atgggctgca	60
	ccctgtctga ctacaacatc					120
			.			180
	gtgggatgca aatcttcgtg					240
	ccagtgacac catcgagaac				•	-
	accagcagag gttgatcttt				, v	300
	acaacatcca gaaagagtct					360
	tettegtgaa gaccetgaet					420
	tcgagaatgt caaggcaaag	acccaagaca	aggaaggcat	receeectyat	Cagcagaggt	480
	tga ·					483
	-230- 342					
	<210> 142 <211> 500	j		· · · · · · · · · · · · · · · · · · ·	43 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	•
	<211> 500 <212> DNA	van transfer to the			garaga ay sagar	•
	<213> homo sapie		1 1 2 1 N 1 1 H			٠
	<400> 142	- 			West Control	
	7400> T47	200200000	an accept at a	caccoccoc	aacaaaata	60
	gaatteggea egaggeggeg	- 1	-			120
	gccggcgage ccggtccccg		the contract of the contract o	· · · · · · · · · · · · · · · · · ·		180
	gaatcacccc atgttggtgg					240
	ctgcgacaac tggatgaaca					300
	caagttctgg cggatgcccg	•				
	ccccgacgag atcatcgaca				•	360
	aggcctgcag cagcagaagc				· .	420
	gtttggtggc cggggccgag		gggcacagge	agaagccagc	Cagagaagaa	480
	gcctggcaga caggcgggca					500
	<210> 143					
	<211> 400					• •
	<212> DNA					-
	<213> homo sapie				A R A September	
	and the second of the second o				•	
	gaatteggea egagetegga					60
	ctcagaagaa agcgatcggc	cccgaggcag	gaaggccggc	tccggtgcag	ggcgcgccgc	120
	ctgcgggctg cttcgggcca	gggtcgaccc	gagggccagc	gcaagcagcg	gcaacaggag	180
	cgccaggagg acatgaggct					240~
	cagcatcaca gattataacc	ctccgtaaat	catctgcatc	ccagctccca	tcaaaagcca	300
	gcctgaagga cccatggaca					360
	gtttgcacaa catttgcatc			·.		400
	- -		, -			•

<210> 144

ti kali

<211> 243 <212> DNA <213> homo sapien <400> 144 gaatteggea egageeaget cetaacegeg agtgateege eageeteege eteeegaggt 60 gcccggattg cagacggagt ctccttcact cagtgctcaa tggtgcccag gctggagtgc 120 agtggtgtga teteggeteg etacaacate caceteccag cageetgeet tggeetecca 180 aagtgccgag attgcagcct ctgcccggcc gtcaccccgt ctgggaagtg aggagcgttt 240 ctg 243 <210> 145 <211> 450 <212> DNA <213> homo sapien <400> 145 gaattcggca cgaggacagc aggaccgtgg aggccgcggc aggggtggca gtggtggcgg . 60 cggcggcggc ggcggtggtg gttacaaccg cagcagtggt ggctatgaac ccagaggtcg 120 tggaggtggc cgtggaggca gaggtggcat gggcggaagt gaccgtggtg gcttcaataa 180 atttggtggc cctcgggacc aaggatcacg tcatgactcc gaacaggata attcagacaa 240 caacaccatc tttgtgcaag gcctgggtga gaatgttaca attgagtctg tggctgatta 300 cttcaagcag attggtatta ttaagacaaa caagaaaacg ggacagccca tgattaattt 360 gtacacagac agggaaactg gcaagctgaa gggagaggca acggtctctt ttgatgaccc 420 accttcagct aaagcagcct attgactggt 450 <210> 146 <211> 451 <212> DNA <213> homo sapien <400> 146 gaatteggea egageeateg agteeetgee titegaettg cagagaaatg tetegetgat 60 gcgggagatc gacgcgaaat accaagagat cctgaaggag ctagacgagt gctacgagcg 120 cttcagtcgc gagacagacg gggcgcagaa gcggcggatg ctgcactgtg tgcagcgcgc 180 gctgatccgc accaggagct gggcgacgag aagatccaga tcgtgagcca gatggtggag 240 ctggtggaga accgcacgeg gcaggtggac agccacgtgg agctgttcga ggcgcagcag 360 gagetgggeg acacageggg caacagegge aaggetggeg eggacaggee caaaggegag. gcggcagcgc aggctgacaa gcccaacagc aagcgctcac ggcggcagcg caacaacgag 420 aaccgtgaga acgcgtccag caaccacgac c 451 <210> 147 <211> 400 <212> DNA <213> homo sapien <400> 147 gaatteggea egagetegga tgteageagg egteecaace eageaggaac tggeteaatt ctcagaagaa agcgatcggc cccgaggcag gaaggccggc tccggtgcag ggcgcgccgc 120 ~ ctgcgggctg cttcgggcca gggtcgaccc gagggccagc gcaagcagcg gcaacaggag 180 cgccaggagg acatgaggct ctgcctgcag tcagcaactt ggaatattca gacttcagac 240 cagcatcaca gattataacc ctccgtaaat catctgcatc ccagctccca tcaaaagcca 300 gcctgaagga cccatggaca cgtgactcca gtgttctcaa caacatctta gatcaagttg 360 400 gtttgcacaa catttgcatc tacttgggac aaagcaagaa

. ONE

```
<210> 148
      <211> 503
       <212> DNA
      <213> Homo sapien
      <400> 148
aaaagaattc ggcacgagcg gcgccgctca tccccctctc ccagcagatt cccactggaa
                                                                        60
attcgttgta tgaatcttat tacaagcagg tcgatccggc atacacaggg agggtggggg
                                                                        120
cgagtgaage tgcgcttttt ctaaagaagt ctggcctctc ggacattatc cttgggaaga
                                                                        180
tatgggactt ggccgatcca gaaggtaaag ggttcttgga caaacagggt ttctatgttg
                                                                        240
cactgagact ggtggcctgt gcacagagtg gccatgaagt taccttgagc aatctgaatt
                                                                        300
tgagcatgcc accgcctaaa tttcacgaca ccagcagccc tctgatggtc acaccgccct
                                                                        360
ctgcagaggc ccactgggct gtgagggtgg aagaaaaggc caaatttgat gggatttttg
                                                                        420
aaagcctctt gcccatcaat ggtttgctct ctggagacaa agtcaagcca gtcctcatga
                                                                        480
actcaaagct gcctcttgat gtc
                                                                       503
      <210> 149
      <211> 1061
      <212> DNA
      <213> homo sapien
      <400> 149
gaatteggea egaggeettt teeageaace ceaaggteea ggtggaggee ategaagggg
gagecetgea gaagetgetg gteateetgg ceaeggagea geegeteaet geaaagaaga
                                                                       120
aggtectgtt tgcactgtgc tecetgetge gecaetteee etatgeecag eggeagttee
                                                                      . 180
tgaagctcgg ggggctgcag gtcctgagga ccctggtgca ggagaagggc acggaggtgc
                                                                       240
                                                                       300
tcgccgtgcg cgtggtcaca ctgctctacg acctggtcac ggagaagatg ttcgccgagg
                                                                       360
aggaggetga getgacccag gagatgtece cagagaaget geageagtat egecaggtae
                                                                       420
acctectgee aggeetgtgg gaacaggget ggtgegagat caeggeeeae etectggege
                                                                       480
tgcccgagca tgatgcccgt gagaaggtgc tgcagacact gggcgtcctc ctgaccacct
geegggaeeg etacegteag gaeeeceage teggeaggae aetggeeage etgeaggetg
                                                                       540
agtaccaggt gctggccage etggagetge aggatggtga ggacgaggge tacttecagg
                                                                       600
agctgctggg ctctgtcaac agcttgctga aggagctgag atgaggcccc acaccagtac
                                                                       660
                                                                       720
tggactggga tgccgctagt gaggctgagg ggtgccagcg tgggtgggct tctcaggcag
gaggacatct tggcagtgct ggcttggcca ttaaatggaa acctgaaggc catcctcttt
                                                                       780
ctgctgtgtg tctgtgtaga ctgggcacag ccctgtggcc ggggggtcag gtgagtggtt
                                                                       840
gggtgatggg ctctgctgac gtgcagggct cagcccaggg catccaggaa caggctccag
                                                                       900
ggcaggaacc tgggcccagg agttgcaagt ctctgcttct taccaagcag cagctctgta
                                                                       960
ccttgggaag tcgcttaatt gctctgagct tgtttcctca tctgtcagga gtgccattaa
                                                                      1020
aggagaaaa tcacgtaaaa aaaaaaaaaa aaaactcga g
                                                                      1061
      <210> 150
      <211> 781
      <212> DNA
      <213> homo sapien
      <400> 150
gaatteggea egagaaatgg eggeaggggt egaageggea geegaagtgg eggegaeaga
acccaaaatg gaggaagaga geggegegee etgegtgeeg ageggeaacg gageteeggg
                                                                       120
cccgaagggt gaagaacgac ctactcagaa tgagaagagg aaggagaaaa acataaaaag
                                                                       180
aggaggcaat cgctttgagc catattccaa cccaactaaa agatacagag ccttcattac
                                                                       240
aaatatacct tttgatgtga aatggcagtc acttaaagac ctggttaaag aaaaagttgg
                                                                       300
tgaggtaaca tacgtggagc tcttaatgga cgctgaagga aagtcaaggg gatgtgctgt
                                                                       360
                                                                       420
tgttgaattc aagatggagg agagcatgaa aaaagctgct gaagttctaa acaagcatag
tetgagtgga aggecaetga aagteaagga agateetgat ggtgaacatg caaggagage
                                                                       480
```

2340

2400 -

2460

2520

 $G_{\mathcal{A}^{*}} = \mathcal{A}$

đạya, -1,15 K, 1 114 (\$

1. 1. 1. 1. 1. 1. 1241

2 5 to 1 . **最高的**

46.5

6.85

3. M. C.

The same of

					the state of the s		
	aatgcaaaag	gctggaagac	ttggaagcac	agtatttgta	gcaaatctgg	attataaagt	540
			aagtatttag				600
			aaagtcgtgg				660
			ctatgtttaa				720
						aacgccacag	780
	C						781
٠. ;	<210>	151					•
~ ;	<2115	2275	e Alice San			•	•
	7.54.784 <212 5	> DNA	,				
: :	: 6:<213×	Homo sapie	n			er en la caracteria.	-
٠.	2 5 5	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	Section 200				
		> 151			• •		
	cttaagtgga	tcctgcatca	ggagggagca	gacaccggag	aaagaaaaac	aagttgtgct	60
	gtttgaggaa	gcaagttgga	cctgcactcc	agcctgtgga	gatgaaccta	ggactgtgat	120
			ctgaccacag				180
						atgaagaagt	240
•			ccaaggagct				300
	tctactaaaa	gcgcaaaaga	aggcccagag	aagggagcac	atgctaaaac	ttgaggctga	360
			tacttcaagt				. 420
٠.			aagggggttt				480
			tttcaaaact				540
:			ctgtctaaat				600
¥.	cagttcccaa	aaatgccaag	gaaaaggaag	taccactgga	ggaagaaatg	ctaatacaat	660
-,	cagagaaaaa	aacacaatta	tcgaagactg	aatctgtcaa	agagtcagag	tctctaatgg	720
-	aatttgccca	gccagagata	caaccacaag	agtttcttaa	cagacgctat	atgacagaag	780
	tagattattc	aaacaaacaa	ggcgaagagc	aaccttggga	agcagattat	gctagaaaac	840
,	caaatctccc	aaaacgttgg	gatatgetta	ctgaaccaga	tggtcaagag	aagaaacagg	900
	agtectttaa	gtcctgggag	gcttctggta	agcaccagga	ggtatccaag	cctgcagttt	960
	ccttagaaca	gaggaaacaa	gacacctcaa	aactcaggtc	tactctgccg	gaagagcaga	1020
	agaagcagga	gatctccaaa	tccaagccat	ctcctagcca	gtggaagcaa	gatacaccta	1080
	aatccaaagc	agggtatgtt	caagaggaac	aaaagaaaca	ggagacacca	aagctgtggc	1140
	cagttcagct	gcagaaagaa	caagatccaa	agaagcaaac	tccaaagtct	tggacacctt	1200
	ccatgcagag	cgaacagaac	accaccaagt	catggaccac	tcccatgtgt	gaagaacagg	1260
	attcaaaaca	gccagagact	ccaaaatcct	gggaaaacaa	tgttgagagt	caaaaacact	1320
			atttctccaa				1380
			cccaggaagt				1440
			tcttcctcta				1500
			actcagattc				1560
			tcaagtgcaa				1620
			aaagaacaaa				1680
•			gttaatgcac				1740
			ggctacaatc				1800
			tctatacatg				1860
			ggaactattc				1920
	cagcacagac	gaatgtgttt	cccagaccta	ctcagccatt	tgtcaatagc	cggggatctg	1980
	ttagaggatg	tactcotoot	gggagattaa	taaccaattc	ctatcoatcc	cctaataatt	2040
	ataaaggttt	tgatacttat	agaggactcc	cttcaatttc	caatggaaat	tatagccagc	2100
	tgcagttcca	agctagagag	tattctggag	caccttattc	ccaaagggat	aatttccagc	2160
	agtgttataa	gcgaggaggg	acatctggtg	gtccacgagc	aaattcgaga	gcagggtgga	2220
	gtgattcttc	tcaggtgagc	agcccagaaa	gagacaacga	aacctttaac	agtggtgact	2280
			accardaccc				2340

ctggacaagg agactcccgt agcatgaccc ctgtggatgt gccagtgaca-aatccagcag ccaccatact gccagtacac gtctaccete tgcctcagca gatgcgagtt gccttctcag

cagccagaac ctctaatctg gcccctggaa ctttagacca acctattgtg tttgatcttc

ttctgaacaa cttaggagaa acttttgatc ttcagcttgg tagatttaat tgcccagtga

atggcactta	cgttttcatt	tttcacatgc	taaagctggc	agtgaatgtg	ccactgtatg	2580
tcaacctcat	gaagaatgaa	gaggtcttgg	tatcagccta	tgccaatgat	ggtgctccag	2640
accatgaaac	tgctagcaat	catgcaattc	ttcagctctt	ccagggagac	cagatatggt	2700
tacgtctgca	caggggagca	atttatggaa	gtagctggaa	atattctacg	ttttcaggct	2760
atcttcttta	tcaagattga	aagtcagtac	agtattgaca	ataaaaggat	ggtgttctaa	2820
 ttagtgggat	tgaaggaaaa	gtagtctttg	ccctcatgac	tgattggttt	aggaaaatgt	2880
ttttgttcct	agagggagga	ggtccttact	tttttgttt	ccttcctgag	gtgaaaaatc	2940
aagctgaatg	acaattagca	ctaatctggc	actttataaa	ttgtgatgta	gcctcgctag	3000
tcaagctgtg	aatgtatatt	gtttgcactt	aatccttaac	tgtattaacg	ttcagcttac	3060
		•			aataaaaaag	3120
ttacatgcaa	aaaaaaaaa	aaaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	3180
aaaaaaaaa	aaaaaaaaa	.caaaaaaaaaa.	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	3240
aaaaaaaaa	aaaaaaaaa	aaaaaaaac	tcgag	•	149	3275

<210> 152 <211> 2179 <212> DNA

<213> homo sapien

<400> 152

.: 1:

1. 1. 6

 \cdot

. e. 3 ...

13 to 3 4

1 4 m

** *** ****

100

 $\mathbb{M} \setminus \mathbb{A}_{+}$

·

Jaka .

· 3.5.7

....

. i :

: · · · ·

gaatteggea ceaggeacta ttaaatgtga ggeageetee atetaetaea acatttgtge 60 tgaatcaaat aaatcatctt ccacccttgg gatctacaat tgtaatgact aaaacaccac 120 ctgtaacaac caacaggcaa accatcactt taactaagtt tatccagact actgcaagca 180 cacgcccgtc agtctcagca ccaacagtac gaaatgccat gacctctgca ccttcaaaag 240 accaagttca gcttaaagat ctactgaaaa ataatagtct taatgaactg atgaaactaa 300 agccacctgc taatattgct cagccagtag caacagcagc tactgatgta agcaatggta 360 cagtaaagaa agagtettet aataaagaag gagetagaat gtggataaac gacatgaaga 420 480 tgaggagttt ttccccaacc atgaaggttc ctgttgtaaa agaagatgat gaaccagagg 540 aagaagatga agaagaaatg ggtcatgcag aaacctatgc agaatacatg ccaataaaat 600 taaaaattgg cctacgtcat ccagatgctg tagtggaaac cagctcttta tccagtgtta 660 ctcctcctga tgtttggtac aaaacatcca tttctgagga aaccattgat aatggctggt tatcagcatt gcagcttgag gcaattacat atgcagccca gcaacatgaa actttcctac 720 780 ctaatggaga tegtgetgge ttettaatag gtgatggtge eggtgtagga aaaggaagga cgatagcagg aatcatctat gaaaattatt tgttgagtag aaaacgagca ttgtggttta 840 gtgtttcaaa tgacttaaag tatgatgctg aaagagattt aagggatatt ggagcaaaaa 900 960 acattttggt tcattcgtta aataagttta aatacggaaa aatttcttcc aaacataatg 1020 ggagtgtgaa aaagggtgtt atttttgcta cttactcttc acttattggt gaaagccagt ctggcggcaa gtataaaact aggttaaaac aacttctgca ttggtgcggt gatgacttcg 1080 1140 atggagtgat agtgtttgat gagtgtcata aagccaaaaa cttatgtcct gttggttctt 1200 caaagccaac caagacaggc tragcagttt tagagcttca gaacaaattg ccaaaagcca gagttgttta tgctägtgca actggtgctt ctgaaccacg caacatggcc tatatgaacc 1260 1320 gtcttggcat atggggtgag ggtactccat ttagagaatt cagtgatttt attcaagcag tagaacggag aggagttggt gccatggaaa tagttgctat ggatatgaag cttagaggaa 1380 tgtacattgc tcgacaactg agctttactg gagtgacctt caaaattgag gaagttcttc 1440 tttctcagag ctacgttaaa atgtataaca aagctgtcaa gctgtgggtc attgccagag 1500 ageggtttca gcaagetgca gatetgattg atgetgagca acgaatgaag aagtecatgt 1560 1620 ggggtcagtt ctggtctgct caccagaggt tcttcaaata cttatgcata gcatccaaag 1680 ttaaaagggt tgtgcaacta gctcgagagg aaatcaagaa tggaaaatgt gttgtaattg 1740 gtctgcagtc tacaggagaa gctagaacat tagaagcttt ggaagagggc gggggagaat 1800tgaatgattt tgtttcaact gccaaaggtg tgttgcagtc actcattgaa aaacattttc 1860 ctgctccaga caggaaaaaa ctttatagtt tactaggaat cgatttgaca gctccaagta 1920 acaacagttc gccaagagat agtccttgta aagaaaataa aataaagaag cggaaaggtg 1980 aagaaataac tcgagaagcc aaaaaagcac gaaaagtagg tggccttact ggtagcagtt ctgacgacag tggaagtgaa tctgatgcct ctgataatga agaaagtgac tatgagagct 2040 2100 ctaaaaacat gagttctgga gatgatgacg atttcaaccc atttttagat gagtctaatg

and the second s

	aggatgatga aaaaaaaaaa	•	tggttaatta	aaaaaaaaa	aaaaaaaaaa	aaaaaaaaa	2160 2179
	aaaaaaaaa	aaaccegag					
	-210-	167					
- 10 10	<210>		4	4.			
		2109		• :			• •
	-	DNA			·	ti e dite	•
	<213>	Homo sapie	en :	asy or some			
1993 B							
	<400>					<u>474.1-19</u>	۰.
	cagagagccc	caggcatcga	ggagaaggcg	gcggagaatg	gggccctggg	grcccccgag	. 60
elle S						ggagaaagcg	120
						gaatgggggc	180
. 1999 · ·						attccccagg	240
						ggagaagacg	300
inor .	cccgagagtt	ggggtccagc ¹	ccccacgatc	ggggagccag	ccccagagac	ctctctggag	360
			agtggtctcc				420
						gagageeee	480
			agccccaggg				540
rain de la companya d La companya de la companya dela companya de la companya dela companya de la companya de la companya de la companya dela companya de la						cgtggacgca	600
						gccaccgcca	660
in and the second	ccaasaacsc	agccgaggag	actagaacca	acacccccaa	gagecaggec	ggaggtggcc	720
	ccggaggaa	ageogagge	cccagacage	agggccggcg	gagacacggc	actcagcgga	780
	ceegagggag	ccccaagcc	cgagaggaag	ggccccgaga	toccacgact	attettogae	840
	tterrasees	ctcacaagec	cadcdadcad	arcaaagcca	agetetecea	acteteacta	900
	cegggacece	cccayggaa	cagogageag	ccadaaccaa	acccacaaca	gccccgtgg	960
							1020
			ggctggcggg				1080
•	gcggaggagg	acggggagga	cgaggacgag	gacgaggagg	aggacgagga	ggcggcggcg	1140
•	ccdddcdcdd	cggcggggcc	geggggeeee	gggagggcgc	gageageeee	ggtgcccgtc	1200
	gragraaca	gcgccgacgc	ggacgcggcc	egeeegeege	gggggccgcc	caagtctccg	1260
	cacaaaacca	acgagccaga	ggacagcgag	ccggagagga	agegeaagae	actalacata	1320
23	cacggggacg	tgaccgtcta	ccccccgac	caggagacgc	caaccaacga	gctgagcgtc	1380
	caggcccccc	ccgaggggga	cacggacccg	teaacgeete	eagegeeeee	gacacctccc	1440
	caccccgcca-	ccccggaga	tgggtttcce	-agcaacgaca	geggetttgg	aggcagtttc	
4. id h.	gagtgggcgg	aggatttccc	cctcctccc	cctccaggcc	ccccgcrgrg	cttctcccgc	1500
785 ·						cgacgcccgg	1560
4	cccgcaggcc	ccgtggagaa	ttgattcccc	gaagacccga	ccccgctgca	cccrcagaag	1620
6 B &	aggggttgag	aatggaatcc	tctgtggatg	acggcgccac	tgccaccacc	gcagacgccg	1680
\$ \$ x 1	cctctgggga	ggcccccgag	gctgggccct	cccctccca	ctcccctacc	atgtgccaaa	1740
	cgggaggccc	cgggcccccg	cccccagc	ccccagatg	gctcccctga	cccccctgac	1800
	ccctcggag	ccaaatgagg	caggaatccc	cccgcccctc	catagagagc	cgcctttctc	1860
\$500	ggaactgaac	tgaactcttt	tgggcctgga	gcccctcgac	acageggagg	tecetectea	1920
	cccactcctg	gcccaagaca	ggggccgcag	gcttcgggga	cccggacccc	ccatttcgcg	1980
	tctccccttt	ccctccccaq	cccggcccct	ggaggggcct	ctggttcaaa	ccttcgcgtg	2040
	gcattttcac	attatttaaa	aaaqacaaaa	acaacttttt	ggaggaaaaa	aaaaaaaaa	2100
•	aaactcgag		3				2109
•	uuuu cogug			•			
	<210>	. 154	· .				•
		1411	•		:	•	
	<2117	DNA		• .			
					e Live		
	<213>		311	age of the second	J. \$437. 104	and the second seco	
149 542		•			e e e e e e e e e e e e e e e e e e e	一种企业等模型。在1997年	
· 035 .	- topus - <4005	154				J	
***	gaattcggca	ccaggggaga	tgaggaagtt	cgatgttcct	agcatggagt	ctacccttaa	60
32	ccagccagcc	atğctagaga	cgttatactc	agatccacat	taccgagccc	atttccccaa	120
	cccaagacct	gatacaaata	aggatgtata	caaágtattg	ccagaatcca	agaaggcacc	180
	_	-					

意味()。 。

स्थान्त्रीतः वृद्धाः

122

W. It.

				. 	•
gggcagtggt gcagtatttg	ададдаасдо	. accacatact	agcagtagto	gaatacteee	240
tttgggactc cagcctgcgc					300
aagteetgae cettggeate		/	•		
					360
gttggaattg atccgtttac			•		420
ccatcctgct gctttcgctc					480
cctgaacagt aacgagcatc					540
gcatatctct cagctggagc			_		600
tttgggccgc cctgcccct			-		660
agagaacact ttcttacggg	and the same of th				720
gatggagett gaaaagaaac					780
tctaaaagtg acactacaga	and the first of t			,	840
aggtegtgat aaacatatca					•
ccgggagaag cagcagcgta	the same and the same to the same to the same				960
agaagaccat cagaaacaga	1.3 A-m				1020
gcaagagaga gtggctgagc			· , ·		1080
gaaggaggtt cagctggaaa	the contract of the contract o		. ,		1140
taggtaatgc cctgtgtact	A 11 200			_	1200
cttgtgtgtt caacagtgtt	the transfer of the state of th				1260
aattgaaagt cacttatggc					1320
gtcagaggca ggctaatttc			gctatacaga	gaaaccctgt	1380
Ctcaaacaaa aaaaaaaaa	aaaaactcga	. g	भूशकात् भूगात्र	riustification, militari	1411
and the second s		ar Marin		1. 类似的 1. 一	
<510> 122	والمحاصي وماج والمال	artist and a state of the second		1000年6月8日	. :
	J. 18 10 / 18 July 10 10 10 10 10 10 10 10 10 10 10 10 10		경기선 - 경기가 가득 수		
<212> DNA <213> homo sapio				A CONTRACTOR	
<213> homo sapio	en			igi, in parket 6	
<400> 155 ctggagtgaa gggagctagt		7/20/20 194			
ctggagtgaa gggagctagt	ggtaaaggga	gctggtggag	agaraacaac	aggggtaagg	60
ggcaggggac accetetaga					120
cccgccctg tgttggtccc					180
gtcagttgtg gggttcagag			2m 7.13		240
cccagtcgtc cgtattagga		••		•	300
ggaacctgtc tittgatttg			· · · · · · · · · · · · · · · · · · ·	•	360
cccctaggc acagggggtg	· 1965年 1967年 196				420
cgaggcattc ttcgtgctca					480
ggaageceae egaegeeage		and the second of the second o			540
gcaatccctc aactacggct	gcatcgttga	gaatccacag	acacacgagg	tattgcacta	600
tgtggagaaa cccagcacat	ttatcagtga	catcatcaac	tgcggcacct	acctcttttc	660
tcctgaagcc ttgaagcc			1 - 12-17-63		678
A STATE OF THE PARTY OF THE PAR	LANK I I I	Jakan Landar			-
\Z10> 130		Carlo Same			
\Z11> 2000				anthur Andrew	
<212> DNA		·		1,3 ×4 ×7 × 3 × 1.3 × 5	•
<213> Homo sapie	en ·		•		
	•		• :	Participation of the second	•
<400> 156	•		3.298	4218	
gggaaggcgg ctgcgctgct	gggcgggggc	gggagctgga	gccggagctg	gagccggggc	60
cagaacccaa atcaacactt		•			120

gggaaggcgg ctgcgctgct gggcggggc gggagctgga gccggagctg gagccggggc 60
cggggcccgg gtcagcgctt gagccgggag aagagtttga gatcgtggac cgaagccagc 120
tgcccggccc aggcgacctg cggagcgcaa cgaggccgcg ggcggccgag ggctggtcgg 180
cgcccatcct gaccctggca cgcagggcca ccgggaacct gtcggcgagc tgcgggagcg 240
cgctgcgcgc ggccgcgggg ctgggcggcg gggacagcgg ggacggcacg gcgcgcag 300
cttctaagtg ccagatgatg gaggagcgtg ccaacctgat gcacatgatg aaactcagca 360
tcaaggtgtt gctccagtcg gctctgagcc tgggccgcag cctggatgcg gaccatgcc 420
ccttgcagca gttctttgta gtgatggagc actgcctcaa acatgggctg aaagttaaga 480

					•		
	agagtttat	tggccaaaat	aaatcattct	ttggtccttt	ggagctggtg	gagaaacttt	540
_ '	gtccagaagc	atcagatata	gcgactagtg	tcagaaatct	tccagaatta	aagacagctg	600.
	tgggaagagg	ccgagcgtgg	ctttatcttg	cactcatgca	aaagaaactg	gcagattatc	660
	tgaaagtgct	tatagacaat	aaacatctct	taagcgagtt	ctatgagcct	gaggetttaa	720
	tgatggagga	agaagggatg	gtgattgttg	gtctgctggt	gggactcaat	gttctcgatg	780
	ccaatctctg	cttgaaagga	gaagacttgg	attctcaggt	tggagtaata	gatttttccc	840
	tctaccttaa	ggatgtgcag	gatcttgatg	gtggcaagga	gcatgaaaga	attactgatg	900
		aaaaaattat					960
		caagatagat					1020
٠.	cagetgeaac	agaccgaatt	tgctcacttc	aagaagaaca	gcagcagtta	agagaacaaa	1080
	atgaattaat	tcgagaaaga	agtgaaaaga	gtgtagagat	aacaaaacag	gataccaaag	1140
	ttgagetgga	gacttacaag	caaactcggc	aaggtctgga	tgaaatgtac	agtgatgtgt	1200
	ggaagcagct	aaaagaggag	aagaaagtcc	ggttggaact.	ggaaaaagaa	ctggagttac	1260
	aaattggaat	gaaaaccgaa	atggaaattg	caatgaagtt	actggaaaag	gacacccacg	1320
	agaagcagga	cacactagtt	gccctccgcc	agcagctgga	agaagtcaaa	gcgattaatt	1380
	tacagatgtt	tcacaaagct	cagaatgcag	agagcagttt	gcagcagaag	aatgaagcca	1440
	tcacatcctt	tgaaggaaaa	accaaccaag	ttatgtccag	catgaaacaa	atggaagaaa	1500
	ggttgcagca	ctcggagcgg	gcgaggcagg	gggctgagga	gcggagccac	aagctgcagc	1560
	aggagetggg	cgggaggatc	ggcgccctgc	agctgcagct	ctcccagctg	cacgagcaat	1620
	gctcaagcct	ggagaaagaa	ttgaaatcag	aaaaagagca	aagacaggct	cttcagcgcg	1680
	aattacagca	cgagaaagac	acttcctctc	tactcaggat	ggagctgcaa	caagtggaag	1740
	gactgaaaaa	ggagttgcgg	gagetteagg	acgagaaggc	agagetgeag	aagatctgcg	1800
•	aggagcagga	acaagccctc	caggaaatgg	gcctgcacct	cagccagtcc	aagctgaaga	1860
٠.	tggaagatat	aaaagaagtg	aaccaggcac	tgaagggcca	cgcctggctg	aaagatgacg	1920
-	aagcgacaca	ctgtaggcag	tgtgagaagg	agttctccat	ttcccggaga	aagcaccact	1980
٠.	gccggaactg	tggccacatc	ttctgcaaca	cctgctccag	caacgagctg	gccctgccct	2040
	cctacccaa	gccggtgcga	gtgtgcgaca	gctgccacac	cctgctcctg	cagcgctgct	2100
	cetecaegge	ctcctgaacg	teegteetea	ggagcacagc	ctcacggaca	gtgccaaacc	2160
	ctgtgggtct	ccaggggctt	gggaaatgtg	ttctttccca	agagtatcaa	aggaaagaat	2220
	caaatttctt	gcccggtcac	tggcactcca	gaagacagcg	tgccggaacc	ggcagctctc	2280
,	acctttctgt	gacttgttcg	gaattaactc	ctctggatgg	aaacttccat	cttacttggt	2340
	tacatcacgg	ctctggttca	gatacaactt	catgattttg	ctactatcat	tttcactt	2400
	tcaaagaatt	taacctattt	tacagcagtt	cagttctgct.	agtgagtagt	tttcctctcc	2460
	taccttcctt	ctaaaaacct	gattcatgca	cagcgtttga	cacacatgga	gtctgccagt	2520
	gtgccttctc	tgcttcagac	aagagatetg	ccatttcatg	cccttgtgac	tacctatcat	2580
	tggccctgca	ataaaatcat	ttattttca	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	2640
,	aaaaaaaaa	aaaaaaaaa	aactcgag				2668
				14 to 14 to 18			,
	<210>	157			A STATE OF THE STA	The second second	
	<211>	2313					•

114	aaaaaaaaa aaaaaaaaaa aactcgag	
244	<210> 157 <211> 2313 <212> DNA	
	<213> homo sapien	•
	<400> 157	
	gaatteggea ceaggeegge egggegeete ageeatggee etgegeaagg aactgeteaa	- 60
7: 22	gtccatctgg tacgccttta ccgcgctgga cgtggagaag agtggcaaag tctccaagtc	120
• • • • • • • • • • • • • • • • • • • •	ccagctcaag gtgctgtccc acaacctgta cacggtcctg cacatccccc atgaccccgt	180
	ggcctggag gaacacttcc gagatgatga tgacggccct gtgtccagcc agggatacat	240
	gcctacctc aacaagtaca tcctggacaa ggtggaggag ggggcttttg ttaaagagca	300
	ctttgatgag ctgtgctgga cgctgacggc caagaagaac tatcgggcag atagcaacgg	. 360
الله الله الله الله الله الله الله الله	gaacagtatg ctctccaatc aggatgcctt ccgcctctgg tgcctcttca acttcctgtc	420
	tgaggacaag taccetetga teatggttee tgatgaggtg gaatacetge tgaaaaaggt	480
	actcagcagc atgagcttgg aggtgagctt gggtgagctg gaggagcttc tggcccagga	540
	ggcccaggtg gcccagacca ccggggggct cagcgtctgg cagttcctgg agctcttcaa	600
	ttegggeege tgeetgeggg gegtgggeeg ggaeaceete ageatggeea tecaegaggt	660

				·		-	
	ctaccaggag	ctcatccaag	atgtcctgaa	gcagggctac	ctgtggaagc	gagggcacct	720
	gagaaggaac	tgggccgaac	gctggttcca	gctgcagccc	agctgcctct	gctactttgg	780
	gagtgaagag	tgcaaagaga	aaaggggcat	tatcccgctg	gatgcacact	gctgcgtgga	840
	ggtgctgcca	gaccgcgacg	gaaagcgctg	catgttctgt	gtgaagacag	ccacccgcac	900
	gtatgagatg	agegeeteag	acacgcgcca	gcgccaggag	tggacagctg	ccatccagat	960
	ggcgatccgg	ctgcaggccg	aggggaagac	gtccctacac	aaggacctga	agcagaaacg	1020
	gcgcgagcag	egggagcagc	gggagcggcg	ccgggcggcc	aaggaagagg	agctgctgcg	1080
-	gctgcagcag	ctgcaggagg	agaaggagcg	gaagctgcag	gagctggagc	tgctgcagga	1140
	ggcgcagcgg	caggccgagc	ggctgctgca	ggaggaggag	gaacggcgcc	gcagccagca	1200
•!	ccgcgagctg	cagcaggcgc	tcgagggcca	actgcgcgag	gcggagcagg	cccgggcctc	1260
	catgcaggct	gagatggagc	tgaaggagga	ggaggctgcc	cggcagcggc	agcgcatcaa	1320
<i>:</i> '	ggagctggag	gagatgcagc	agcggttgca	ggaggccctg	caactagagg	tgaaagctcg	1380
	gcgagatgaa	gaatctgtgc	gaatcgctca	gaccagactg.	ctggaagagg	aggaagagaa	1440
	gctgaagcag	ttgatgcagc	tgaaggagga	gcaggagcgc	tacatcgaac	gggcgcagca	1500
	ggagaaggaa,	gagetgeage	aggagatggc	acagcagagc	cgctccctgc	agcaggccca	1560
	gcagcagctg	gaggaggtgc	ggcagaaccg	gcagagggct	gacgaggatg	tggaggctgc	1620
	ccagagaaaa	ctgcgccagg	ccagcaccaa	cgtgaaacac	tggaatgtcc	agatgaaccg	1680
-,	gctgatgcat	ccaattgagc	ctggagataa	gcgtccggtc	acaagcagct	ccttctcagg	1740
٠.	cttccagccc	cctctgcttg	cccaccgtga	ctcctcccta	aagcgcctga	cccgctgggg	1800
	atcccagggc	aacaggaccc	cctcgcccaa	cagcaatgag	cagcagaagt	ccctcaatgg	1860
	tggggatgag	gctcctgccc	cggcttccac	ccctcaggaa	gataaactgg.	atccagcacc	1920
	agaaaattag						1980
	cacagctggc						2040
	caggggccca	_		7 2 -	•		2100
	ccagctccaa	· .				· · · · · · · · · · · · · · · · · · ·	2160
	ctgtgcttta	••					2220
	ggctacctgc	,			atttctaaat	aaaaactgct	2280
	cttagaatga	aaaaaaaaa	aaaaaaactc	gag			2313

<210> 158

<211> 2114

<212> DNA

<213> homo sapien

<400> 158

gagaataaca gaaatgtcca tttggagcac tcagagcaga atcctggttc atcagcaggt 120 gacacctcag cagcgcacca ggtggtttta ggagaaaact tgatagccac agccctttgt 180 240 ggggacacaa gccttcggga gagcctccat ccagtcactc ggtctcttaa ggcagggtgc 300 catactaage agettgeete caggaattge tetgaagaga aateeceaca aaceteeate 360 ctaaaggaag gtaacaggga cacaagcttg gatttccgac ctgtagtgtc tccagcaaat 420 ggggttgaag gagtccgagt ggatcaggat gatgatcaag atagctcttc cctgaagctt 480 tctcagaaca ttgctgtaca gactgacttt aagacagctg attcagaggt aaacacagat 540 60.0 caagatattg aaaagaattt ggataaaatg atgacagaga gaaccctgtt gaaagagcgt taccaggagg teetggacaa acagaggeaa gtggagaate ageteeaagt geaattaaag 660 cagetteage aaaggagaga agaggaaatg aagaateace aggagatatt aaaggetatt **720** caggatgtga caataaagcg ggaagaaaca aagaagaaga tagagaaaga gaagaaggag 780 tttttgcaga aggagcagga tctgaaagct gaaattgaga agctttgtga gaagggcaga 840 900 agagaggtgt gggaaatgga actggataga ctcaagaatc aggatggcga aataaatagg 960 aacattatgg aagagactga acgggcctgg aaggcagaga tcttatcact agagagccgg aaagagttac tggtactgaa actagaagaa gcagaaaaag aggcagaatt gcaccttact 1020 tacctcaagt caactcccc aacactggag acagttcgtt ccaaacagga gtgggagacg 1080 1140 agactgaatg gagttcggat aatgaaaaag aatgttcgtg accaatttaa tagtcatatc cagttagtga ggaacggagc caagctgagc agccttcctc aaatccctac tcccacttta 1200

1260

cctccacccc catcagagac agacttcatg cttcaggtgt ttcaacccag tccctctctg

```
1320
 geteetegga tgeeettete cattgggeag gteacaatge ceatggttat geeeagtgea
 gateceeget cettgtettt eccaatectg aaecetgeee ttteecagee cagecageet
                                                                                                                   1380
 tecteaceee treetggete ceatggeaga aatageeetg gettgggtte cettgteage
                                                                                                                  1440
 cctggtgccg aattcggcac gaggtaccac tggtctgtgt gctagaggag ggtgttgcca
                                                                                                                  1500
 tagaaccagt ggccacagtt gtggtggtgg tggtcagcac tgtgggggtg tgggtggtcc
                                                                                                                  1560
 ccgggacgga ggaggggtc accgtgaagc cactggttgt gggtgtggtg gttgtgctga
                                                                                                                  1620
 tecacactgg aggegtgegt geegteeetg ggetgaagga gggggtgaet gtgaageeeg
                                                                                                                  1680
tggttgtggt agtcggcact ttggtagtgt gagctgttcc tggggtggaa gagggggtgg
                                                                                                                  1740
 ccacagagec ggtggceetg gttgtggtgg ccgtggtggt aageactgtg gaggtgtggg
                                                                                                                  1800
 cagtctctgg agtggaggag ggtgtggctg tggacatggt ggccgtgggt gtggtggtct
                                                                                                                  1860
 gtgataggcg ggtccaggtg gtgcccaggg aggaggaggg gatggctgta aagctggtag
                                                                                                                  1920
                                                                                                                  1980
 ctgtgggtgt ggtggctgtg cttctcagtg ctggaagggc ggttgcagtc cctggactgg
 agaagggagt ggctttggag ctggtgactg tgggtgtcgt ggccgtggtg ctcacatgtg
                                                                                                                  2040
 gggtgccagc agttgcctgg gtggaggagg cggtggccgt ggatccggtg ggcaccgtca
                                                                                                                  2100
                                                                                                                  2114
 cgggagtact tcta
          <210> 159
                                      <211> 278
                                     <213> homo sapien
                BO DENDER HOMER AND A CONTRACT OF THE THE THE THE CONTRACT CONTRACT CONTRACT OF THE
                           好,你就要把人工的分配,只要在了数点还是解码的数据的影响。 医多种致凝血物等 人名克尔特特人 化氯甲烷酸
          <400> 159.
                                                                                                                     60
 gaatteggea caggtaactt tgeetggggt atttaaaaaa aaaaaaaaaa aaaaaaaaag
tcaaatatct gagtactaat ttcctgaaaa gtatgttccg atagatgaac agatcattaa
                                                                                                                   120
 tgcagaatga gaatcactcc taaaataggt aatggtaaaa attaaattga caattacctc
                                                                                                                    180
*tctctatgca gaaggaaata tcacctatat gacatcatca tcatctattg atacttgctg
                                                                                                                    240
 gcagtgctaa taatggtttt aatgccaatt tgtaagaa
                                                                                                                    278
          <210> 160
           <211> 848
          <212> DNA
           <213> homo sapien
           <400> 160
                             THE PROPERTY OF THE PROPERTY O
 gaatteggea egageeceag aggagetegg cetgegetge gecaegatgt eeggggagte
 agccaggage ttggggaagg gaagcgcgcc cccggggccg gtcccggagg gctcgatccg
                                                                                                                    120
 catctacage atgaggttet gecegtttge tgagaggaeg egtetagtee tgaaggecaa
                                                                                                                    180 :
 gggaatcagg catgaagtca tcaatatcaa cctgaaaaat aagcctgagt ggttctttaa
                                                                                                                    240
 gaaaaatccc trtggtctgg tgccagttct ggaaaacagt cagggtcagc tgatctacga
                                                                                                                    300
 gtctgccatc acctgtgagt acctggatga agcataccca gggaagaagc tgttgccgga
                                                                                                                    360
                                                                                                                    420
 tgacccctat gagaaagctt gccagaagat gatcttagag ttgttttcta aggtgccatc
                                                                                                                    480
 cttggtagga agctttatta gaagccaaaa taaagaagac tatgctggcc taaaagaaga
atttcgtaaa gaatttacca agctagagga ggttctgact aataagaaga cgaccttctt
                                                                                                                    540
 tggtggcaat tctatctcta tgattgatta cctcatctgg ccctggtttg aacggctgga
                                                                                                                    600
 agcaatgaag ttaaatgagt gtgtagacca cactccaaaa ctgaaactgt ggatggcagc
                                                                                                                    660
                                                                                                                   720
 catgaaggaa gatcccacag tctcagccct gcttactagt gagaaagact ggcaaggttt
                                                                                                                    780
 cctagagete tacttacaga acageeetga ggeetgtgae tatgggetet gaagggggea
 840
                                                                                                                    848
                                    大学的现在分词 医克克斯氏试验检尿病
 aactcgag
                                       医格尔氏性乳腺 医电压管管管外结膜 戴 化原体
```

· 要用, 自己未完全的复数形式 144

Professor & Colorada Cara

and the contract of the second of the

<210> 161

<211> 432

<212> DNA

<213> homo sapien .

		·			-	
	<400> 161		the state of the state of		** *	•
	gaatteggea egagggeaga	ccaagatcct	ggaggaggac	ctggaacaga	tcaagctgtc	60
	cttgagagag cgaggccggg					120
	ggaagggaag ggcccaagta					180
	gcgggataag gagaaggagg					240
•	caaagaccag ctggagcagc					300
	cctcctgtcc cagcgagagc					360
	ggaacaaggg gagctgaagg					420
	cctageccag ag	agaagaaaa				432
	A A A A A A A A A A A A A A A A A A A			÷.		
	<210> 162					
	<211> 433					
	<212> DNA	•	化氯氯化铁铁铁石		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	<213> homo sapie				1470-12	
	<213> nono sapie		• • • • • •			·
	-400- 162				•	
•	<400> 162	taaattactc	etacteccat	ctccaactcc	tootacetee	60
	gattcggcac gagccggagc					120
	ttcaagctgg gagagggctc					180
	gccgccatga gcaaacggaa					240
	ctcacagaac tcgcaaactt					•
	tacagaaaag cagcatctgt					300
	gctaagaaat tgcctggagt	aggaacaaaa	accgccgaaa	agactgatga	grecetagea	360
	actggaaaat tacgtaaact	ggaaaagatt	eggeaggacg	acacgageee	acceaccaac	420
	ttcctgactc gag		and the second			. 433
		***			-d v	.
	<210> 163	•	an musika ing s			
	<211> 432		•			
	<212> DNA			•		
•	<213> homo sapie	÷11		·		
	-400- 163				•	
	<400> 163	ccaaccacct	ascaracarc	acatacataa	actecaagag	60
	gaatteggea ceagatgagg	ccttcacgagge	gacggacage	accaccctcc	tgcaccctga	120
	cacctacagt gagtgtgaga	cececacyga	caaggacacc	accataccet	craagracet	180
	gctgcaacct gaaggggacg ggacgccatg gaggagcccg	accatege	cetectecte	ctccacaca	ggcct caccc	240
	ggacgccatg gaggagcccg	contration	concasaces	cactttgagg	actacootoa	300
	ccatggccag tctgtcatca	cggcgaccgg	gggcgaggag	caccecage	actacagtaa	360
	aggcagtgag gcggagctgt	ctccayagac	cccacycaac	acceacead	toocaacota	420
	ccccgctttc ctcacgccca	gcccyacaaa	geggeeeeee	agcaagaagg		432
	cctgcaccag tc	P 32 34 44				232
	<210> 164				to the contrated	
	<210> 164 <211> 395					
	<211> 395		a a mark transition of the second			
	<212> DNA					
	<213> homo sapie	en :	n north de la sea de la companya de La companya de la co		or we will be to for	
						,
	<400> 164		to see the second of the secon	-		
	gacacttgaa tcatgggtga	cgttaaaaat	tttctgtatg	cctggtgtgg	caaaaggaag	60
	atgaccccat cctatgaaat					120
	gaggttcagg tggaaggtta					180
	gcacaaagca atgctgccag					240
	agtgaagaag ttccagcttt					300
	actacagcaa atgctgaagg					360
	ggttcctgaa aaaaaaaaaa					395
			-		• . •	
				•		

5-5 7 ·

. . . .

435 11

400

1

- 1

18:00

1 2 6 7

150

<210> 165

```
<211> 503
              <212> DNA
              <213> homo sapien
              <400> 165
    gaatteggea ceaggaaege teggtgagag geggaggage ggtaaetaee eeggttgege
                                                                                                                         60
    acagetegge geteetteee geteeteae acaceggeet cageeggeae eggeagtaga
                                                                                                                        120
    agatggtgaa agaaacaact tactacgatg ttttgggggt caaacccaat gctactcagg
                                                                                                                        180
    aagaattgaa aaaggettat aggaaactgg eettgaagta eeateetgat aagaaceeaa
                                                                                                                        240
    atgaaggaga gaagtttaaa cagatttctc aagcttacga agttctctct gatgcaaaga
                                                                                                                        300
    aaagggaatt atatgacaaa ggaggagaac aggcaattaa agagggtgga gcaggtggcg
                                                                                                                        360
    gttttggctc ccccatggac atctttgata tgttttttgg aggaggagga aggatgcaga
                                                                                                                        420
   gagaaaggag aggtaaaaat gttgtacatc agctctcagt aaccctagaa gacttatata
                                                                                                                        480
    atggtgcaac aagaaaactg gcthoonggo bethat our period of the consequent
                                                                                                                        503
              <210> 166
              <211> 893
              <212> DNA
             <213> homo sapien
                                                                                    九二级 机工工工厂
             <400> 166
  gaatteggea egagaggaac ttetettgae gagaagagag accaaggagg ceaageaggg
                                                                                                                        -60
   gctgggccag aggtgccaac atggggaaac tgaggctcgg ctcggaaggg tgagagtgag
                                                                                                                        120
    actacatete aaaaaaaaa aaaaaaaaa aaaagaaaga aaagaaaaga aaaaagaaag
                                                                                                                       180
   aaeggaagta gttgtaggta gtggtatggt ggtatgagte tgttttetgt tacttataac
                                                                                                                       240
                                                                                                                       300
   aacaacaaca acaaaaaacg etgaaactgg gtaatttata aagaaaagga aaaaaagcag
                                                                                                                       360
   aaaaaaatca ggaagaagag aaaggaaaag aagacaaata aatgaaattt atgtattaca
   gttctgaagg ctgagacatc ccaggtcaag ggtccacact tggcgagggc tttcttgctg
                                                                                                                       420
                                                                                                                       480
   gtggagactc tttgtggagt cctgggacag tgcagaagga tcacgcctcc ctaccgctcc
   aageccagee cteagecatg geatgeccee tggatcagge cattggeete etegtggeca
                                                                                                                       540
                                                                                                                       600
   tettecacaa gtaeteegge agggagggtg acaagcacae eetgagcaag aaggagetga
   aggagetgat ccagaaggag etcaccattg getegaaget geaggatget gaaattgeaa
                                                                                                                       660
                                                                                                                       720
   ggctgatgga agacttggac cggaacaagg accaggaggt gaacttccag gagtatgtca
                                                                                                                       780
   ccttcctggg ggccttggct ttgatctaca atgaagccct caagggctga aaataaatag
                                                                                                                       840
   ggaagatgga gacaccctct gggggtcctc tctgagtcaa atccagtggt gggtaattgt
                                                                                                                       893
   <210> 167
             <211> 549
    <212> DNA
                                ,是是这种的表现,这种特殊的人就是这种的情况,但是是被各种的特殊的。
    # 1 - <213> homo sapien - was again to be a larger to the
    -60
   gaatteggea, egageeeaga, teeegaggte egacagegee eggeeeagat ecceaegeet
   gccaggagca agccgagagc cagccggccg gcgcactccg actccgagca gtctctgtcc
                                                                                                                       120
                                                                                                                       180
  ttegaceega geeeegegee ettteeggga eeeetgeeee gegggeageg etgeeaacet:
                                                                                                                       240 -
  geoggecatg gagacecegt eccageggeg egecaeeege ageggggege aggecagete
                                                                                                                       300
   cacteegetg tegeceacec.geateaceeg.getgeaggag.aaggaggace tgeaggaget.
                                                                                                                       360°
   caatgatcgc ttggcggtct acategaccg tgtgcgctcg ctggaaacgg agaacgcagg
                                                                                                                       420
   gctgcgcctt cgcatcaccg agtctgaaga ggtggtcagc cgcgaggtgt ccggcatcaa
                                                                                                                       480
  ggccgcctae gaggccgagc tcggggatgc ccgcaagacc cttgactcag tagccaagga
gcgcgcccgc ctgcagctgg agctgagcaa agtgcgtgaa gagtttaagg agctgaaagc
                                                                                                                       540
  gcgcaatac product of the control of 
                                                                                                                       549
```

838

. .

.

υž.

Q & 13

 $\cdot \cdot \cdot \cdot$

<210> 168 <211> 547 <212> DNA <213> homo sapien <400> 168 gaatteggea egagatggeg geaggggteg aageggegge ggaggtggeg gegaeggaga 60 tcaaaatgga ggaagagagc ggcgcgcccg gcgtgccgag cggcaacggg gctccgggcc 120 ctaagggtga aggagaacga cctgctcaga atgagaagag gaaggagaaa aacataaaaa 180 gaggaggcaa tegetttgag ecatatgeca atecaactaa aagatacaga geetteatta 240 caaacatacc ttttgatgtg aaatggcagt cacttaaaga cctggttaaa gaaaaagtfg 300 gtgaggtaac atacgtggag ctcttaatgg acgctgaagg aaagtcaagg ggatgtgctg 360 ttgttgaatt caagatggaa gagagcatga aaaaagctgc ggaagtccta aacaagcata 420 gtctgagcgg aagaccactg aaagtcaaag aagatcctga tggtgaacat gccaggagag 480 caatgcaaaa ggctggaaga cttggaagca cagtatttgt agcaaatctg gattataaag 540 ttggctg 547 <210> 169 <211> 547 <212> DNA <213> homo sapien gaatteggea ceaggagtee gactgtgete getgeteage geegeaceeg gaagatgagg ctegecgtgg gagecetget ggtetgegee gteetgggge tgtgtetgge tgteectgat 120 aaaactgtga gatggtgtgc agtgtcggag catgaggcca ctaagtgcca gagtttccgc 180 gaccatatga aaagcgtcat tccatccgat ggtcccagtg ttgcttgtgt gaagaaagcc 240 tectacetty attgeateag gecattgeg geaaacgaag eggatgetgt gacactggat 300 gcaggtttgg tgtatgatgc ttacctggct cceaataacc tgaagcctgt ggtggcagag 360 ttctatgggt caaaagagga tccacagact ttctattatg ctgttgctgt ggtgaagaag 420 gatagtggct tccagatgaa ccagcttcga ggcaagaagt cctgccacac gggtctaggc 480 **540**. 547· aaacctc <210> 170 <211> 838 <212> DNA <213> homo sapien <400> 170. gaatteggea ceagaggage teggeetgeg etgegeeacg atgteegggg agteageeag 60 gagettgggg aagggaageg egeeceeggg geeggteeeg gagggetega teegeateta 120 cagcatgagg ttctgcccgt ttgctgagag gacgcgtcta gtcctgaagg ccaagggaat 180 caggcatgaa gtcatcaata tcaacctgaa aaataagcct gagtggttct ttaagaaaaa 240 300 tecettiggt etggigecag tietggaaaa eagteagggi eageigatet aegagietge 360 catcacctgt gagtacctgg atgaagcata cccagggaag aagctgttgc cggatgaccc 420 ctatgagaaa gettgecaga agatgatett agagttgttt tetaaggtge cateettggt 480 aggaagettt attagaagee aaaataaaga agaetatgat ggeetaaaag aagaattteg 540 taaagaattt accaagctag aggaggttct gactaataag aagacgacct tctttggtgg 600·~ caattctatc tctatgattg attacctcat ctggccctgg tttgaacggc tggaagcaat gaagttaaat gagtgtgtag accacactcc aaaactgaaa ctgtggatgg cagccatgaa 660 720 ggaagatece acagteteag ecetgettae tagtgagaaa gaetggeaag gttteetaga 780 getetaetta cagaacagee etgaggeetg tgactatggg etetgaaggg ggeaggagte

1 5 5

ONE

不遵言

40000

特拉斯

0,34

44

្សាស្ថិត

特特化

, · · ·

- 50 **8**20 -- 00 s

17

 $\{Y_i\}_{i=1}^n$

.12:

118

<210> 171 <211> 547 <212> DNA <213> homo sapien <400> 171 gaatteggea ceagegggat ttgggtegea gttettgttt gtggattget gtgategtea **60**⁻ cttgacaatg cagatetteg tgaagactet gactggtaag accateacce tegaggttga 120 gcccagtgac accategaga atgtcaagge aaagatecaa gataaggaag gcatecetee 180 "tgaccagcag aggetgatet ttgetggaaa acagetggaa gatgggegea ecetgtetga 240 ctacaacate cagaaagagt ccaceetgea eetggtgete egteteagag gtgggatgea 300 aatcttcgtg aagacactca ctggcaagac catcaccctt gaggtcgage ccagtgacac 360 categagaac gteaaageaa agateeagga eaaggaagge attegteetg accageagag 420 gttgatettt geeggaaage agetggaaga tgggegeace etgtetgaet acaacateea 480. gaaagagtet accetgeace tggtgeteeg teteagaggt gggatgeaga tettegtgaa 540 gaccctg **建筑** (4.) (4) 547 Carried State of the Contract <210> 172 一次程 🛪 <211> 608 <212> DNA <213> homo sapien 医三氏环状 医三氏征 医医皮膜囊囊 原语 医克克氏病 化电影电影 <400> 172 gaatteggea ceagagaett etecetetga ggeetgegea eeceteetea teageetgte 60 caccctcate tacaatggtg ccctgccatg tcagtgcaac cctcaaggtt cactgagtte 120 tgagtgcaac cctcatggtg gtcagtgcct gtgcaagcct ggagtggttg:ggcgccgctg 180 tgacctctgt gcccctggct actatggctt tggccccaca ggctgtcaag gcgcttgcct 240 gggctgccgt gatcacacag ggggtgagca ctgtgaaagg tgcattgctg gtttccacgg 300 360 ggacccaegg ctgccatatg ggggccagtg ccggccctgt-ccctgtcctg aaggccctgg gagccaacgg cactttgcta cttcttgcca ccaggatgaa tattcccagc agattgtgtg 420 480 ccactgccgg gcaggctata cggggctgcg atgtgaaget tgtgcccctg ggcactttgg 540 ggacccatca aggccaggtg gccggtgcca actgtgtgag tgcagtggga acattgaccc 600 aatggateet gatgeetgtg acceecacae_ggggeaatge etgegetgtt tacaccacae 608 agagggtc <210> 173 <211> 543 <212> DNA <213> homo sapien the state of the second months and the property of the second <400> 173 gaatteggea ceagagatea teegeeagea gggtetggee teetacgaet acgtgegeeg 60 cegecteacy getgaggace tyttegagge teggateate tetetegaga ectacaacet 120 geteeggag gecaceagga geeteegtga geetetegag geggagteeg eetggtgeta 180 240 cetetatige acgigeteeg tigetigetet etacetigee getteeagge agacaetgag 300 catctaccag geteteaaga aagggetget gagtgeegag gtggeeegee tgetgetgga ggcacaggca gccacaggct tcctgctgga cccggtgaag ggggaacggc tgactgtgga 360 420 tgaagetgtg eggaagggee tegtggggee egaactgeae gacegeetge teteggetga 480 gegggeggte aceggetace gtgaccecta caeegageag aceatetege tettecagge 540 catgaagaag gaactgatcc ctactgagga ggccctgcgg ctgtggatgc ccagctggcc · **543** acc

<210> 174 <211> 548

<212> DNA

<213> homo sapien

<400> 174 gaattcggca cgagaaatgg cggcaggggt cgaagcggcg gcggaggtgg cggcgacgga 60 gatcaaaatg gaggaagaga gcggcgcgcc cggcgtgccg agcggcaacg gggctccggg 120 ccctaagggt gaaggagaac gacctgctca gaatgagaag aggaaggaga aaaacataaa 180 aagaggaggc aatcgctttg agccatatgc caatccaact aaaagataca gagccttcat 240 tacaaacata ccttttgatg tgaaatggca gtcacttaaa gacctggtta aagaaaaagt 300 tggtgaggta acatacgtgg agctcttaat ggacgctgaa ggaaagtcaa ggggatgtgc 360 tgttgttgaa ttcaagatgg aagagagcat gaaaaaagct gcggaagtcc taaacaagca 420 tagtctgage ggaagaccae tgaaagtcaa agaagateet gatggtgaac atgecaggag 480 agcaatgcaa aaggtgatgg ctacgactgg tgggatgggt atgggaccag gtggccagg 540 aatgatta assembly 548

<210> 175

. .

7 - 3

<211> 604

<212> DNA

<213> homo sapien

化物品类型物品 医乳体性 医静脉性 第二

<400> 175

gaatteggea ceagagg	jacc tccaggacat	gttcatcgtc	cataccatcg	aggagattga	60
gggcctgatc tcagccc	catg accagttcaa	gtccaccctg	ccggacgccg	atagggagcg	120
cgaggccatc ctggcca	itcc acaaggaggc	ccagaggatc	gctgagagca	accacatcaa	180
gctgtcgggc agcaaco	cct acaccaccgt	caccccgcaa	atcatcaact	ccaagtggga	240
gaaggtgcag cagctgg	tgc caaaacggga	ccatgccctc	ctggaggagc	agagcaagca	300
gcagtccaac gagcacc	tgc gccgccagtt	cgccagccag	gccaatgttg	tggggccctg	360
gatccagacc aagatgo					420
ggaccagctg agccacc	tga agcagtatga	acgcagcatc	gtggactaca	agcccaacct	480
ggacctgctg gagcago	agc accagettat	ccaggaggcc	ctcatcttcg	acaacaagca	540
caccaactat accatgg				-	600
ccgg					604

<210> 176

<211> 486

<212> DNA

<213> homo sapien

<400> 176

gaattcggca	ccagccaagc	tcactattga	atccacgccg	ttcaatgtcg	cagaggggaa	60
ggaggttctt	ctactcgccc	acaacctgcc	ccagaatcgt	attggttaca	gctggtacaa	120
aggcgaaaga	gtggatggca	acagtctaat	tgtaggatat	gtaataggaa	ctcaacaagc	180
taccccaggg	cccgcataca	gtggtcgaga	gacaatatac	cccaatgcat	ccctgctgat	240
ccagaacgtc	acccagaatg	acacaggatt	ctatacccta	caagtcataa	agtcagatct	300
tgtgaatgaa	gaagcaaccg	gacagttcca	tgtatacccg	gagctgccca	agccctccat	360
ccccagcaac	aactccaacc	ccgtggagga	caaggatgct	gtggccttca	cctgtgaacc	. 420
tgaggttcag	aacacaacct	acctgtggtg	ggtaaatggt	cagageetee	cggtcagtcc	480
caaggc	377 P - 27	California de la calendaria de la calend	and the second of the second		,	486

<211> 387

<212> DNA

<213> homo sapien

三分 化二氯化甲酚甲酚苯甲酚酚

<400> 177

gaatteggea ceagggacag cagaceagae agteacagea geettgacaa aacgtteetg

					-	7 →
	gaactcaagc tcttctccac	agaggaggac	agagcagaca	gcagagacca	tggagtctcc	120
	ctcggccct cccacagat	· .				. 180
	tctaaccttc tggaacccgc	•	,	· · ·		240
	tgtcgcagag gggaaggagg	• .				300
	ctacagetgg tacaaaggtg					360
	aggaactcaa caagctaccc					387
		333			•	307
	<210> 178				•	
	<211> 440					_
_	<212> DNA					
-	<213> homo sapi		•	13.57 公務。		
	<400> 178	·	•			
	gaatteggea egaggagaag	cagaaaaaca	aggaatttag	ccagacttta	gaaaatgaga	60
	aaaatacctt actgagtcag				•	120
	aagtaaccaa aatgaacctg		T 14. 7.		• `	180
	aactaaagga gacagcagaa	•				240
	tagcagaact taatggaagc		•		* . <i>t</i>	300
	aaaatgagct attggaatct					360
	aagaaaagca gcagttagtc			,		420
•	atttggagaa aatacaaggt				~3 <u>3</u> 3	440
	,	,	• .		*	
	<210> 179 //	a 1.55 + 34 T		-		
	-211- 443		•	,:*;	ا مانيان درون درون درون درون درون درون درون درو	
	<211> 443 <212> DNA	A Company of the			AND AND A	
	<213> homo sapie					
	They began that I have not the	War Start		· 特別記述 如整	en de la companya de La companya de la co	
	<400> 179			· · · · · · · · · · · · · · · · · · ·	an Indian	
	gaattcggca ccagcgggg	gctacggcgg	cggctacggc	ggcgtcctga	ccgcgtccga	6 0
	cgggctgctg gcgggcaacg	agaagctaac	catgcagaac	ctcaacgacc	gcctggcetc	120
	ctacctggac aaggtgcgcg	ccctggaggc	ggccaacggc	gagetagagg	tgaagatccg	180
_	cgactggtac cagaagcagg	ggcctgggcc	etecegegac-	tacagecact	actacacgac	240
	catccaggac ctgcgggaca	agattcttgg	tgccaccatt	gagaactcca	ggattgtcct	300
	gcagatcgac aacgcccgtc	tggctgcaga	tgacttccga	accaagtttg	agacggaaca	360
	ggctctgcgc atgagcgtgg	aggccgacat	caacggcctg	cgcagggtgc	tggatgagct	420
٠	gaccctggcc aggaccgacc	tgg		\$* g		443
	ang the care seems to be	• :			•	•
	<210> 180		en e	y tak at a sa		•
	.717. P.173			. , .		•
	<212> UNA <213> homo sapie	n' a la l		4.84		
	1. 78 s					
	<400> 180					
	gaattcggca cgaggttatg					. 60
	caaacaacca gaggattaag					120
	ccaagtcggt agtccttatg					180
	agtactcctt agagccagtt					240
	tcttgaagga ctgtgtaggc	ccagaagtgg	agaaagcctg	tgccaaccca	gctgctgggt	300
•	ctgtcatcct gctggagaac				ggaaaagatg	360
	cttctgggaa caaggttaaa	gccgagccag	ccaaaataga (agc	ي مدم الله الله الله الله الله الله الله الله	403
	• • • • •	•		and the second		
	<210> 181			ager en le	- 13	
	~211× AQ2			•		•

<211> 493 <212> DNA

<213> homo sapien

60

120

180

240

300

360

420

480

493°

Single-Nielski

<400> 181 gaatteggea ceageagagg tetecagage ettetete etgtgeaaaa tggeaactet taaggaaaaa ctcattgcac cagttgcgga agaagaggca acagttccaa acaataagat cactgtagtg ggtgttggac aagttggtat ggcgtgtgct atcagcattc tgggaaagtc tetggctgat gaacttgctc ttgtggatgt tttggaagat aagcttaaag gagaaatgat ggatctgcag catgggagct tatttcttca gacacctaaa attgtggcag ataaagatta ttctgtgacc gccaattcta agattgtagt ggtaactgca ggagtccgtc agcaagaagg ggagagtcgg ctcaatctgg tgcagagaaa tgttaatgtc ttcaaattca ttattcctca gatcgtcaag tacagtcctg attgcatcat aattgtggtt tccaacccag tggacattct tacgtatgtt acc <210> 182 <211> 209 <212> PRT <213> homo sapien <400> 182 Ala Phe Ser Ser Asn Pro Lys Val Gln Val Glu Ala Ile Glu Gly Gly **10** Ala Leu Gln Lys Leu Leu Val Ile Leu Ala Thr Glu Gln Pro Leu Thr Ala Lys Lys Val Leu Phe Ala Leu Cys Ser Leu Leu Arg His Phe 35 Pro Tyr Ala Gln Arg Gln Phe Leu Lys Leu Gly Gly Leu Gln Val Leu 60 55 Arg Thr Leu Val Glu Glu Lys Gly Thr Glu Val Leu Ala Val Arg Val 75 Val Thr Leu Leu Tyr Asp Leu Val Thr Glu Lys Met Phe Ala Glu Glu 90 1 - January 24 - 95 - 1 - 1 - 1 85 Glu Ala Glu Leu Thr Gln Glu Met Ser Pro Glu Lys Leu Gln Gln Tyr 105 - 110 · Arg Gln Val His Leu Leu Pro Gly Leu Trp Glu Gln Gly Trp Cys Glu 115 Ile Thr Ala His Leu Leu Ala Leu Pro Glu His Asp Ala Arg Glu Lys 130 135 140 × 3 Val Leu Gln Thr Leu Gly Val Leu Leu Thr Thr Cys Arg Asp Arg Tyr 145 -150 155 Arg Gln Asp Pro Gln Leu Gly Arg Thr Leu Ala Ser Leu Gln Ala Glu 175 170 165 Tyr Gln Val Leu Ala Ser Leu Glu Leu Gln Asp Gly Glu Asp Glu Gly 180 185. 190 Tyr Phe Gln Glu Leu Leu Gly Ser Val Asn Ser Leu Leu Lys Glu Leu Arg <210> 183 <211> 255 <212> PRT <213> homo sapien <400> 183

Met Ala Ala Gly Val Glu Ala Ala Ala Glu Val Ala Ala Thr Glu Pro

10

15

									_						
Lys	Met	Glu	Glu	G1u	Ser	Gly	Ala.	_	Cys	Val	Pro	Ser	Gly	Asn	Gly
			20		÷			25					30		
λla	Dro	Glv	Pro	Lvs	Glv	Glu	Glu	Ara	Pro	Thr	Gln	Asn	Glu	Lys	Arg
ALG	FIU	_		11 0	- 4		40	3			\$ 'S.	45.			
	× -	35				_ :	40						-	<u></u>	0
Lys	Glu	Lys	Asn	Ile	Lys	Arg	GIA	GIA	Asn	arg	Pne	GIU	PIO	ıyı	Ser
	50					55					60	•	~		
Acn	Dro	Thr	LVS	Ara	Tvr	Arg	Ala	Phe	Ile	Thr	Asn	Ile	Pro	Phe	Asp
	110		J	3	70	- J				75		₹*			80
65				_	-	_		•	3		G3 -5	T	77-3	<u></u>	
Val	Lys	Trp	Gln	Ser	Leu	Lys	Asp	Leu	Val	rys	GIU	rys	Val	GTA	Giu
				85		•			90		-	75		95 .	
· Wal	Thr	Tur	Val	Glu	Leu	Leu	Met	Asp	Ala	Glu	Gly	Lys	Ser	Arg	Gly
V 41	1111	-1-	100					105			•	_	110		
				~7.	Db -	* -	24.54		01	C	Mot	Taea	·	λla	712
Cys	Ala	Val	Val	GIU	hue	Lys		GIU	GIU	Ser	Mec		rya	WIG	ALG
•		115	. :		•		120	•				125		•	~
Glu	Val	Leu	Asn	Lys	His	Ser	Lėu	Ser	Gly.	Arg	Pro	Leu	Lys	Val	Lys
		$_{\cdot}:::$.∠*¥			135	* *			".	140	in a			:
673	3.00	Dwo			GI.		λla	Ara	Ara	Ala	Met	Gln	Lvs	Ala	Gly
		PLO	wah			111.5	714	71. 3		155	••••	-	-3,-		160
145		<i>.</i> .			150		• •				_ :			3	
Arg	Leu	Gly	Ser	Thr	Val	Phe	Val	Ala	Asn	Leu	Asp	ıyr	rys		Gly.
;		•		165			,		170			•	•	175	
Tro	Tvs	LVS	Leu	Lvs	Glu	Va1	Phe	Ser	Met	Ala	Gly	Val	Val	Val	Arg
	 ,	_	180					185			. –	. 1.4%	190	•	
• •						Tares	Acn		Tare	Ser	Ara	Glv	TTA	G1Ý	Ile
AT à	Asp	_		GIU	wsh	nys		GTA	пуз	JCL				071	
		195					200					205	_		5 1
Val	Thr	Phe	Glu	Gln	Ser	Ile	Glu	Ala	Val	Gln	Ala	Ile	ser	Met	Phe
•	210	: .				215			- /.		220		•		
Aen			Leu	Leu	Phe	Asp	Arg	Pro	Met	His	Val	Lys	Met	Asp	Glu
	_	~			230	·		•		235		- .			240
225			0			3.5-	Dha	Dho	Dro		G1	Ara	uic	Ser	•
Arg	Ala	Leu	Pro			Asp	rne	FIIE		ETO	Gru	y.	1113		
				245	.,	-			250					255	
					5		•								

<210> 184

<211> 188

<212> PRT

<213> Homo sapien

<400> 184

130

Leu Ser Gly Ser Cys Ile Arg Arg Glu Gln Thr Pro Glu Lys Glu Lys

1 5 10 15

Gln Val Val Leu Phe Glu Glu Ala Ser Trp Thr Cys Thr Pro Ala Cys
20 25 30

Gly Asp Glu Pro Arg Thr Val Ile Leu Leu Ser Ser Met Leu Ala Asp
35 40 45

His Arg Leu Lys Leu Glu Asp Tyr Lys Asp Arg Leu Lys Ser Gly Glu
50 55 60

His Leu Asn Pro Asp Gln Leu Glu Ala Val Glu Lys Tyr Glu Glu Val
65 70 75 80

Leu His Asn Leu Glu Phe Ala Lys Glu Leu Gln Lys Thr Phe Ser Gly
85 90 95

Leu Ser Leu Asp Leu Leu Lys Ala Gln Lys Lys Ala Gln Arg Arg Glu
100 105 110

His Met Leu Lys Leu Glu Ala Glu Lys Lys Lys Leu Arg Thr Ile Leu
115 120 125

Gln Val Gln Tyr Val Leu Gln Asn Leu Thr Gln Glu His Val Gln Lys

Asp Phe Lys Gly Gly Leu Asn Gly Ala Val Tyr Leu Pro Ser Lys Glu 150 145 Leu Asp Tyr Leu Ile Lys Phe Ser Lys Leu Thr Cys Pro Glu Arg Asn 165 170 175 Glu Ser Leu Arg Gln Thr Leu Glu Gly Ser Thr Val 180 185 <210> 185

<211> 746 <212> PRT

<213> Homo sapien

<400> 185 Asp Lys His Leu Lys Asp Leu Leu Ser Lys Leu Leu Asn Ser Gly Tyr Phe Glu Ser Ile Pro Val Pro Lys Asn Ala Lys Glu Lys Glu Val Pro Leu Glu Glu Met Leu Ile Gln Ser Glu Lys Lys Thr Gln Leu Ser Lys Thr Glu Ser Val Lys Glu Ser Glu Ser Leu Met Glu Phe Ala Gln 50 Pro Glu Ile Gln Pro Gln Glu Phe Leu Asn Arg Arg Tyr Met Thr Glu 75 Val Asp Tyr Ser Asn Lys Gln Gly Glu Glu Gln Pro Trp Glu Ala Asp Tyr Ala Arg Lys Pro Asn Leu Pro Lys Arg Trp Asp Met Leu Thr Glu Pro Asp Gly Gln Glu Lys Lys Gln Glu Ser Phe Lys Ser Trp Glu Ala 120 **. 125** Ser Gly Lys His Gln Glu Val Ser Lys Pro Ala Val Ser Leu Glu Gln 130 135 Arg Lys Gln Asp Thr Ser Lys Leu Arg Ser Thr Leu Pro Glu Glu Gln 155 150 Lys Lys Gln Glu Ile Ser Lys Ser Lys Pro Ser Pro Ser Gln Trp Lys 175 165 Gln Asp Thr Pro Lys Ser Lys Ala Gly Tyr Val Gln Glu Glu Gln Lys 190 185 180 Lys Gln Glu Thr Pro Lys Leu Trp Pro Val Gln Leu Gln Lys Glu Gln Asp Pro Lys Gln Thr Pro Lys Ser Trp Thr Pro Ser Met Gln Ser 210 220 Glu Gln Asn Thr Thr Lys Ser Trp Thr Thr Pro Met Cys Glu Glu Gln 235 230 Asp Ser Lys Gln Pro Glu Thr Pro Lys Ser Trp Glu Asn Asn Val Glu Ser Gln Lys His Ser Leu Thr Ser Gln Ser Gln Ile Ser Pro Lys Ser 270 Trp Gly Val Ala Thr Ala Ser Leu Ile Pro Asn Asp Gln Leu Leu Pro 285 275 280 Arg Lys Leu Asn Thr Glu Pro Lys Asp Val Pro Lys Pro Val His Gln Pro Val Gly Ser Ser Ser Thr Leu Pro Lys Asp Pro Val Leu Arg Lys 305 315 Glu Lys Leu Gln Asp Leu Met Thr Gln Ile Gln Gly Thr Cys Asn Phe 335 330

Met Gln Glu Ser Val Leu Asp Phe Asp Lys Pro Ser Ser Ala Ile Pro 340 Thr Ser Gln Pro Pro Ser Ala Thr Pro Gly Ser Pro Val Ala Ser Lys 360 355 Glu Gln Asn Leu Ser Ser Gln Ser Asp Phe Leu Gln Glu Pro Leu Gln 370 375 Val Phe Asn Val Asn Ala Pro Leu Pro Pro Arg Lys Glu Gln Glu Ile 390 395 385 Lys Glu Ser Pro Tyr Ser Pro Gly Tyr Asn Gln Ser Phe Thr Thr Ala Ser Thr Gln Thr Pro Pro Gln Cys Gln Leu Pro Ser Ile His Val Glu 420 Gln Thr Val His Ser Gln Glu Thr Ala Ala Asn Tyr His Pro Asp Gly and 4-435 440 Thr Ile Gln Val Ser Asn Gly Ser Leu Ala Phe Tyr Pro Ala Gln Thr 460 455 Asn Val Phe Pro Arg Pro Thr Gln Pro Phe Val Asn Ser Arg Gly Ser 465 470 475 Val Arg Gly Cys Thr Arg Gly Gly Arg Leu Ile Thr Asn Ser Tyr Arg Ser Pro Gly Gly Tyr Lys Gly Phe Asp Thr Tyr Arg Gly Leu Pro Ser 500 Ile Ser Asn Gly Asn Tyr Ser Gln Leu Gln Phe Gln Ala Arg Glu Tyr Ser Gly Ala Pro Tyr Ser Gln Arg Asp Asn Phe Gln Gln Cys Tyr Lys Arg Gly Gly Thr Ser Gly Gly Pro Arg Ala Asn Ser Arg Ala Gly Trp 545 **355** 550 Ser Asp Ser Ser Gln Val Ser Ser Pro Glu Arg Asp Asn Glu Thr Phe **570** Asn Ser Gly Asp Ser Gly Gln Gly Asp Ser Arg Ser Met Thr Pro Val 580 585 Asp Val Pro Val Thr Asn Pro Ala Ala Thr Ile Leu Pro Val His Val 600 Tyr Pro Leu Pro Gln Gln Met Arg Val Ala Phe Ser Ala Ala Arg Thr Ser Asn Leu Ala Pro Gly Thr Leu Asp Gln Pro Ile Val Phe Asp Leu 635 630 Leu Leu Asn Asn Leu Gly Glu Thr Phe Asp Leu Gln Leu Gly Arg Phe 650 Asn Cys Pro Val Asn Gly Thr Tyr Val Phe Ile Phe His Met Leu Lys 660 665 670 Leu Ala Val Asn Val Pro Leu Tyr Val Asn Leu Met Lys Asn Glu Glu 447 675 Francisco Jan. 680 **685** Val Leu Val Ser Ala Tyr Ala Asn Asp Gly Ala Pro Asp His Glu Thr 700 Ala Ser Asn His Ala Ile Leu Gln Leu Phe Gln Gly Asp Gln Ile Trp 705 710 720 715 Leu Arg Leu His Arg Gly Ala Ile Tyr Gly Ser Ser Trp Lys Tyr Ser 725 730 NY THE DE Thr Phe Ser Gly Tyr Leu Leu Tyr Gln Asp 740 745

<210> 186 <211> 705 <212> PRT <213> Homo sapien

<400> 186 Ala Leu Leu Asn Val Arg Gln Pro Pro Ser Thr Thr Thr Phe Val Leu 1 Asn Gln Ile Asn His Leu Pro Pro Leu Gly Ser Thr Ile Val Met Thr 25 20 Lys Thr Pro Pro Val Thr Thr Asn Arg Gln Thr Ile Thr Leu Thr Lys 40 Phe Ile Gln Thr Thr Ala Ser Thr Arg Pro Ser Val Ser Ala Pro Thr **50**. Val Arg Asn Ala Met Thr Ser Ala Pro Ser Lys Asp Gln Val Gln Leu 75 Lys Asp Leu Leu Lys Asn Asn Ser Leu Asn Glu Leu Met Lys Leu Lys Pro Pro Ala Asn Ile Ala Gln Pro Val Ala Thr Ala Ala Thr Asp Val 105-100 Ser Asn Gly Thr Val Lys Lys Glu Ser Ser Asn Lys Glu Gly Ala Arg 120 Met Trp Ile Asn Asp Met Lys Met Arg Ser Phe Ser Pro Thr Met Lys 130 Val Pro Val Val Lys Glu Asp Asp Glu Pro Glu Glu Glu Asp Glu Glu 150 155 145 Glu Met Gly His Ala Glu Thr Tyr Ala Glu Tyr Met Pro Ile Lys Leu 170 165 Lys Ile Gly Leu Arg His Pro Asp Ala Val Val Glu Thr Ser Ser Leu 185 الهولا بعراني الراجي **190**. و الراجي 180 Ser Ser Val Thr Pro Pro Asp Val Trp Tyr Lys Thr Ser Ile Ser Glu 200 Glu Thr Ile Asp Asn Gly Trp Leu Ser Ala Leu Gln Leu Glu Ala Ile A 215 210 Thr Tyr Ala Ala Gln Gln His Glu Thr Phe Leu Pro Asn Gly Asp Arg 225 230 Ala Gly Phe Leu Ile Gly Asp Gly Ala Gly Val Gly Lys Gly Arg Thr 245 250 255 Ile Ala Gly Ile Ile Tyr Glu Asn Tyr Leu Leu Ser Arg Lys Arg Ala 270 £. =. 265 260 Leu Trp Phe Ser Val Ser Asn Asp Leu Lys Tyr Asp Ala Glu Arg Asp 280 285 275 Leu Arg Asp Ile Gly Ala Lys Asn Ile Leu Val His Ser Leu Asn Lys 295 300 Phe Lys Tyr Gly Lys Ile Ser Ser Lys His Asn Gly Ser Val Lys Lys 315 310 305 Gly Val Ile Phe Ala Thr Tyr Ser Ser Leu Ile Gly Glu Ser Gln Ser 325 330 Gly Gly Lys Tyr Lys Thr Arg Leu Lys Gln Leu Leu His Trp Cys Gly 340 345 350 Asp Asp Phe Asp Gly Val Ile Val Phe Asp Glu Cys His Lys Ala Lys 360 **355** -365 Asn Leu Cys Pro Val Gly Ser Ser Lys Pro Thr Lys Thr Gly Leu Ala 375 380 370 Val Leu Glu Leu Gln Asn Lys Leu Pro Lys Ala Arg Val Val Tyr Ala 395 390 385 Ser Ala Thr Gly Ala Ser Glu Pro Arg Asn Met Ala Tyr Met Asn Arg

410 405 Leu Gly Ile Trp Gly Glu Gly Thr Pro Phe Arg Glu Phe Ser Asp Phe 425 Ile Gln Ala Val Glu Arg Arg Gly Val Gly Ala Met Glu Ile Val Ala 435 Met Asp Met Lys Leu Arg Gly Met Tyr Ile Ala Arg Gln Leu Ser Phe 450 Thr Gly Val Thr Phe Lys Ile Glu Glu Val Leu Leu Ser Gln Ser Tyr Val Lys Met Tyr Asn Lys Ala Val Lys Leu Trp Val Ile Ala Arg Glu Arg Phe Gln Gln Ala Ala Asp Leu Ile Asp Ala Glu Gln Arg Met Lys **505** 500 Lys Ser Met Trp Gly Gln Phe Trp Ser Ala His Gln Arg Phe Phe Lys Tyr Leu Cys Ile Ala Ser Lys Val Lys Arg Val Val Gln Leu Ala Arg **530** Glu Glu Ile Lys Asn Gly Lys Cys Val Val Ile Gly Leu Gln Ser Thr 545 Gly Glu Ala Arg Thr Leu Glu Ala Leu Glu Glu Gly Gly Gly Glu Leu 575 565 **570** Asn Asp Phe Val Ser Thr Ala Lys Gly Val Leu Gln Ser Leu Ile Glu 585 Lys His Phe Pro Ala Pro Asp Arg Lys Lys Leu Tyr Ser Leu Leu Gly Ile Asp Leu Thr Ala Pro Ser Asn Asn Ser Ser Pro Arg Asp Ser Pro 610 615 Cys Lys Glu Asn Lys Ile Lys Lys Arg Lys Gly Glu Glu Ile Thr Arg Glu Ala Lys Lys Ala Arg Lys Val Gly Gly Leu Thr Gly Ser Ser Ser Asp Asp Ser Gly Ser Glu Ser Asp Ala Ser Asp Asn Glu Glu Ser Asp **665**. Tyr Glu Ser Ser Lys Asn Met Ser Ser Gly Asp Asp Asp Phe Asn 685 Pro Phe Leu Asp Glu Ser Asn Glu Asp Asp Glu Asn Asp Pro Trp Leu 700 690 695 Ile 705

<210> 187
<211> 595
<212> PRT
<213> Homo sapien

Glu Ser Pro Arg His Arg Gly Glu Gly Gly Glu Trp Gly Pro Gly

1 5 10 15

Val Pro Arg Glu Arg Arg Glu Ser Ala Gly Glu Trp Gly Ala Asp Thr

20 25 30

Pro Lys Glu Gly Gly Glu Ser Ala Gly Glu Trp Gly Ala Glu Val Pro

35 40 45

Arg Gly Arg Gly Glu Gly Ala Gly Glu Trp Gly Pro Asp Thr Pro Lys

50 55 60

Glu Arg Gly Gln Gly Val Arg Glu Trp Gly Pro Glu Ile Pro Gln Glu

65 70 75 His Gly Glu Ala Thr Arg Asp Trp Ala Leu Glu Ser Pro Arg Ala Leu 90 Gly Glu Asp Ala Arg Glu Leu Gly Ser Ser Pro His Asp Arg Gly Ala 105 Ser Pro Arg Asp Leu Ser Gly Glu Ser Pro Cys Thr Gln Arg Ser Gly 115 120 Leu Leu Pro Glu Arg Arg Gly Asp Ser Pro Trp Pro Pro Trp Pro Ser Pro Gln Glu Arg Asp Ala Gly Thr Arg Asp Arg Glu Glu Ser Pro Arg 145 150 Asp Trp Gly Gly Ala Glu Ser Pro Arg Gly Trp Glu Ala Gly Pro Arg 170 Glu Trp Gly Pro Ser Pro Ser Gly His Gly Asp Gly Pro Arg Arg Arg Pro Arg Lys Arg Gly Arg Lys Gly Arg Met Gly Arg Gln His Glu 195 200 Ala Ala Ala Thr Ala Ala Thr Ala Ala Thr Ala Thr Gly Gly Thr Ala 215 Glu Glu Ala Gly Ala Ser Ala Pro Glu Ser Gln Ala Gly Gly Pro 225 230 Arg Gly Arg Ala Arg Gly Pro Arg Gln Gln Gly Arg Arg Arg His Gly 245 Thr Gln Arg Arg Gly Pro Pro Gln Ala Arg Glu Glu Gly Pro Arg Asp Ala Thr Thr Ile Leu Gly Leu Gly Thr Pro Ser Gly Glu Gln Arg 275 280 Ala Asp Gln Ser Gln Ala Leu Pro Ala Leu Ala Gly Ala Ala Ala Ala **295**. His Ala His Ala Ile Pro Gly Ala Gly Pro Ala Ala Pro Val Gly 310 305 Gly Arg Gly Gly Gly Trp Arg Gly Gly Arg Gly Gly Ser Ala Gly Ala Gly Gly Gly Arg Gly Gly Arg Gly Arg Gly Arg Gly Gly Gly Arg Gly Gly Gly Ala Gly Arg Gly Gly Ala Ala Gly 355 360 Pro Arg Glu Gly Ala Ser Ser Pro Gly Ala Arg Arg Gly Glu Gln Arg 370 375 Arg Arg Gly Arg Gly Pro Pro Ala Ala Gly Ala Ala Gln Val Ser Ala 385 390 395 Arg Gly Arg Arg Ala Arg Gly Gln Arg Ala Gly Glu Glu Ala Gln Asp 410 Gly Leu Leu Pro Arg Gly Arg Asp Arg Leu Pro Leu Arg Pro Gly Asp 420 Ala Asn Gln Arg Ala Glu Arg Pro Gly Pro Pro Arg Gly Gly His Gly 4.5 (435) Pro Val Asn Ala Ser Ser Ala Pro Asp Thr Ser Pro Pro Arg His Pro 450 455 Arg Arg Trp Val Ser Gln Gln Arg Gln Arg Leu Trp Arg Gln Phe Arg 465 (19 1) (19 1) (19 470 27) (19 1) (19 1) (475 1) Val Gly Gly Phe Pro Pro Pro Pro Pro Ser Arg Pro Pro Ala Val 485 490 495 Leu Leu Pro Leu Leu Arg Leu Ala Cys Ala Gly Asp Pro Gly Ala Thr 500 505

Arg Pro Gly Pro Arg Pro Ala Arg Arg Pro Arg Gly Glu Leu Ile **525** 520 Pro Arg Arg Pro Asp Pro Ala Ala Pro Ser Glu Glu Gly Leu Arg Met 540 **535** 530 Glu Ser Ser Val Asp Asp Gly Ala Thr Ala Thr Thr Ala Asp Ala Ala 550 Ser Gly Glu Ala Pro Glu Ala Gly Pro Ser Pro Ser His Ser Pro Thr 570 565 Met Cys Gln Thr Gly Gly Pro Gly Pro Pro Pro Pro Gln Pro Pro Arg 580 **58**5 Trp Leu Pro **595** <210> 188 <211> 376 <212> PRT <213> Homo sapien 1 600亿元 化水水 经存货 医内侧性 医骨髓 医骨 医二氏管 <400> 188 Glu Met Arg Lys Phe Asp Val Pro Ser Met Glu Ser Thr Leu Asn Gln 10% - 15% - 15% - 15% - 15% - 15% Pro Ala Met Leu Glu Thr Leu Tyr Ser Asp Pro His Tyr Arg Ala His Ça **25** Cy Çiger (Egili (1997) Azibi **30**€ (Phe Pro Asn Pro Arg Pro Asp Thr Asn Lys Asp Val Tyr Lys Val Leu Pro Glu Ser Lys Lys Ala Pro Gly Ser Gly Ala Val Phe Glu Arg Asn Gly Pro His Ala Ser Ser Ser Gly Val Leu Pro Leu Gly Leu Gln Pro 70 70 80°-65 Ala Pro Gly Leu Ser Lys Ser Leu Ser Ser Gln Val Trp Gln Pro Ser Pro Asp Pro Trp His Pro Gly Glu Gln Ser Cys Glu Leu Ser Thr Cys (* j105 * j.) z z z z z z z z z 110 100 Arg Gln Gln Leu Glu Leu Ile Arg Leu Gln Met Glu Gln Met Gln Leu 120 m 197 graf graf and 125 m of 125 Gln Asn Gly Ala Met Cys His His Pro Ala Ala Phe Ala Pro Leu Leu - 135 (1) (1) (2) (2) (2) (2) (140 (2) (3) (3) (4) Pro Thr Leu Glu Pro Ala Gln Trp Leu Ser Ile Leu Asn Ser Asn Glu 160 145 150 His Leu Leu Lys Glu Lys Glu Leu Leu Ile Asp Lys Gln Arg Lys His 170 165 Ile Ser Gln Leu Glu Gln Lys Val Arg Glu Ser Glu Leu Gln Val His 185 · 拉格· 海绵影 (196 1.90) (二 . Ser Ala Leu Leu Gly Arg Pro Ala Pro Phe Gly Asp Val Cys Leu Leu 205 195 Arg Leu Gln Glu Leu Gln Arg Glu Asn Thr Phe Leu Arg Ala Gln Phe 220 Ala Gln Lys Thr Glu Ala Leu Ser Lys Glu Lys Met Glu Leu Glu Lys 235 225 230 Lys Leu Ser Ala Ser Glu Val Glu Ile Gln Leu Ile Arg Glu Ser Leu 245 250 **255** Lys Val Thr Leu Gln Lys His Ser Glu Glu Gly Lys Lys Gln Glu Glu 265 Arg Val Lys Gly Arg Asp Lys His Ile Asn Asn Leu Lys Lys Cys

Gln Lys Glu Ser Glu Gln Asn Arg Glu Lys Gln Gln Arg Ile Glu Thr Leu Glu Arg Tyr Leu Ala Asp Leu Pro Thr Leu Glu Asp His Gln Lys 310 315 Gln Thr Glu Gln Leu Lys Asp Ala Glu Leu Lys Asn Thr Glu Leu Gln 330 Glu Arg Val Ala Glu Leu Glu Thr Leu Leu Glu Asp Thr Gln Ala Thr 1.74 345 340 Cys Arg Glu Lys Glu Val Gln Leu Glu Ser Leu Arg Gln Arg Glu Ala 360 Asp Leu Ser Ser Ala Arg His Arg 370 375

<210> 189

<211> 160

<212> PRT

<213> Homo sapien

<400> 189

Met Leu Glu Ala His Arg Arg Gln Arg His Pro Phe Leu Leu Gly Thr Thr Ala Asn Arg Thr Gln Ser Leu Asn Tyr Gly Cys Ile Val Glu Asn Pro Gln Thr His Glu Val Leu His Tyr Val Glu Lys Pro Ser Thr 40 Phe Ile Ser Asp Ile Ile Asn Cys Gly Ile Tyr Leu Phe Ser Pro Glu 60 **5**5 ° Ala Leu Lys Pro Leu Arg Asp Val Phe Gln Arg Asn Gln Gln Asp Gly Gln Leu Glu Asp Ser Pro Gly Leu Trp Pro Gly Ala Gly Thr Ile Arg 90 Leu Glu Gln Asp Val Phe Ser Ala Leu Ala Gly Gln Gly Gln Ile Tyr Val His Leu Thr Asp Gly Ile Trp Ser Gln Ile Lys Ser Ala Gly Ser 120 125 Ala Leu Tyr Ala Ser Arg Leu Tyr Leu Ser Arg Tyr Gln Asp Thr His \$ 130 DEFENDED \$25 \$25 \$135 FOR SECOND 140 Pro Glu Arg Leu Ala Lys His Thr Pro Gly Gly Pro Trp Ile Arg Gly

7 <210 > 190 to the second of the second of

<211> 146

<213> Homo sapien

<400> 190: 38

Met Asp Pro Arg Ala Ser Leu Leu Leu Leu Gly Asn Val Tyr Ile His

1 5 10 15

Pro Thr Ala Lys Val Ala Pro Ser Ala Val Leu Gly Pro Asn Val Ser
20 25 30

Ile Gly Lys Gly Val Thr Val Gly Glu Gly Val Arg Leu Arg Glu Ser
35 40 45

Ile Val Leu His Gly Ala Thr Leu Gln Glu His Thr Cys Val Leu His
50 55 60

Ser Ile Val Gly Trp Gly Ser Thr Val Gly Arg Trp Ala Arg Val Glu

65 70 75 Gly Thr Pro Ser Asp Pro Asn Pro Asn Asp Pro Arg Ala Arg Met Asp 85 90 Ser Glu Ser Leu Phe Lys Asp Gly Lys Leu Leu Pro Ala Ile Thr Ile 100 105 110 Leu Gly Cys Arg Val Arg Ile Pro Ala Glu Val Leu Ile Leu Asn Ser 120 Ile Val Leu Pro His Lys Glu Leu Ser Arg Ser Phe Thr Asn Gln Ile . . . **130** Ile Leu 145 (1953) 2 de <210> 191 <211> 704 <212> PRT <213> Homo sapien 人名西斯森 医对外性结合物 人名 <400> 191 京都 一般的 海北军 电电影 地名 地區 对外的 Glu Gly Gly Cys Ala Ala Gly Arg Gly Arg Glu Leu Glu Pro Glu Leu 5 Glu Pro Gly Pro Gly Pro Gly Ser Ala Leu Glu Pro Gly Glu Glu Phe 20 25 Glu Ile Val Asp Arg Ser Gln Leu Pro Gly Pro Gly Asp Leu Arg Ser 40 Ala Thr Arg Pro Arg Ala Ala Glu Gly Trp Ser Ala Pro Ile Leu Thr The sales with the 60 was love with the be-Leu Ala Arg Arg Ala Thr Gly Asn Leu Ser Ala Ser Cys Gly Ser Ala 70 75 Leu Arg Ala Ala Gly Leu Gly Gly Gly Asp Ser Gly Asp Gly Thr 85 90 Ala Arg Ala Ala Ser Lys Cys Gln Met Met Glu Glu Arg Ala Asn Leu 100 100 Met His Met Met Lys Leu Ser Ile Lys Val Leu Leu Gln Ser Ala Leu 120 **(元) 1997年 8月 125 名** Ser Leu Gly Arg Ser Leu Asp Ala Asp His Ala Pro Leu Gln Gln Phe **130**. 135 140 Phe Val Val Met Glu His Cys Leu Lys His Gly Leu Lys Val Lys 150 155 ggs 25 50 50 160 Ser Phe Ile Gly Gln Asn Lys Ser Phe Phe Gly Pro Leu Glu Leu Val 165 179 Glu Lys Leu Cys Pro Glu Ala Ser Asp Ile Ala Thr Ser Val Arg Asn 180 185 190 Leu Pro Glu Leu Lys Thr Ala Val Gly Arg Gly Arg Ala Trp Leu Tyr 195 200 Leu Ala Leu Met Gln Lys Lys Leu Ala Asp Tyr Leu Lys Val Leu Ile 215 Asp Asn Lys His Leu Leu Ser Glu Phe Tyr Glu Pro Glu Ala Leu Met 225 230 235 Met Glu Glu Gly Met Val Ile Val Gly Leu Leu Val Gly Leu Asn 245 250 255 · 255 · 255 · 3 Val Leu Asp Ala Asn Leu Cys Leu Lys Gly Glu Asp Leu Asp Ser Gln 260 270 Val Gly Val Ile Asp Phe Ser Leu Tyr Leu Lys Asp Val Gln Asp Leu **275** ·

280

Asp Gly Gly Lys Glu His Glu Arg Ile Thr Asp Val Leu Asp Gln Lys

290 295 300 Asn Tyr Val Glu Glu Leu Asn Arg His Leu Ser Cys Thr Val Gly Asp 305 310 315 Leu Gln Thr Lys Ile Asp Gly Leu Glu Lys Thr Asn Ser Lys Leu Gln 325 330 Glu Glu Leu Ser Ala Ala Thr Asp Arg Ile Cys Ser Leu Gln Glu Glu 345 Gln Gln Gln Leu Arg Glu Gln Asn Glu Leu Ile Arg Glu Arg Ser Glu 360 355 365 Lys Ser Val Glu Ile Thr Lys Gln Asp Thr Lys Val Glu Leu Glu Thr 375 Tyr Lys Gln Thr Arg Gln Gly Leu Asp Glu Met Tyr Ser Asp Val Trp 385 390 Lys Gln Leu Lys Glu Glu Lys Lys Val Arg Leu Glu Leu Glu Lys Glu 410 Leu Glu Leu Gln Ile Gly Met Lys Thr Glu Met Glu Ile Ala Met Lys Leu Leu Glu Lys Asp Thr His Glu Lys Gln Asp Thr Leu Val Ala Leu 435 440 Arg Gln Gln Leu Glu Glu Val Lys Ala Ile Asn Leu Gln Met Phe His 450 455 Lys Ala Gin Asn Ala Glu Ser Ser Leu Gin Gin Lys Asn Glu Ala Ile 470 465 475 Thr Ser Phe Glu Gly Lys Thr Asn Gln Val Met Ser Ser Met Lys Gln Met Glu Glu Arg Leu Gln His Ser Glu Arg Ala Arg Gln Gly Ala Glu 500 Glu Arg Ser His Lys Leu Gln Gln Glu Leu Gly Gly Arg Ile Gly Ala 515 Leu Gln Leu Gln Leu Ser Gln Leu His Glu Gln Cys Ser Ser Leu Glu 535 **540** Lys Glu Leu Lys Ser Glu Lys Glu Gln Arg Gln Ala Leu Gln Arg Glu 550 555 **560** : Leu Gln His Glu Lys Asp Thr Ser Ser Leu Leu Arg Met Glu Leu Gln -570 Gln Val Glu Gly Leu Lys Lys Glu Leu Arg Glu Leu Gln Asp Glu Lys
580 585 590 v 580. Pert 585 Ala Glu Leu Gln Lys Ile Cys Glu Glu Gln Glu Gln Ala Leu Gln Glu **595** 600 ° 605 Met Gly Leu His Leu Ser Gln Ser Lys Leu Lys Met Glu Asp Ile Lys 620 Glu Val Asn Gln Ala Leu Lys Gly His Ala Trp Leu Lys Asp Asp Glu 625 630 635 Ala Thr His Cys Arg Gln Cys Glu Lys Glu Phe Ser Ile Ser Arg Arg 650 645 Lys His His Cys Arg Asn Cys Gly His Ile Phe Cys Asn Thr Cys Ser 660 665 670 Ser Asn Glu Leu Ala Leu Pro Ser Tyr Pro Lys Pro Val Arg Val Cys 675 680 Asp Ser Cys His Thr Leu Leu Leu Gln Arg Cys Ser Ser Thr Ala Ser 690 695 700

<210> 192 <211> 331 <212> PRT

<213> Homo sapien

<400> 192 Arg Ala Gly Ala Ser Ala Met Ala Leu Arg Lys Glu Leu Leu Lys Ser Ile Trp Tyr Ala Phe Thr Ala Leu Asp Val Glu Lys Ser Gly Lys Val Ser Lys Ser Gln Leu Lys Val Leu Ser His Asn Leu Tyr Thr Val Leu His Ile Pro His Asp Pro Val Ala Leu Glu Glu His Phe Arg Asp Asp 50 Asp Asp Gly Pro Val Ser Ser Gln Gly Tyr Met Pro Tyr Leu Asn Lys 75 70 65 Tyr Ile Leu Asp Lys Val Glu Glu Gly Ala Phe Val Lys Glu His Phe Asp Glu Leu Cys Trp Thr Leu Thr Ala Lys Lys Asn Tyr Arg Ala Asp Ser Asn Gly Asn Ser Met Leu Ser Asn Gln Asp Ala Phe Arg Leu Trp Cys Leu Phe Asn Phe Leu Ser Glu Asp Lys Tyr Pro Leu Ile Met Val 135 Pro Asp Glu Val Glu Tyr Leu Leu Lys Lys Val Leu Ser Ser Met Ser 155 150 Leu Glu Val Ser Leu Gly Glu Leu Glu Glu Leu Leu Ala Gln Glu Ala 170 Gln Val Ala Gln Thr Thr Gly Gly Leu Ser Val Trp Gln Phe Leu Glu 185 Leu Phe Asn Ser Gly Arg Cys Leu Arg Gly Val Gly Arg Asp Thr Leu 205 195 Ser Met Ala Ile His Glu Val Tyr Gln Glu Leu Ile Gln Asp Val Leu Lys Gln Gly Tyr Leu Trp Lys Arg Gly His Leu Arg Arg Asn Trp Ala **7.47 235** 230 Glu Arg Trp Phe Gln Leu Gln Pro Ser Cys Leu Cys Tyr Phe Gly Ser 250 245 Glu Glu Cys Lys Glu Lys Arg Gly Ile Ile Pro Leu Asp Ala His Cys **265**. Cys Val Glu Val Leu Pro Asp Arg Asp Gly Lys Arg Cys Met Phe Cys 285 280 Val Lys Thr Ala Thr Arg Thr Tyr Glu Met Ser Ala Ser Asp Thr Arg 290 300 .295 Gln Arg Gln Glu Trp Thr Ala Ala Ile Gln Met Ala Ile Arg Leu Gln 310 315 Ala Glu Gly Lys Thr. Ser Leu His Lys Asp Leu 330 1988 SAN BURNELL TO BE <210> 193

<212> PRT <213> Homo sapien

<400> 193

Lys Asn Ser Pro Leu Leu Ser Val Ser Ser Gln Thr Ile Thr Lys Glu Asn Asn Arg Asn Val His Leu Glu His Ser Glu Gln Asn Pro Gly Ser

			20					25					30		
Ser	Ala	Gly 35	Asp	Thr	Ser	Ala	Ala 40	His	Gln	Val	Val	Leu 45	Gly	Glu	Asn
	50					55	Leu	<i>-</i> .			60				_
65	•		·		70		Ala			75					80
		٠.		85			Thr		90					95	
			100				Asn	105					110		
		115		×			Asn 120		. 😭		.•	125			_
٠	130				• ; •	135	Gly			. :	140				
145					150		Ser			155				•	160
-		• .		165			Ala		170					175	
9 44			180				Lys	185					190		
		195					200 Gln					205		· · ·	
1.	210					215	Leu				220		* * * * * * * * * * * * * * * * * * * *		
225	٠.				230		Lys	•		235					240
		. :	÷	245			Lys		250					25 5	
Lys	Gly	Arg	260 Arg	Glu	V al	Trp	Glu	265 Met	Glu	Leu	Asp	Arg	270 Leu	Lys	Asn
Gln	_	275 Gly		_	Asn	• –	280 Asn	Ile	Met	Glu	Glu	285 Thr	Glu	Arg	Ala
	290 Lys	Ala	Glu	Ile		295 Ser	Leu	Glu	Ser		J Lys	Glu	Leu	Leu	
305 Leu	Lys	Leu	Glu		310 Ala	Glu	Lys	Glu		315 Glu	Leu	His	Leu		320 Tyr
Leu	Lys	Ser	Thr	325 Pro	Pro	Thr	Leu	Glu 345		Val	Arg	Ser	Lys 350	335 Gln	Glu
Trp	Glu	Thr 355		Leu	Asn	Gly	Val 360	•	. ***;	Met	Lys	Lys 365	. – – .	Val	Arg
. Asp	Gln 370	-	Asn	Ser	His	Ile 375	Gln	Leu	Val	Arg	Asn 380		Ala	Lys	Leu .
Ser 385	Ser	Leu	Pro		Ile 390	Pro	Thŕ	Pro	Thr	Leu 395	Pro	Pro	Pro	Pro	Ser 400
Glu	Thr	Asp		Met 405	Leu	Gln	Val	Phe	Gln 410	Pro	Ser	Pro	Ser	Leu 415	Ala
Pro	Arg	Met	Pro 420	Phe	Ser	Ile	Gly	Gln 425	Val	Thr	Met	Pro	Met 430	Val	Met.
Pro	Ser	Ala 435	Asp	Pro	Arg	Ser	Leu 440	Ser	Phe	Pro	Ile	Leu 445	Asn	Pro	Ala
Leu	Ser 450	Gln	Pro	Ser	Gln	Pro 455	Ser	Ser	Pro	Leu	Pro 460	Gly	Ser	His	Gly,
											-				

Arg Asn Ser Pro Gly Leu Gly Ser Leu Val Ser 475 465

<210> 194

<211> 241

<212> PRT

<213> Homo sapien

<400> 194

Met Ser Gly Glu Ser Ala Arg Ser Leu Gly Lys Gly Ser Ala Pro Pro

Gly Pro Val Pro Glu Gly Ser Ile Arg Ile Tyr Ser Met Arg Phe Cys

Pro Phe Ala Glu Arg Thr Arg Leu Val Leu Lys Ala Lys Gly Ile Arg

His Glu Val Ile Asn Ile Asn Leu Lys Asn Lys Pro Glu Trp Phe Phe

Lys Lys Asn Pro Phe Gly Leu Val Pro Val Leu Glu Asn Ser Gln Gly 65

Gln Leu Ile Tyr Glu Ser Ala Ile Thr Cys Glu Tyr Leu Asp Glu Ala 1, 2, 90 Brown and Common 2019 9517 7

Tyr Pro Gly Lys Lys Leu Leu Pro Asp Asp Pro Tyr Glu Lys Ala Cys - 110 B 105 100

Gln Lys Met Ile Leu Glu Leu Phe Ser Lys Val Pro Ser Leu Val Gly 120

Ser Phe Ile Arg Ser Gln Asn Lys Glu Asp Tyr Ala Gly Leu Lys Glu 1. 140 2 200 100 100 100 130

Glu Phe Arg Lys Glu Phe Thr Lys Leu Glu Glu Val Leu Thr Asn Lys

-155 Lys Thr Thr Phe Phe Gly Gly Asn Ser Ile Ser Met Ile Asp Tyr Leu

5 (6 T-175) 165 170 Ile Trp Pro Trp Phe Glu Arg Leu Glu Ala Met Lys Leu Asn Glu Cys

185 - 180 Val Asp His Thr Pro Lys Leu Lys Leu Trp Met Ala Ala Met Lys Glu

200 205 Asp Pro Thr Val Ser Ala Leu Leu Thr Ser Glu Lys Asp Trp Gln Gly

215 210 Phe Leu Glu Leu Tyr Leu Gln Asn Ser Pro Glu Ala Cys Asp Tyr Gly

oring the state of the state of the

235

225 Leu

<210> 195

<211> 138

<212> PRT

<213> Homo sapien

<400> 195

Gln Thr Lys Ile Leu Glu Glu Asp Leu Glu Gln Ile Lys Leu Ser Leu 10 - 15 to 15 to 15 to Arg Glu Arg Gly Arg Glu Leu Thr Thr Gln Arg Gln Leu Met Gln Glu

25 20

Arg Ala Glu Glu Gly Lys Gly Pro Ser Lys Ala Gln Arg Gly Ser Leu 40 45

Glu His Met Lys Leu Ile Leu Arg Asp Lys Glu Lys Glu Val Glu Cys

50 Gln Gln Glu His Ile His Glu Leu Gln Glu Leu Lys Asp Gln Leu Glu **65**. Gln Gln Leu Gln Gly Leu His Arg Lys Val Gly Glu Thr Ser Leu Leu Leu Ser Gln Arg Glu Gln Glu Ile Val Val Leu Gln Gln Gln Leu Gln 105 Glu Ala Arg Glu Gln Gly Glu Leu Lys Glu Gln Ser Leu Gln Ser Gln 115 Leu Asp Glu Ala Gln Arg Ala Leu Ala Gln - 130 "金珠"的"安安"的"郑"等 <210> 196 <211> 102 <212> PRT <213> Homo sapien <400> 196 Met Ser Lys Arg Lys Ala Pro Gln Glu Thr Leu Asn Gly Gly Ile Thr Asp Met Leu Thr Glu Leu Ala Asn Phe Glu Lys Asn Val Ser Gln Ala 20 25 Ile His Lys Tyr Asn Ala Tyr Arg Lys Ala Ala Ser Val Ile Ala Lys y y 3 (4 × 2 × 35°) × 35° × 4 × 4 × 3°° Tyr Pro His Lys Ile Lys Ser Gly Ala Glu Ala Lys Lys Leu Pro Gly Val Gly Thr Lys Ile Ala Glu Lys Ile Asp Glu Phe Leu Ala Thr Gly **65 70** 75 Lys Leu Arg Lys Leu Glu Lys Ile Arg Gln Asp Asp Thr Ser Ser Ser Ile Asn Phe Leu Thr Arg 100 <210> 197 <211> 138 <212> PRT <213> Homo sapien <400> 197 Glu Ala Asn Glu Val Thr Asp Ser Ala Tyr Met Gly Ser Glu Ser Thr Tyr Ser Glu Cys Glu Thr Phe Thr Asp Glu Asp Thr Ser Thr Leu Val 25 ·His Pro Glu Leu Gln Pro Glu Gly Asp Ala Asp Ser Ala Gly Gly Ser 35 -Ala Val Pro Ser Glu Cys Leu Asp Ala Met Glu Glu Pro Asp His Gly 60 EV 2 2 GET 2 Ala Leu Leu Leu Pro Gly Arg Pro His Pro His Gly Gln Ser Val 65 70 75 80 75 Ile Thr Val Ile Gly Gly Glu Glu His Phe Glu Asp Tyr Gly Glu Gly 90 Ser Glu Ala Glu Leu Ser Pro Glu Thr Leu Cys Asn Gly Gln Leu Gly 105

Cys Ser Asp Pro Ala Phe Leu Thr Pro Ser Pro Thr Lys Arg Leu Ser

```
Ser Lys Lys Val Ala Arg Tyr Leu His Gln
    130
     <210> 198°
     <211> 100
     <212> PRT
     <213> Homo sapien
     <400> 198
Met Gly Asp Val Lys Asn Phe Leu Tyr Ala Trp Cys Gly Lys Arg Lys
Met Thr Pro Ser Tyr Glu Ile Arg Ala Val Gly Asn Lys Asn Arg Gln
Lys Phe Met Cys Glu Val Gln Val Glu Gly Tyr Asn Tyr Thr Gly Met
       35
Gly Asn Ser Thr Asn Lys Lys Asp Ala Gln Ser Asn Ala Ala Arg Asp
Phe Val Asn Tyr Leu Val Arg Ile Asn Glu Ile Lys Ser Glu Glu Val
              70 3 70
                                         80 /
                                    75 .
:65
Pro Ala Phe Gly Val Ala Ser Pro Pro Pro Leu Thr Asp Thr Pro Asp
Thr Thr Ala Asn
     <211> 127
< 212> PRT 3.
· ;
     <213> Homo sapien
     <400> 199
Met Val Lys Glu Thr Thr Tyr Tyr Asp Val Leu Gly Val Lys Pro Asn
Ala Thr Gln Glu Glu Leu Lys Lys Ala Tyr Arg Lys Leu Ala Leu Lys
           20
Tyr His Pro Asp Lys Asn Pro Asn Glu Gly Glu Lys Phe Lys Gln Ile
Ser Gln Ala Tyr Glu Val Leu Ser Asp Ala Lys Lys Arg Glu Leu Tyr
                      55 .
Asp Lys Gly Gly Glu Gln Ala Ile Lys Glu Gly Gly Ala Gly Gly Gly
Phe Gly Ser Pro Met Asp Ile Phe Asp Met Phe Phe Gly Gly Gly Gly 95
Arg Met Gln Arg Glu Arg Gly Lys Asn Val Val His Gln Leu Ser
     100
Val Thr Leu Glu Asp Leu Tyr Asn Gly Ala Thr Arg Lys Leu Ala
                120
       115
                                         · "好说,你没有,也要懂了你呢?" "你说
     <210> 200
     <211> 90
     <212> PRT
     <213> Homo sapien
     <400> 200
Met Ala Cys Pro Leu Asp Gln Ala Ile Gly Leu Leu Val Ala Ile Phe
                      10
```

<210> 201 <211> 120 <212> PRT

<213> Homo sapien

<400> 201

Met Glu Thr Pro Ser Gln Arg Arg Ala-Thr Arg Ser Gly Ala Gln Ala 15 j Ser Ser Thr Pro Leu Ser Pro Thr Arg Ile Thr Arg Leu Gln Glu Lys Glu Asp Leu Gln Glu Leu Asn Asp Arg Leu Ala Val Tyr Ile Asp Arg Val Arg Ser Leu Glu Thr Glu Asn Ala Gly Leu Arg Leu Arg Ile Thr 55 Glu Ser Glu Glu Val Val Ser Arg Glu Val Ser Gly Ile Lys: Ala Ala **65** " **75** 70 Tyr Glu Ala Glu Leu Gly Asp Ala Arg Lys Thr Leu Asp Ser Val Ala Lys Glu Arg Ala Arg Leu Gln Leu Glu Leu Ser Lys Val Arg Glu Glu 105 110 Phe Lys Glu Leu Lys Ala Arg Asn 115 120

<210> 202 <211> 177 <212> PRT <213> Homo sapien

<400> 202

Glu Val Thr Tyr Val Glu Leu Leu Met Asp Ala Glu Gly Lys Ser Arg 100 105 110 Gly Cys Ala Val Val Glu Phe Lys Met Glu Glu Ser Met Lys Lys Ala Ala Glu Val Leu Asn Lys His Ser Leu Ser Gly Arg Pro Leu Lys Val
130
135
140
Lys Glu Asp Pro Asp Gly Glu His Ala Arg Arg Ala Met Gln Lys Ala
145
150
150
160
Gly Arg Leu Gly Ser Thr Val Phe Val Ala Asn Leu Asp Tyr Lys Val
165
175

<210> 203 <211> 164 <212> PRT <213> Homo sapien

<400> 203

Met Arg Leu Ala Val Gly Ala Leu Leu Val Cys Ala Val Leu Gly Leu -- 10 ₂₀₀ Cys Leu Ala Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser Glu His Glu Ala Thr Lys Cys Gln Ser Phe Arg Asp His Met Lys Ser Val 35 Ile Pro Ser Asp Gly Pro Ser Val Ala Cys Val Lys Lys Ala Ser Tyr Leu Asp Cys Ile Arg Ala Ile Ala Ala Asn Glu Ala Asp Ala Val Thr 65 70 75 Leu Asp Ala Gly Leu Val Tyr Asp Ala Tyr Leu Ala Pro Asn Asn Leu 85 90 Lys Pro Val Val Ala Glu Phe Tyr Gly Ser Lys Glu Asp Pro Gln Thr 100 Phe Tyr Tyr Ala Val Ala Val Val Lys Lys Asp Ser Gly Phe Gln Met 115 120 Asn Gln Leu Arg Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser Ala Gly Trp Asn Ile Pro Ile Gly Leu Leu Tyr Cys Asp Leu Pro Glu 145 150 Pro Arg Lys Pro

<210> 204 <211> 241 <212> PRT <213> Homo sapien

<400> 204

Gln Leu Ile Tyr Glu Ser Ala Ile Thr Cys Glu Tyr Leu Asp Glu Ala 85 Tyr Pro Gly Lys Lys Leu Leu Pro Asp Asp Pro Tyr Glu Lys Ala Cys 105 Gln Lys Met Ile Leu Glu Leu Phe Ser Lys Val Pro Ser Leu Val Gly 115 120 125 Ser Phe Ile Arg Ser Gln Asn Lys Glu Asp Tyr Asp Gly Leu Lys Glu 130 135 Glu Phe Arg Lys Glu Phe Thr Lys Leu Glu Glu Val Leu Thr Asn Lys 155 Lys Thr Thr Phe Phe Gly Gly Asn Ser Ile Ser Met Ile Asp Tyr Leu 165 Ile Trp Pro Trp Phe Glu Arg Leu Glu Ala Met Lys Leu Asn Glu Cys 180 185 Val Asp His Thr Pro Lys Leu Lys Leu Trp Met Ala Met Lys Glu 200 Asp Pro Thr Val Ser Ala Leu Leu Thr Ser Glu Lys Asp Trp Gln Gly 215 Phe Leu Glu Leu Tyr Leu Gln Asn Ser Pro Glu Ala Cys Asp Tyr Gly 235 230 240 Leu

<210> 205 <211> 160 <212> PRT

- X

<213> Homo sapien

<400> 205

Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe 70 Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser 85 Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile 100 105 110 Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp 115 120 Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His 135 130 · · · 140 Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu 150

<210> 206

<211> 197

<212> PRT

<213> Homo sapien

7 1 L

<400> 206 Thr Ser Pro Ser Glu Ala Cys Ala Pro Leu Leu Ile Ser Leu Ser Thr 1 . Leu Ile Tyr Asn Gly Ala Leu Pro Cys Gln Cys Asn Pro Gln Gly Ser Leu Ser Ser Glu Cys Asn Pro His Gly Gly Gln Cys Leu Cys Lys Pro Gly Val Val Gly Arg Arg Cys Asp Leu Cys Ala Pro Gly Tyr Tyr Gly Phe Gly Pro Thr Gly Cys Gln Gly Ala Cys Leu Gly Cys Arg Asp His Thr Gly Gly Glu His Cys Glu Arg Cys Ile Ala Gly Phe His Gly Asp Pro Arg Leu Pro Tyr Gly Gly Gln Cys Arg Pro Cys Pro Cys Pro Glu . 100 Gly Pro Gly Ser Gln Arg His Phe Ala Thr Ser Cys His Gln Asp Glu Tyr Ser Gln Gln Ile Val Cys His Cys Arg Ala Gly Tyr Thr Gly Leu 135 Arg Cys Glu Ala Cys Ala Pro Gly His Phe Gly Asp Pro Ser Arg Pro **150** ... Gly Gly Arg Cys Gln Leu Cys Glu Cys Ser Gly Asn Ile Asp Pro Met 170 Asp Pro Asp Ala Cys Asp Pro His Thr Gly Gln Cys Leu Arg Cys Leu 180 His His Thr Glu Gly 195 <210> 207 <211> 175

<211> 175 <212> PRT <213> Homo sapien

<400> 207 Ile Ile Arg Gln Gln Gly Leu Ala Ser Tyr Asp Tyr Val Arg Arg Arg Leu inr ala Glu Asp Leu Phe Glu Ala Arg lle lle Ser Leu Glu inr Tyr Asn Leu Leu Arg Glu Gly Thr Arg Ser Leu Arg Glu Ala Leu Glu Ala Glu Ser Ala Trp Cys Tyr Leu Tyr Gly Thr Gly Ser Val Ala Gly Val Tyr Leu Pro Gly Ser Arg Gln Thr Leu Ser Ile Tyr Gln Ala Leu Lys Lys Gly Leu Leu Ser Ala Glu Val Ala Arg Leu Leu Glu Ala Gln Ala Ala Thr Gly Phe Leu Leu Asp Pro Val Lys Gly Glu Arg Leu 100 105 110 Thr Val Asp Glu Ala Val Arg Lys Gly Leu Val Gly Pro Glu Leu His Asp Arg Leu Leu Ser Ala Glu Arg Ala Val Thr Gly Tyr Arg Asp Pro **130** 135 Tyr Thr Glu Gln Thr Ile Ser Leu Phe Gln Ala Met Lys Lys Glu Leu 150 Ile Pro Thr Glu Glu Ala Leu Arg Leu Trp Met Pro Ser Trp Pro

165 170 179

<210> 208
<211> 177
<212> PRT
<213> Homo sapien

<400> 208

Met Ala Ala Gly Val Glu Ala Ala Ala Glu Val Ala Ala Thr Glu Ile Lys Met Glu Glu Ser Gly Ala Pro Gly Val Pro Ser Gly Asn Gly Ala Pro Gly Pro Lys Gly Glu Gly Glu Arg Pro Ala Gln Asn Glu Lys Arg Lys Glu Lys Asn Ile Lys Arg Gly Gly Asn Arg Phe Glu Pro Tyr Ala Asn Pro Thr Lys Arg Tyr Arg Ala Phe Ile Thr Asn Ile Pro Phe 65 70 Asp Val Lys Trp Gln Ser Leu Lys Asp Leu Val Lys Glu Lys Val Gly Glu Val Thr Tyr Val Glu Leu Leu Met Asp Ala Glu Gly Lys Ser Arg Gly Cys Ala Val Val Glu Phe Lys Met Glu Glu Ser Met Lys Lys Ala 120 Ala Glu Val Leu Asn Lys His Ser Leu Ser Gly Arg Pro Leu Lys Val 135 Lys Glu Asp Pro Asp Gly Glu His Ala Arg Arg Ala Met Gln Lys Val 145 150 155 Met Ala Thr Thr Gly Gly Met Gly Met Gly Pro Gly Gly Pro Gly Met 165 170 Ile

<210> 209 <211> 196 <212> PRT <213> Homo sapien

Glu Met Asn Gly Thr Leu Glu Asp Gln Leu Ser His Leu Lys Gln Tyr 130 135 Glu Arg Ser Ile Val Asp Tyr Lys Pro Asn Leu Asp Leu Leu Glu Gln 145 150 Gln His Gln Leu Ile Gln Glu Ala Leu Ile Phe Asp Asn Lys His Thr 165 Asn Tyr Thr Met Glu His Ile Arg Val Gly Trp Glu Gln Leu Leu Thr Thr: Ile Ala Arg 多一点,我们都是一种特别的人的。 <210> 210 网络安全人物学 医二苯甲基 <211> 156 <212> PRT <213> Homo sapien - The track of the law got the second <400> 210 Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly Lys Glu wolvest a finite pass of the transmitted to the new york Val Leu Leu Ala His Asn Leu Pro Gln Asn Arg Ile Gly Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Ser Leu Ile Val Gly Tyr 40 Val Ile Gly Thr Gln Gln Ala Thr Pro Gly Pro Ala Tyr Ser Gly Arg Glu Thr Ile Tyr Pro Asn Ala Ser Leu Leu Ile Gln Asn Val Thr Gln Asn Asp Thr Gly Phe Tyr Thr Leu Gln Val Ile Lys Ser Asp Leu Val Asn Glu Glu Ala Thr Gly Gln Phe His Val Tyr Pro Glu Leu Pro Lys 105 100 Pro Ser Ile Ser Ser Asn Asn Ser Asn Pro Val Glu Asp Lys Asp Ala 120 Val Ala Phe Thr Cys Glu Pro Glu Val Gln Asn Thr Thr Tyr Leu Trp 130 135 Trp Val Asn Gly Gln Ser Leu Pro Val Ser Pro Lys Francisco Company <210> 211 海水工 基础 网络拉马格拉 化邻 <211> 92 April 18 <212> PRT (2) (2) (2) (2) (2) (2) (2) (2)
 (3) (2) (2) (2) (2) (2) <213> Homo sapien Met Glu Ser Pro Ser Ala Pro Pro His Arg Trp Cys Ile Pro Trp Gln Arg Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Pro Pro Thr. 20 25 30 Thr Ala Lys Leu Thr Ile Glu Ser Thr Pro Phe Asn Val Ala Glu Gly 35 45 45 Lys Glu Val Leu Leu Val His Asn Leu Pro Gln His Leu Phe Gly 50 Tyr Ser Trp Tyr Lys Gly Glu Arg Val Asp Gly Asn Arg Gln Ile Ile Gly Tyr Val Ile Gly Thr Gln Gln Ala Thr Pro Gly

90

<210> 212 <211> 142 <212> PRT <213> Homo sapien

<400> 212

<210> 213 <211> 142 <212> PRT <213> Homo sapien

<400> 213

<210> 214 <211> 129 <212> PRT

THE PART OF LOW SELECTION

and the second of the second o

<213> Homo sapien

<400> 214 . . . Val Met Arg Val Asp Phe Asn Val Pro Met Lys Asn Asn Gln Ile Thr Asn Asn Gln Arg Ile Lys Ala Ala Val Pro Ser Ile Lys Phe Cys Leu · 11 - 11 (2) マ(**30**を (-Asp Asn Gly Ala Lys Ser Val Val Leu Met Ser His Leu Gly Arg Pro Asp Gly Val Pro Met Pro Asp Lys Tyr Ser Leu Glu Pro Val Ala Val Glu Leu Arg Ser Leu Leu Gly Lys Asp Val Leu Phe Leu Lys Asp Cys TO STAN THE REPORT OF THE PARTY OF THE PARTY OF THE REPORT OF THE PARTY OF THE PART Val Gly Pro Glu Val Glu Lys Ala Cys Ala Asn Pro Ala Ala Gly Ser Val Ile Leu Leu Glu Asn Leu Arg Phe His Val Glu Glu Glu Gly Lys 100 Gly Lys Asp Ala Ser Gly Asn Lys Val Lys Ala Glu Pro Ala Lys Ile Glu

<210> 215 yr get gitt with <211> 148 <213> Homo sapien

1988 1946 克州 (128) 经基础管理 (中国的管理等)

THE SECURITY CAR AND THE PROPERTY OF BUILDING WINDOWS AND A PARTY. <400> 215 Met Ala Thr Leu Lys Glu Lys Leu Ile Ala Pro Val Ala Glu Glu Glu **15** . 10 Ala Thr Val Pro Asn Asn Lys Ile Thr Val Val Gly Val Gly Gln Val Gly Met Ala Cys Ala Ile Ser Ile Leu Gly Lys Ser Leu Ala Asp Glu Leu Ala Leu Val Asp Val Leu Glu Asp Lys Leu Lys Gly Glu Met Met Asp Leu Gln His Gly Ser Leu Phe Leu Gln Thr Pro Lys Ile Val Ala Asp Lys Asp Tyr Ser Val Thr Ala Asn Ser Lys Ile Val Val Val Thr Ala Gly Val Arg Gln Gln Glu Gly Glu Ser Arg Leu Asn Leu Val Gln _[35]§ 105 → PR 110 Arg Asn Val Asn Val Phe Lys Phe Ile Ile Pro Gln Ile Val Lys Tyr 120 Ser Pro Asp Cys Ile Ile Ile Val Val Ser Asn Pro Val Asp Ile Leu Thr Tyr Val Thr 187 188 and 200 per rive 128 per and off vill 129 call

<211> 527 <212> PRT

Gln 1	Arg	Ala	Pro	Gly 5	Ile	Glu	ı Glu	Lys	Ala 10	Ala	Glu	Asn	Gly	Ala 15	Leu
Gly	Ser	Pro		_	Glu		_		Leu	Glu	Asn	Gly	Glu 30		Thr
Pro	Pro	_	Arg	Glu	Glu	Lys	Ala	Leu	ı Glu	Asn	-	Glu			Ser
		Ala	Gly	Glu	Lys	Val	Leu	'Val	Asn	Gly	Gly	Leu	Thr	Pro	Pro
Lys	· ·-	Glu	Asp		•-	Ser	Glu	Asn	Gly	Gly	Leu	Arg	Phe	Pro	Arg
		Glu	Arg			Glu	Thr	Gly	Pro	Trp			Pro	Gly 95	
Trp	Glu	Lys	Thr	Pro	Glu	Ser	Trp	Gly	Pro	Ala	Pro	Thr		Gly	Glu
Pro	Ala	Pro	Glu	Thr	Ser	Leu	G1u	Arg	Ala	Pro	Ala		Ser		Val
V al			Arg	Asn	,	Gly	Glu	Thr	Ala	Pro	Gly	Pro		Gly	Pro
Ala 145	Pro				•	Leu	•	-	Gly		Glu		Arg	Ala	Pro 160
		Gly	Gly	Ala 165	Pro		Ala	Pro	Gly 170	Ala		Arg	Leu	Asp 175	
Gly	Ser	Gly	Gly 180	Arg	Ala	Pro	Val	Gly 185	Thr	Gly	Thr	Ala	Pro 190	Gly	Gly
G1y	Pro	Gly 195		Gly	Val	Asp	Ala 200	Lys	Ala	Gly		Val 205	Asp	Asn	Thr
Arg	Pro 210	Gln	Pro	Pro	Pro	Pro 215		Leu	Pro	Pro	Pro 220	Pro	Glu	Ala	Gln
Pro 225		Arg	Leu	Glu	Pro 230	Ala	Pro	Pro	Arg	Ala 235	Arg	Pro	Glu	Val	Ala 240
		: -	Oi	245	. •				Ser 250			_		255	
			260	- Z		_		265	Lys		:		270	,	4
		275	_		•.		280		Gly			285			. .,
	290		_	•	,	295			Leu		300				
305				•	310		: :		Gly	315		, i		2	320
	_		<u> </u>	325	_				330				-	335	- ;
•	•	-	340	• •				345	Glu				350		
	•	355	••		1:		360	•	Gly			365			
	370		_		_	375			Val	•	380		-		
385	_		_		390				Arg	395					400
	_			405					Glu 410				_,,	415	
•			420		-			425	Val	-			430		
Thr	Pro	Thr	Asn	Glu	Leu	Ser	Val	Gln _.	Ala	Pro	Pro	Glu	Gly	Asp	Thr

Figure 1986 Seria Seria Seria Company Company Company Company Company Company Company Company Company Company

The course of a reconstruction of earlies in the second of the artist of the second of the second of the

think the strain of

CARSTAN CONTRACT -

(19) 中国发生了最后 · 有自己的 [1] (1)

and the plant of the

经收款的 医腹腔 计连续数 化二甲磺胺二氢苯酚

22、多级 医麻醉性

[19] · · · · · · · · · · · · · · · · · · ·	• • .	435	• • • •	· · · · · · · · ·			440		· .		Tale Transmission	445			
Asp	Pro	Ser	Thr	Pro	Pro	Ala	Pro	Pro	Thr	Pro	Pro	His	Pro	Ala	Thr
	450	***				455			•		460	<u>.</u> -			
Pro	Gly	Asp	Gly	Phe	Pro	Ser	Asn	Asp	Ser	Gly	Phe	Gly	Gly	Ser	Phe
465				radio de	470	Color Sale				475		· 7.	• .		480
Glu	Trp	Ala	Glu	Asp	Phe	Pro	Leu	Leu	Pro	Pro	Pro	Gly	Pro	Pro	Leu
	· -	•			.*		3		490					495	
Cys			Arg	Phe	Ser	Val	Ser	Pro	Ala	Leu	Glu	Thr	Pro	Gly	Pro
I want drive as Till		i jarah Karangan Karangan	500	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	i iese.			505			an e		510		•
Pro	Ala	Arg	Ala	Pro	Asp	Ala	Arg	Pro	Ala	Gly	Pro	Val	Glu	Asn	-
		515			· 731		520		ur.	~	434	525	₹.		
	4 193		· · ·		5					·		rug@i (;]		• • • •
			¥		4		•		2.45 3.45						

LANCER RECORDER DE SERVE CON COMPANS DE L'ANNE DE L'ANNE DE L'ANCE DE PROPERT DE L'ÉTE LE L'ANDRÉ LE LANCE COMM

Less of the religion of the second of the factor of the first of the f

PCT

09/040.831

09/122,192

09/122,191

09/219,245

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



WO 99/38973

5 August 1999 (05.08.99)

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, A61K 38/17, C07K 14/47, 16/18, A61K 35/14	А3	(11) International Publication Number: (43) International Publication Date:
(21) International Application Number: PCT/US	S99/016	
(22) International Filing Date: 26 January 1999	(26.01.9	BY, CA, CH, CN, CU, CZ, DI GH, GM, HR, HU, ID, IL, IS,
	•	LC, LK, LR, LS, LT, LU, LV
		MX, NO, NZ, PL, PT, RO, RU,
(30) Priority Data:		TM, TR, TT, UA, UG, UZ, V
09/015,029 28 January 1998 (28.01.98)) (JS (GH, GM, KE, LS, MW, SD, S
09/015,022 28 January 1998 (28.01.98)) (JS (AM, AZ, BY, KG, KZ, MD, R
09/040,828 18 March 1998 (18.03.98)	τ	JS (AT, BE, CH, CY, DE, DK, E

18 March 1998 (18.03.98)

22 December 1998 (22.12.98)

23 July 1998 (23.07.98)

23 July 1998 (23.07.98)

- (71) Applicant: CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).
- (72) Inventors: REED, Steven, G.; 2843 122nd Place N.E., Bellevue, WA 98005 (US). LODES, Michael, J.; 9223 36th Avenue S.W., Seattle, WA 98126 (US). FRUDAKIS, Tony, N.; P.O. Box 99232, Seattle, WA 99232–0232 (US). MOHAMATH, Raodoh; 4205 South Morgan, Seattle, WA 98118 (US).
- (74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

US

US

US

US

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
9 December 1999 (09.12.99)

(54) Title: COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR THEIR USE

(57) Abstract

Compounds and methods for treating lung cancer are provided. The inventive compounds include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such polypeptides, or polynucleotides encoding such polypeptides, are also provided, together with polynucleotides for preparing the inventive polypeptides.

INTERNATIONAL SEARCH REPORT

Inte ional Application No PCT/US 99/01642

CLASSI	FICATION OF SUBJECT MATTER .C12N15/12 A61K38/17 C07K14/47 C07K16/18 A6	1K35/14
ccording to	International Patent Classification (IPC) or to both national classification and IPC	
3. FIELDS	SEARCHED	
Ainimum da IPC 6	cumentation searched (classification system followed by classification symbols) C12N C12Q A61K C97K	
) Occumental	tion searched other than minimum documentation to the extent that such documents are included in the field	s searched
	lata base consulted during the international search (name of data base and, where practical, search terms u	sed)
· ·	HIN DEED COURTING OF BIGHT HIGH HIGH HIGH STATE OF STATE	
		And the second of the second
	and the second of the second o	Salar Andrews
. 000188	ENTS CONSIDERED TO BE RELEVANT	
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ategory	Cardon of document, with articulation, where appropriates of the relevant persons	
\	WO 96 30389 A (MILLENIUM PHARMACEUTICALS, INC.; SHYJAN A.) 3 October 1996	1-60
	see page 112 - page 127	
1	WO 96 02552 A (CYTOCLONYL PHARMACEUTICS,	1-60
	INC.; TORCZYNSKI R. ET AL.) 1 February	the contract of the second
	see the whole document	
١	YOU L ET AL.: "Identification of early	1,2,4-7
	growth response gene-1 (Egr-1) as a	
	phorbol myristate-induced gene in lung cancer cells by differential mRNA display"	
	AM. J. RESPIR. CELL MOL. BIOL.,	
•	vol. 17, no. 5, November 1997,	
	pages 617-624, XP002106654 see page 618, left-hand column, paragraph	
;	3	
· ·	/	
X Fur	ther documents are listed in the continuation of box C. X Patent family members are	isted in armex.
Special c	ategories of cited documents: "I" later document published after the or priority date and not in conflict.	e international filing date
A" docum	nent defining the general state of the art which is not cited to understand the principle idered to be of particular relevance	or theory underlying the
E° earlier	document but published on or after the international "X" document of particular relevance	; the claimed invention
filing L" docum	nent which may throw doubts on priority claim(s) or involve an inventive step when	the document is taken alone
citati	h is cited to establish the publication date of another "Y" document of particular relevance on or other special reason (as specified) cannot be considered to involve document is combined with one	en inventive step when the
other	ments, such combination being	obvious to a person skilled
	nent published prior to the international filing date but than the priority date claimed "&" document member of the same p	eatont family
Date of the	e actual completion of the international search Date of mailing of the internation	nal search report
	21 June 1999 22 10 1	999
Name and	I mailing address of the ISA . Authorized officer	
	European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk	
	Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016 CUPIDO, M	

....rnational application No. PCT/US 99/01642

1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 16, 17, 24-26, 32, 33, 48-53 and 56-5 directed to a method of treatment of the human/animal the search has been carried out and based on the alle effects of the composition. 2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed require an extent that no meaningful international Search can be carried out, specifically: 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentent Box II Observations where unity of invention is tacking (Continuation of item 2 of first sheet)	is are body eged rements to such ces of Rule 6.4(a).	
because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 16, 17, 24-26, 32, 33, 48-53 and 56-5 directed to a method of treatment of the human/animal the search has been carried out and based on the alle effects of the composition. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requires an extent that no meaningful International Search can be carried out, specifically: Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentence.	eged rements to such ces of Rule 6.4(a).	
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirement that no meaningful International Search can be carried out, specifically: Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentence.	ces of Rule 6.4(a).	. · · · · · · · · · · · · · · · · · · ·
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third senten	ces of Rule 6.4(a).	
because they are dependent claims and are not drafted in accordance with the second and third senten		·,
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet))	
ook it Coservations where unity of invention is lacking (Continuation of item 2 of first sheet)	
his international Searching Authority found multiple inventions in this international application, as follows:		
The state of the s	•	
see FURTHER INFORMATION sheet	•	-
	•	
		- •
As all required additional search fees were timely paid by the applicant, this International Search Report	t covers all	-
Searchable Clasms.		·
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not any additional fee.	ot invite payment	
and the control of the second of the control of the The control of the control of		
As only some of the required additional search fees were timely paid by the applicant, this International	Search Report	
covers only those claims for which fees were paid, specifically claims Nos.:	Carte of the samples	
residente de la finalectación de la completación de la completación de la completación de la completación de l La completación de la seguina de la completación de la completación de la completación de la completación de l La completación de la completación		٠.
and an extra of the contract o	of the fire that the fire and the control of the	
and the second the transfer of the second of		
o kolemati sa katalangan katalang ang mang mang mengang mengangkan katalang di mengangkan mengang mengang meng Katalang katalang katalanggan penggungan penggungan penggungan mengangkan penggungan penggungan penggungan pen	TO MERCHANIS	
No required additional search fees were timely paid by the applicant. Consequently, this International S restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	earch Report is	
see FURTHER INFORMATION sheet, subject 1.		
		-
Remark on Protest The additional search fees were accompanied by the	he applicant's protest	
- The transfer desired accompanied by a	ablanca as become	
No protest accompanied the payment of additional	search fees.	

INTERNATIONAL SEARCH REPORT

Information on patent family members

tote onal Application No PCT/US 99/01642

Patent document cited in search report		Publication date 03-10-1996	Patent family member(s)		Publication date
WO 9630389	A .		US 5633161 A		
110 200000	••		AU	708746 B	12-08-1999
•			AU	5437896 A	16-10-1996
·			CA	2216717 A	03-10-1996
		•	EP	0817792 A	14-01-1998
			US	5674739 A	07-10-1997
WO 9602552		01-02-1996	US	5589579 A	31-12-1996
NO SOCESSE	••		AU	7 00 915 B	14-01-1999
		•	AU	3359295 A	16-02-1996
		•	BR	9508417 A	18-11-1997
		•	CA	2195403 A	01-02-1996
	•	•	EP	0804451 A	05-11-1997
•			JР	10503087 T	24-03-1998
			ŪS	5773579 A	30-06-1998

3. 《水污染疾病》 1. Buth 1.75460 - ! 医三氢氯化二氢氯

ger la 14

there are see